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CHAPTER 1 
GENERAL INTRODUCTION 
IA Thyroid hormone synthesis 
Iodine enters the thyroid follicular cells as inorganic iodide and is 
incorporated through a series of metabolic steps into the main thyroid 
hormones thyroxine (T4 ) and 3,3',5-triiodothyronine (T3 ). Consecutive steps 
in this metabolic sequence are: 1) active transport of iodide by the 
thyroid follicular cell; 2) iodination of tyrosyl residues of thyroglobulin 
at the apical membrane; 3) coupling of mono- and diiodotyrosine molecules 
within thyroglobulin to form T4 and T3; 4) proteolysis of thyroglobulin, 
with release of T4 , T3 and iodotyrosines; and 5) deiodination of iodo-
tyrosines within the thyroid and reutilization of the liberated iodide. The 
iodothyronines are then secreted into the blood. 
The production and secretion of iodothyronines by the thyroid are 
under control of thyroid stimulating hormone (TSH) secreted by the anterior 
pituitary gland. TSH binds to a specific plasma membrane receptor on the 
surface of the follicular cells and exerts its action mainly via the second 
messenger cAMP (1). The secretion of TSH is regulated by two interacting 
elements: neural control by the hypothalamus (stimulation by TRH, 
inhibition by somatostatin (2) and dopamine (3)) and negative feedback 
control by thyroid hormones (4-6). 
The main product secreted by the thyroid is T4 (structural formulas of 
the iodothyronines are shown in Fig. 1). In the normal adult the mean T4 
secretion rate is -115 nmol/d per 70 kg body weight (BW). Thyroidal 
secretion of T3 amounts to-g and of 3,3',5'-triiodothyronine (reverse T3 , 
rT 3) to -z nmol/d per 70 kg BW (for a review, see ref. 7). As the total 
production rates of T3 (-43 nmol/d) and rT3 (45-90 nmol/d) are much higher 
(7), it will be clear that the production of these iodothyronines occurs 
predominantly outside the thyroid. Contribution of thyroidal seretion to 
the circulating diiodothyronines 3,3'-T2 , 3,5-T2 and 3',5'-T2 is negligible 
(8,9). 
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Figure 1 
T I 
3 
3, 31-T 2 
Structural formulas of iodothyronines. 
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IB Regulation of thyroid hormone bioavailability 
In the hypothesis formulated by Robbins and Rall (10) it is proposed 
that the "free hormone concentration in serum governs hormone delivery to 
the cell and ultimately regulates hormonal action". This hypothesis is 
based on the assumption that 1) free but not protein-bound hormone is taken 
up by tissues; 2) the rate of tissue uptake and, hence, the availability of 
intracellular hormone are determined by the free hormone concentration in 
plasma; and 3) the biological effect of a hormone is positively correlated 
with its intracellular concentration. With respect to thyroid hormone, the 
free concentrations of T4 and T3 in plasma are undoubtly important 
determinants of the thyroid status of the organism. However, the existence 
of multiple regulatory mechanisms makes that this relationship becomes less 
obvious under different circumstances. In the subsequent paragraph a number 
of factors which are important in regulating thyroid hormone bioavai-
lability are discussed. These are: 1) the free thyroid hormone con-
centration in serum; 2) active uptake of thyroid hormone into the tissues; 
3) extrathyroidal metabolism of iodothyronines; and 4) free hormone , 
gradients between intracellular compartments. 
1: The free thyroid hormone concentration 
The iodothyronines circulate in the blood largely bound to three spe-
cific plasma transport proteins. These are T4-binding globulin (TBG), T4-
binding prealbumin (TBPA) and albumin which carry approximately 75, 15 and 
10% of plasma T4 , respectively (for a review, see ref. 11). The 
distribution of T3 over these proteins is less certain. Values range 
between 38-80% for TBG, 9-27% for TBPA and 11-35% for albumin (11). In 
normal serum free T4 (FT4 ) and FT3 average approximately 0.02% and 0.2% of 
total T4 and T3 levels. 
Several inherited variations involving each of the major transport 
proteins have now been described. Among these, the condition known as 
congenital TBA elevation, which was first described by Hennemann et al. 
(12) deserves special mention. In these euthyroid subjects total T4 is 
increased due to an abnormally increased T4 binding in the albumin region. 
However, FT4 measured by equilibrium dialysis, total T3 and the response of 
TSH to TRH are normal. Recent studies suggest that this 'abnormal' T4-
binding albumin (TBA) is also present in normal serum, although in a lesser 
amount (13). 
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2: Active uptake of thyroid hormone into tissues 
Originally, it was postulated that thyroid hormones, by way of their 
lipophilic nature, would pass the lipid bilayer of the cell membrane by 
passive diffusion (14). Recently, however, evidence has been obtained that 
thyroid hormone is, at least in part, transported through the plasma 
membrane by an energy-dependent, carrier-mediated process (for a review, 
see ref. 15). These studies have demonstrated that the kinetics of uptake 
of T4 and T3 by rat hepatocytes consist of three components. The first, 
non-saturable process probably represents the partition of hormone in the 
lipid bilayer of the plasma membrane. The second component is thought to 
result from the interaction of T4 and T3 with binding sites on the external 
cell surface. The third process is involved with the transport of T4 and T3 
across the cell membrane. It appears that T4 and rT3 share a common pathway 
to enter the cell that is different from that of T3• More direct evidence 
for the presence of an active transport system for thyroid hormone was 
obtained with the use of a monoclonal antibody (ER-22) directed against the 
rat hepatocyte plasma membrane (16,17). Active transport systems for 
thyroid hormones have also been found in cultured GH3 pituitary tumor cells 
and human fibroblasts (15). Preliminary experiments in our laboratory 
suggest the existence of active iodothyronine uptake systems in human liver 
cells (Krenning et al, unpublished work). 
3: Extrathyroidal metabolism of iodothyronines 
Iodothyronines undergo two principal metabolic reactions, i.e. deiodi-
nation of the tyrosyl (inner) or phenolic (outer) ring, and conjugation of 
the phenolic hydroxyl group with glucuronic acid or sulfuric acid (Fig. 2). 
They are also subject to deamination and decarboxylation of the amino acid 
side chain, and to ether link cleavage. These pathways are not mutually 
exclusive but are interrelated in a complex manner. Deiodination of 
iodothyronines is, at least in man, quantitatively the most important 
metabolic route and will be discussed here. Glucuronidation and sulfation 
will be the subject of chapter II. The remaining two metabolic pathways, 
deamination and ether link cleavage are least important and will not be 
discussed here (for reviews, see refs. 18,19). 
Type I Iodothyronine deiodinase 
Studies in rats have shown that there are at least three different 
iodothyronine-deiodinating enzymes: type I, II and III (for reviews, see 
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T3 glucuronide r3 sulphate 
Figure 2 
Glucuronidation (left) and sulfation (right} of T3 . 
Table 1. THREE TYPES IODOTHYRONINE DEIODINASE 
IT. 111 
T4 T4 T4 
I " I " T3 rT3 T3 rT3 T3 rT3 
,; / 
" T2 T2 T2 
Location liver, kidney brain, BAT, brain, skin, 
pituitary placenta 
Substrate preference rT3>T4-T3 T4>T3 T3>T4 
Thiols stimulation stimulation stimulation 
PTU inhibition no effect no effect 
llypolhyroidism decrease increase decrease 
Hyperthyroidism increase decrease increase 
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refs. 19-23). The characteristics of these enzymes will only be shortly 
discussed here. In rats high type I deiodinase activities are found in 
liver, kidney and thyroid, and low levels in many other tissues. The enzyme 
is an integral membrane protein that in liver appears to be associated with 
the endoplasmic reticulum while in kidney it is located in the plasma 
membranes (23). The physiological cofactor is unknown. Glutathione (GSH), 
thioredoxin and glutaredoxin have all been implied as possible cofactors, 
although they are much less potent in vitro than for instance the synthetic 
dithiol dithiotreitol (DTT). Other characteristics of the type I enzyme, 
which distinguish this enzyme from the other two deiodinases are 1) the 
capability to catalyse both inner ring deiodination (IRD) and outer ring 
deiodination (ORD) of iodothyronines (Table I); 2) the substrate preference 
for rT3 >> T4 > T3 ; 3) the facilitated deiodination of iodothyronine 
sulfate conjugates (chapter IIC); and 4) the inhibition by the thyrostatic 
drug propylthiouracil (PTU). 
The characteristics of the human type I deiodinase activities of 
thyroid (24), kidney (25,26) and liver (27,28) have recently been reported. 
It appears that these organs contain similar if not identical enzymes. In 
addition, evidence has been obtained that the human liver type I deiodinase 
is analogous to the rat liver type I enzyme (28). Further investigations 
into the similarity of the type I deiodinases of humans and rats awaits the 
purification of these enzymes and the elucidation of their aminoacid 
sequences. 
Type II and III iodothyronine deiodinase 
The type II enzyme catalysis the ORD of iodothyronines, while the type 
III enzyme is a specific inner ring deiodinase. Thus, the type II enzyme 
converts T4 to T3 and rT3 to 3,3'-T2 • The type III enzyme deiodinates T4 to 
rT3 and T3 to 3,3'-T2 • The central nervous system (CNS) and placenta 
contain both type II and III deiodinases, while the type II enzyme is also 
found in pituitary gland and brown adipose tissue. In addition, skin 
contains type III enzyme activity (29). Besides PTU-insensitivity there are 
two other unique properties that distinguish the enzymatic reactions 
catalyzed by the type II deiodinase from type I ORD. These are 1) Michaelis 
constants of iodothyronines that are 200-400 fold lower for the type II 
deiodinase than those for the type I enzyme; and 2) (a characteristic 
shared with the type I and III enzymes) the reciprocal regulation of enzyme 
activities by thyroid hormone, i.e. the activity of the type I deiodinase 
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is decreased and that of the type II enzyme is increased in hypothyroidism 
while the reverse is the case in hyperthyroidism. The activity of the type 
III deiodinase changes in parallel with type I enzyme activity according to 
thyroid status. This latter feature enables tissues with type II deiodinase 
activity to maintain intracellular T3 levels within narrow limits despite 
changes in the availability of substrate. For example, in hypothyroidism, a 
decreased T4 supply is counteracted by an increase in type II and a 
decrease in type III tissue levels. This leads on the one hand to an 
increased T3 production and on the other hand to a diminished breakdown of 
this hormone (for a review, see ref. 20). 
Monodeiodination of T4 
In man monodeiodination of T4 accounts for -so% of its disposal (for 
reviews, see refs. 7,18,19). Approximately equal proportions of T4 are used 
for T3 and rT 3 generation. T4 , which is generally considered to have little 
or no bioactivity, is converted by ORO to the metabolically active hormone 
T3 • Reverse T3, which is devoid of thyromimetic activity, is produced by 
IRD of T4 • In this way 80% of plasma T3 and )95% of plasma rT3 are derived 
from peripheral deiodination of T4 , the rem~inder being secreted by the 
thyroid. 
Reverse T3 and T3 production 
Reverse T3 is produced by type I and III IRD of T4 • However, as the 
efficiency of ORD of rT3 by·the type I enzyme is )900-fold higher than that 
of the production of rT3 by type I IRO of T4 , it follows that rT3 once 
produced is rapidly further deiodinated by this enzyme (20). Therefore, rT 3 
produced by type I IRO of T4 is rapidly further degraded by the same enzyme 
and does not contribute to plasma rT3 • It is therefore logical to assume 
that plasma rT3 is predominantly derived from type III IRO of T4 in CNS 
(20) and skin (29), while it is cleared mainly by type I ORO in liver and 
kidney (30). The latter reaction is inhibited by PTU (chapter III) or lOP 
(6), explaining the increased rT3 plasma levels after treatment of rats and 
humans with these drugs (chapters VI & VII; ref. 31). 
T3 is produced by type I and II ORD of T4. In euthyroid rats 60-70% of 
peripheral T3 production is derived from the former pathway (32). At 
present the quantitative contribution of the individual human organs to the 
daily extrathyroidal T3 and rT 3 production is unknown. 
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Diiodothyronine (T2 ) production 
Three diiodothyronines are generated by the monodeiodination of T3 and 
rT 3 , i.e. 3',5'-Tz by IRD of rT 3 , 3,5-T2 by ORD of T3 and 3,3'-Tz by both 
ORD of rT 3 and IRD of T3• Little information is available about the 
possible occurence of the first two reactions. Estimates of the quanti-
tative role of monodeiodination in the disposal of the triiodothyronines 
vary considerably in the literature, depending on the estimates of the 
serum T2 concentrations (for a review, see ref. 18). Based on the means of 
the reported PR's of the T2's ,T3 and rT3 , Engler and Burger computed that 
83% of the daily PR of the triiodothyronines is converted by monodeio-
dination and 17% is disposed of by other mechanisms. Using PRs of these 
iodothyronines determined in their own laboratory, these authors calculated 
that monodeiodination accounted for 46-69% and other pathways for 31-54% of 
triiodothyronines disposal. However, since part of the 3,3'-T2 , and perhaps 
also of the other T2's, is rapidly further metabolized before release into 
the circulation, the calculation of their PR's represents a gross 
underestimation. 
A detailed analysis of the origin of plasma 3,3'-T2 in 
recently been undertaken by Engler et al (33). From the plasma 
of labeled 3,3'-T2 following injection of radioiodinated 
calculated that only 15% of total 3,3'-T2 is derived from ORD 
humans has 
appearance 
rT3 , they 
of plasma 
rT3• Therefore, most plasma 3,3'-T2 originates from the IRD of T3 , although 
only 25% of plasma T3 was calculated to undergo IRD to 3,3'-T2 (33). 
However, based on previous measurements of the MCR of 3,3'-T2 (34) the 
plasma production rate of 3,3'-T2 may amount to approximately 45 nmol/d per 
70 kg BW. If indeed 85% of plasma 3,3'-T2 is produced by IRD of T3 , then in 
combination with the known T3 PR , it may be deduced that as much as 75% of 
plasma T3 is metabolized to 3,3'-T2 • This would be in agreement with the 
study reported by Zucchelli et al (35), which indicated that the clearance 
of labeled T3 injected into humans was almost completely accounted for by 
generation of radioactive 3,3'-T2 in plasma. 
The T2's are further metabolized by stepwise deiodination to a 3- and 
3'-monoiodothyronine (T1 ) and finally thyronine (T0). 
Thyroid hormone changes in non-thyroidal illness 
Non-thyroidal illness (NTI), stress, caloric deprivation and several 
medications (like PTU, propranolol, dexamethasone and X-ray contrast 
agents) influence thyroid hormone economy at various levels, i.e. secre-
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tion, transport, metabolism and action at the cellular level (for reviews, 
see refs. 36-38). A continuum of changes in serum thyroid hormone levels 
relative to the severity of the NT! has been observed (39,40). Total T4 
levels correlate fairly well with clinical outcome; the highest mortality 
occuring in the patients with the lowest total T4 levels (39,40). Total T4 
levels may be increased (in mild disease) or decreased (in more severe 
disease), but serum T3 is consistently decreased and rT3 levels are 
elevated. This is due to decreased production with unaltered clearance of 
T3 and a decreased MCR with unaltered production of rT 3• 
The cause of these changes in iodothyronine serum levels is 
multifactorial (39). As T4 to T3 conversion and rT3 clearance 
catalyzed by type I ORD in the liver (and kidney), this enzyme 
probably 
are both 
has been 
implied as an important factor in the genesis of this syndrome. Recent 
reports, however, suggest that tissue 5'-deiodinase activity, at least in 
vitro, is not consistently decreased in experimental models of NTI, i.e. 
rats bearing the hypercalcemic Walker sarcoma 256 (41) and rats with an 
inflammation syndrome due to injection of turpentine oil (42). Another 
mechanism for the NTI-induced changes in thyroid hormone metabolism is 
through a diminished tissue uptake of iodothyronine substrates resulting 
from a) decreased intracellular ATP concentrations (e.g. shock, food 
deprivation); b) a circulating inhibitor, which interferes with the binding 
of thyroid hormone to serum transport proteins (42), but also blocks the 
entry of iodothyronines into hepatocytes (43,44; for a review, see ref. 
15). 
4: Free hormone gradients between intracellular compartments 
T3 regulates the expression of certain genes by binding to specific 
receptors in the cell nucleus of thyroid hormone responsive tissues. These 
specific T3-binding sites have been found in several tissues of rat and man 
(for reviews, see refs. 45-47). The mechanism by which T3 is transferred 
from the cytoplasm to the nucleus is not clear at the moment, but a recent 
report has suggested that a stereospecific, energy-dependent transport 
system is also involved in this translocation (43). 
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IC Scope of the present study 
As described in the preceding paragraph plasma T3 and rT3 are mainly 
derived from extrathyroidal deiodination of T4• The liver takes a central 
place in iodothyronine metabolism in that it is the prime site for the 
peripheral production of T3 and the clearance of rT3 • Besides, conjugation 
with glucuronic acid and sulfate are, at least in rat, important processes 
for the hepatic T3 metabolism. 
In chapter II a review of two of the most important conjugation 
reactions, glucuronidation (chapter IIA) and sulfation (chapter liB) will 
be given. In chapter IIC the role of conjugation in thyroid hormone 
metabolism and available evidence for the existence of an enterohepatic 
cycle will be discussed. In this chapter the results of our studies of rT3 
and T3 metabolism in isolated rat hepatocytes (chapters III and V) are 
integrated. At the same time the importance of sulfation for the metabolism 
of T3 in rats will be discussed (chapters V and VI). Finally, evidence 
will be presented that in man sulfation plays a role in T3 metabolism, 
although this conjugation reaction seems less important than in rats 
(chapter VII). 
The following chapters III-VII describe investigations related to the 
importance of glucuronidation and sulfation in the metabolism of T3 and 
rT3 • Metabolism of rT 3 is the subject of chapter III. In chapter IV the 
development and characterisation of a radioimmunoassay for T3S is 
described. With this RIA the metabolism of T3 was studied in isolated rat 
hepatocytes (chapter V), in intact rats (chapter VI) and in man (chapter 
VII). 
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CHAPTER II 
IIA Glucuronidation 
Introduction 
Glucuronidation represents one of the major conjugation reactions 
involved in the metabolic conversion of a variety of xenobiotics and 
endogenous compounds to polar water-soluble metabolites (48). The resulting 
glucuronides are frequently the end products of metabolism and are mainly 
excreted via the urine or the bile. Glucuronidation followed by excretion 
is one of the most important pathways of detoxication in man and most other 
mammals. 
The first part of this chapter will focus on glucuronidation in 
general and in the second part glucuronidation of thyroid hormones will be 
described. 
Regulation of glucuronidation 
Numerous drugs and/or their metabolites are converted in vivo into 
glucuronide conjugates. Compounds with functional groups such as OH, COOH, 
NH2 and SH may be glucuronidated directly (a so-called phase II reaction), 
whereas for relatively nonpolar substances introduction of polar groups by 
oxidation, reduction or hydrolysis (so-called phase I reactions) is a 
prerequisite for glucuronidation. UDP-glucuronyltransferases (EC 2.4.1.17) 
(UDPGT) are a family of enzymes which catalyze this conjugation reaction 
by transfer of glucuronic acid from UDP-glucuronic acid to the acceptor 
molecule (Fig. 1). The cosubstrate UDP-glucuronic acid is synthesized in 
vivo from UDP-glucose by the enzyme UDP-glucose dehydrogenase (EC. 
1.1.1.22). UDP-glucose is formed from glucose-1-P and UTP, which are 
abundant in tissues (48). Therefore, depletion of UDP-glucuronic acid will 
not easily occur under normal conditions. However, steady-state rates of 
glucuronidation requiring 10 umol/g liver/h UDP-glucuronic acid have been 
observed in perfused livers. Under these conditions the pool of UDP-
glucuronic acid must be resynthesized every 2 min in order to maintain 
intracellular concentrations above the Km of UDPGT. This suggests that 
cofactor supply can become rate limiting when large doses of substrate are 
presented to the enzyme (49). In a variety of hepatic preparations the 
concentration of UDP-glucuronic acid is 0.3-0.5 mM. The Km of UDPGT for 
UDP-glucuronic acid in native and detergent-activated microsomes from rat 
liver for substrates as 1-naphtol or p-nitrophenol varies between 0.16-0.39 
mM (49), once again strengthening the above mentioned fact that cofactor 
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Glycogen 
Glucose 
Glucokinase Phosphorylase 
G-6-P 
G-1-P UTP 
Pyrophosphorylase 
UDPG PPi NAD+ 
UDPG Dehydro-
genase 
UDPGA NADH R-OH 
Glucuronyl-
transferase 
UDP R-0-Giucuronide 
Figure 1 
Intracellular glucuronidation pathway. 
G-6-P =glucose 6-phosphate; G-1-P =glucose 1-phosphate; UDPG = uridine 
diphosphate glucose; UDPGA = uridine diphosphate glucuronic acid; 
NAD+ =nicotinamide adenine dinucleotide; Pi= inorganic phosphate; 
PPi = inorganic pyrophosphate; R-OH =substrate for glucuronidation. 
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Pi 
supply may become rate-limiting. 
UDPGT's are located in the endoplasmic reticulum of many organs, 
particularly the liver, small intestine and kidneys. Glucuronidation rates 
are not evenly distributed throughout the liver, but glucuronyltransferase 
activities in pericentral hepatocytes exceed those in the periportal region 
threefold (50,51). Recently the complete aminoacid sequence of 2 isoenzymes 
of rat (52,53) and human UDPGT (54) has been deduced from complementary DNA 
clones. 
Glucuronidation of drug metabolites has been studied primarily in 
isolated rat hepatocytes and in the perfused rat liver. From these studies 
substrate supply, among others, has been identified as one of the rate-con-
trolling factors (55). Frequently, there is competition between sulfotrans-
ferases and UDPGT's for the conjugation of common substrates. While the 
contribution of sulfation is usually more important at low substrate 
levels, glucuronidation is general the predominant conjugation step at high 
substrate availability. Glucuronidation, therefore, can be. characterized as 
a high-capacity, high-Km process, whereas sulfation is a low-capacity, low-
Km reaction. The higher capacity of glucuronidation is, among others, the 
result of more rapid production of the cofactor UDP-glucuronic acid than of 
the cofactor for the sulfation reaction (chapter IIB). 
Several drugs, like barbiturates, chloroquine and rifampicine, have 
been known to induce UDPGT activity, whereas conditions such as hyperthy-
roidism, starvation and experimental diabetes decrease enzyme activity 
(56). Galactosamine inhibits glucuronidation rates (chapter V) by trapping 
of UDP-glucose and inhibition of UDP-glucose pyrophos-phorylase (Fig. 2) 
(57). 
~-Glucuronidase activity 
Glucuronides are hydrolyzed by ~-glucuronidases (EC 3.2.1.21) present 
in all animal tissues examined, and also in plants and bacteria (48). The 
enzyme accepts all known glucuronides as substrate, with only a few 
exceptions. The enzyme is located in lysosomes, but unlike most lysosomal 
enzymes, also in microsomes. ~-Glucuronidase occurs in bile, intestinal 
juice, and salivary secretions. In the intestinal lumen it is very active, 
originating mainly from sloughed cells and in the lower reaches also from 
the microflora. As many glucuronides of endogenous and foreign compounds 
are excreted in the bile, the action of ~-glucuronidase in promoting the 
liberation and possible reabsorption of aglycons (enterohepatic circu-
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UTP 
PPi 
Figure 2 
Pyrophosphorylase 
G-1-P 
Galactose-1-Phos-
phate uridylyl-
transferase 
Mode of action of galactosamine (GAM). 
UDP-GAM 
1) Trapping of UDPG; and 2) Inhibition of pyrophosphorylase 
PPi =inorganic pyrophosphate; G-1-P =glucose 1-phosphate; 
UDPG = uridine diphosphate glucose; UDP·GAM = uridine diphosphate 
galactosamine 
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ATP 
ADP 
lation) is physiologically and pharmacologically important. 
Glucuronidation of iodothyronines 
Glucuronidation rates of different iodothyronines in liver vary 
considerably. r 4 and rT3 are (next to deiodination) mainly glucuronidated 
(chapter IIC), while 3,3'-T2 (chapter III, ref. 58) and 3'-Tl are mainly 
sulfated (Visser TJ, unpublished observations). r 3 is intermediate in this 
respect in that glucuronidation and sulfation rates are similar (chapter 
V). Isolation and characterization of the specific iodothyronine UDPGT(s) 
will be needed to further clarify this substrate specificity. 
Hydrolysis of r 4G and T3G by ~-glucuronidase-producing bacteria in the 
human and rat intestine plays an important role in the enterohepatic 
circulation for thyroid hormone (for a review, see chapter IIC). 
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liB Sulfation 
Introduction 
in the biotrans-Sulfate conjugation is another important pathway 
formation of drugs, xenobiotic compounds, hormones and 
compounds. Phenol sulfotransferase (PST) (E.C.2.8.2.1), 
other endogenous 
located in the 
from 3'-phospho-
molecule (59). 
cytosol, catalyzes the transfer of a sulfate group 
adenosine-5'-phosphosulfate (PAPS) to a phenolic acceptor 
Knowledge of the biochemistry, regulation and function of PST in human 
tissues has increased significantly during the past decade. Especially the 
discovery of PST activity in human blood platelets (60), an easily 
accessible tissue, served as an important stimulus for the study of the 
regulation of this enzyme. 
The first part of this chapter will be devoted to 
sulfation in general and in the second part sulfation of 
will be described. 
Regulation of sulfation 
regulation of 
iodothyronines 
Enzyme concentration, cofactor supply, substrate availability (see 
chapter IIA) and activity of sulfate-hydrolysing enzymes (sulfatases) 
influence the degree of sulfation in intact cells. There are at least 4 
forms of rat liver PST that elute sequentially from an ion-exchange column 
(61-63). Forms I and II in rat liver catalyze the sulfate 
simple phenols, while form IV has a higher affinity 
conjugation of 
for catechol 
substrates. Form III in rat liver has not been well characterized. 
All human tissues that have been studied in detail contain at least 2 
forms of PST (64). These 2 forms differ with respect to their physical 
properties, 
relatively 
nitrophenol 
substrate specificity, inhibitors and regulation. One form is 
thermolabile, resistant to inhibition of 2,6-dichloro-4-
(DCNP) and catalyzes the sulfate conjugation of micromolar 
concentrations of dopamine and other catecholamines. The other form is 
thermostabile, relatively sensitive to DCNP inhibition and catalyzes the 
sulfate conjugation of micromolar concentrations of "simple" phenols. 
Thermolabile and thermostable forms of PSTs display similar properties in 
different organs (65). 
Regulation of cofactor supply 
PAPS is the direct sulfate-donating co-substrate in the sulfation 
reaction. For a continuous PAPS supply, which is synthesized intra-
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cellularly (Fig. 3), inorganic sulfate (and ATP) should be available. The 
intracellular inorganic sulfate concentration is dependent on 1) extra-
cellular (serum) sulfate; 2) transport of sulfate across the cell membrane; 
3) availability of sulfate precursors (cysteine); and 4) the rate of 
sulfate production from precursors. 
L-cysteine is derived from catabolism of ingested proteins, but may 
also be generated from methionine via the cystathione pathway (59). 
Krijgsheld and Mulder calculated that the half-maximal concentration of 
inorganic sulfate in serum for sulfation in the intact animal was 0.4 mM 
(66). This suggests that under normal conditions serum sulfate 
concentrations (normal values in rat: 0.8-1.2 mM) are not rate-limiting. 
Quantitative data for humans, where the serum sulfate concentration is 0.2-
0.3 mM, are not available. Enteral sulfate absorption has been demonstrated 
to be rapid and almost complete, unless diarrhea occurs. The serum sulfate 
concentration may increase 2 to 3-fold following oral administration of 
inorganic sulfate (59). The serum sulfate concentration is primarily 
regulated by the kidneys. Below a certain threshold inorganic sulfate is 
completely reabsorbed from the primary urine in the proximal tubule. If the 
serum sulfate levels increase above this threshold sulfate is excreted. 
Sulfate transport across the liver cell membrane 
Sulfate transport is mediated by a carrier process (67). Uptake of 
inorganic sulfate across the plasma membrane is very rapid (600 umol/g 
liver/h) and greatly exceeds the maximal rates of sulfation (2-6 umol/g/h) 
(49). The concentration of the cofactor PAPS in rat liver is about 30 uM 
(68), which may be an important rate determinant for sulfation, since the 
apperent Km of sulfotransferases for PAPS ranges from 2-30 uM. Because of 
these low steady-state concentrations of PAPS, its turnover must be quite 
rapid during sulfation. In certain conditions the pool of PAPS in the liver 
was estimated to be resynthesized every 4 sec (49). 
Sulfatases 
Sulfatases are lysosomal and microsomal enzymes which catalyze the 
hydrolysis of sulfate esters (ROS03-) according to_ the following reaction, 
where ROH can be an alcohol, a phenol, a carbohydrate or a steroid: 
- + 2-ROS03 + 2H 20 ~ ROH + H3o + so4 
The best known of these enzymes are the aryl-sulfatases (EC 3.1.6.1), which 
catalyze the hydrolysis of a variety of arylsulfates and have been detected 
24 
Extracellular 
Sulfate 
r L-Cysteine 
Intracellular 
Sulfate 
ATP 
ATP-S ul phyrylase 
APS PPi 
ATP 
APS KINASE 
PAPS ADP 
R-OH 
Sulfo-
transferase 
PAP R-0-Sulfate 
Figure 3 
Intracellular sulfation pathway. 
APS =adenosine 5'-phosphate; PAPS= 3-phosphoadenosine 5'-phosphosulfate; 
PAP= adenosine 3',5'-diphosphate; PPI =inorganic pyrophosphate; 
R-OH =substrate for sulfation. 
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in most animal tissues, bacteria and plants. The physiological function of 
these enzymes is difficult to understand. As described above, arylsulfates 
are produced by mammals as part of their detoxication mechanism. Once 
formed, subsequent hydrolysis of arylsulfates by sulfatases would reexpose 
the organism to the toxicity of the phenolic compound (for a review, see 
ref. 69). Although much has to be learned about their physiological 
function, these enzymes in general have recently attracted considerable 
attention because deficiency of several sulfatases has been implied to play 
a role in the genesis of a number of human genetic disorders, e.g. Hunter's 
syndrome. This disease is probably caused by the accumulation of dermatan 
sulfate primarily in the brain and bones due to the absence of the enzyme 
iduronate sulfatase (69). 
Sublobular hepatic sulfotransferase and sulfatase distribution 
In contrast to the preferentially pericentral distribution of UDPGT in 
human liver, PST activity was found predominantly in the periportal region. 
Sulfatases were evenly distributed across the liver lobule (51). The 
physiological significance of the different distribution of these enzymes 
has not yet been elucidated. 
Sulfation of iodothyronines 
Sulfation of iodothyronines has long been considered a relatively 
minor pathway. Renewed interest in this subject arose when Otten and Visser 
showed that sulfation of 3,3'-T2 and T3 was not an independent pathway, but 
facilitated deiodination (see chapter IIC) (58,70). The in vitro 
characterisation of iodothyronine PST activity of rat liver was carried out 
by Sekura et al (71). These workers reported that 3'-Tl and 3,3'-T2 were 
good substrates for aryl sulfotransferase I and IV from rat liver. T4 was 
not sulfated by these enzymes and activity towards T3 was intermediate. 
This is in excellent agreement with the in vitro and in vivo findings 
reviewed in chapter IIC. The characterisation of human platelet iodothy-
ronine sulfotransferase (72) should further facilitate investigations into 
the role of sulfation in iodothyronine metabolism in man. 
Desulfation of T3S by microsomal preparations from rat liver, brain 
and kidney has recently been described by Kung et al (73). Rat liver was 5-
to 20-fold as active as kidney and brain. In isolated rat hepatocytes 
incubated with 7-54 uM T3S, 1-1.5%. of substrate was hydrolysed after 3 h. 
As at these high concentrations the preferential pathway of T3s metabo-
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lism, i.e. deiodination, is saturated (chapter V), the physiological role 
of the T3S sulfatase pathway remains to be elucidated. 
As is described in chapter IIC, sulfatases in the intestinal micro-
flora of rats and humans may play a role in the enterohepatic cycle of 
iodothyronines, although under normal conditions type I deiodination is the 
predominant route for the disposal of these conjugates. 
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IIC Conjugation and deiodination of iodothyronines 
Little is known about the possible role of iodothyronine conjugation 
in man. This paragraph, therefore, represents mainly an overview of data 
obtained in rats concerning the importance of conjugation and deiodination 
for thyroid hormone metabolism. In succession, the metabolism of T4 , rT 3 
and T3 will be discussed in isolated rat hepatocytes, in the perfused rat 
liver, in intact rats and finally in man. 
Thyroid hormone metabolism in vitro 
Sato and Robbins investigated the metabolism of outer- and inner ring 
labeled 125I-T in isolated rat hepatocytes (74). At low substrate 
' 4 
concentrations (<10 nM) I- was the main product (45% of added T4), which 
formation gradually diminished at increasing substrate concentrations. The 
ratio of 125I- released from inner ring-labeled 125I-T4 to that from outer 
ring-labeled 125 I-T4 was -1 at all substrate concentrations. Less than 10% 
of added T4 was conjugated to T4G and T4S in a ratio of -2:1. PTU nearly 
completely inhibited I production in these incubations with a resulting 
increase in T4-conjugates to 20% of added T4 without altering the relative 
distribution of T4G and T4S. These results suggest that IRD and ORD are 
equally important for the metabolism of T4 in these cells, much more so 
than glucuronidation and especially sulfation. 
Direct ORD is also the main degradative pathway of rT3 in isolated rat 125 -hepatocytes (chapter III). Normally, I is the main product in incu-
bations with rT3 , which production is effectively inhibited by PTU. In 
accordance with the observations of Sato (74), conjugation of rT3 to mainly 
rT 3G was only a minor pathway at substrate concentrations (10 nM. Reverse 
T3 metabolism is not sulfate-dependent as it is not influenced by either 
sulfate depletion or addition of SAM and DCNP. However, compared with 
control incubations the relative distribution of labeled products in the 
medium differed considerably under these latter conditions, i.e. I 
production declined while 3,3'-T2 accumulated. Normally, 3,3'-T2 is not 
observed due to rapid sulfation of this product and subsequent ORO of 3,3'-
T2s. This underscores the previously mentioned fact that the PR of 3,3'-T2 
is underestimated by analysis of plasma kinetics in humans (chapter lB). 
The metabolism of T3 is quite different from that of T4 and rT3 • In 
the studies described in chapter V, previous observations that sulfation of 
T3 facilitates deiodination (75) were confirmed. Normally, I and T3G are 
the main products after incubation of rat hepatocytes with physiological T3 
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concentrations (i.e. <1-10 nM in the presence of bovine serum albumin 
(BSA)). The metabolism of T3 is sulfate-dependent as it is lowered by 
sulfate depletion or addition of the sulfotransferase inhibitors DCNP and 
PCP. PTU, however, does not inhibit overall T3 metabolism despite a near 
complete reduction in I production, due to the reciprocal accumulation of 
T3s. With HPLC analysis, we also demonstrated the presence of 3,3'-T2s in 
these latter incubations. This, in combination with the accumulation of 
3,3'-T2 and 3,3'-T2G in sulfate-deplete incubations led us to hypothesize 
the presence of an enzyme which shares the characteristics of the type III 
deiodinase in that it catalyzes the IRD of T3 only at low substrate 
concentrations and is not inhibited by PTU. In chapter V evidence is 
provided that such an enzyme is indeed present in adult rat liver. 
So far, the type III enzyme has been demonstrated in rat brain (20), 
skin (29) and placenta (20), but never in adult liver. Fetal rat (76) and 
chicken liver (77), however, do contain a similar enzyme. Recent studies in 
our laboratory, however, show that type III-like deiodinase activity was 
not lower in old (300 g BW) than in young (100 g BW) rats (unpublished 
observations). 
The metabolism of thyroid hormones in the isolated perfused rat liver 
was investigated by Flock and Owen (78). T4 was metabolized less rapidly 
than rT 3 and T3• With all three substrates tested I- was always the main 
product in the perfusate. After Sh 12% of labeled T4 was excreted into the 
bile, mainly as T4G. Biliary excretion of metabolites of rT3 was even 
lower, while that of T3 metabolites, mainly as T3G, amounted to 40% in 5 h. 
Conjugation of rT3 is apparently a minor pathway and its metabolism 
depends primarily on ORD (chapters 1B & III). Therefore, in the following 
section we will only review in vivo data of conjugation and 
of T4 and T3• 
In vivo metabolism of T4 in rats 
deiodination 
The secretion of T4G in rat bile after injection of labeled T4 was 
already demonstrated in 1955 by Taurog et al (79) and confirmed by others 
(80,81). It appears that, retrospectively, T4S has also been detected by 
Flock et al in bile of thiouracil-treated rats, although this conjugate was 
not identified as such by these workers (80,82,83). This was due to the 
unrecognized property of T4s to be resistant to the sulfatase Mylase P used 
by Flock. 
Recently, Rutgers et al undertook a detailed analysis of the biliary 
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and fecal excretion of labeled T4 in rats (84). Eight h after an iv 
injection of [125 I]T4 biliary excretion of total radioactivity amounted to 
14%, mainly as T4G and smaller amounts of T3G and rT3G. In addition, a 
small but significant amount of T4s was present in bile of untreated rats, 
the excretion of which was was increased 5-fold after PTU-treatment. In the 
latter rats, clearance of T4 and production of T3G were decreased and 
excretion of rT3G increased. The PTU-induced >24-fold decrease in the 
T3G/rT3G ratio emphasizes the key role of the type I deiodinase for T3 
production and rT3 clearance. Although apparently sulfation is a signi-
ficant pathway of T4 metabolism in intact rats, its precise contribution 
remains to be assessed. 
Urinary and fecal radioactivity were also investigated in these rats. 
Within 15 h of 125 I-T administration to normal rats 20% and 13% of 4 
injected radioactivity was excreted in the urine and feces, respectively. 
The urinary radioactivity consisted almost entirely of 125I- and fecal 
radioactivity consisted largely of T4 , T3 and rT3 in a ratio of 70:18:2. 
The absence of conjugates in the feces confirms previous studies from de 
Herder et al that the intestinal flora contains bacterial strains capable 
of hydrolysing iodothyronine conjugates (see below). In the PTU-treated 
rats urinary I- excretion diminished and fecal radioactivity excretion 
increased (in a ratio of T4: T3: rT 3 of 68: 7: 6) as was also observed by 
others (85). 
In vivo metabolism of T3 in rats 
As shown in chapter V, glucuronidation and sulfation are important 
pathways in the metabolism of T3• T3G is excreted into the bile (78,80) and 
T3S is rapidly deiodinated by the type I deiodinase (chapter V). Biliary 
excretion of T3s is low, but not absent in normal rats, and is increased 
after treatment with butyl-4-hydroxy-3,5-diiodobenzoate (BHDB) (80,86) and 
PTU (87). 
Plasma T3G levels are virtually undetectable, which can be explained 
by the fact that 1) extrahepatic production of T3G is low (86); 2) hepatic 
clearance of T3G is very efficient (88, 89); and 3) T3G produced by the 
liver is preferentially transported to the bile rather than plasma (78). 
was identified for the first time by Roche et al in plasma and 
thyroidectomized rats after iv injection of [ 125I]T 3 (90-93). 
Normally, plasma T3S is low in the rat and increases after treatment of the 
animals with the type I deiodinase inhibitors PTU (chapter VI, refs. 89,94) 
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or lOP (31). Recent evidence explains why Roche et al were able to detect 
T3s in plasma of rats not treated with these inhibitors. In their studies 
they used thyroidectomized rats, a condition which leads to a decrease in 
type I enzyme activity (6) with a resultant inhibition of T3s metabolism. 
A detailed analysis of plasma T3S was recently undertaken by Rutgers 
et al (94). In rats iv injected 125r-T3S was cleared more rapidly than iv 
injected 125r-T3 despite increased binding to plasma proteins. Treatment of 
rats with PTU decreased plasma T3s clearance with 81%. Biliary T3s 
excretion was markedly enhanced in the latter situation (94). The very 
rapid plasma clearance of T3s may explain, at least in part, the low steady 
state plasma T3s levels in rats (chapter VI). The high capacity of 
isolatred rat hepatocytes for T3 sulfation suggests that the liver is a 
possible source for circulating T3s. However, significant extrahepatic T3S 
production has been observed in dogs (86). The rapid clearance of T3s by 
type I deiodinase containing tissues thus ensures low plasma levels of this 
conjugate in normal rats. 
by 
Biliary excretion of T3 and its metabolites was 
De Herder et al (89). Within 4 h after injection 
recently investigated 
of 125r-T to normal 3 
rats, 22.4% of the tracer was excreted in the bile with 74% of radio-
activity as T3G, 8% as T3S and <1% as 3,3'-T2s. In the same time period 
biliary excretion of rats treated with PTU amounted to 36% of the total 
dose due to a dramatic increase in T3S and 3,3'-T2S excretion, while T3G 
production was not affected. The enhanced excretion of 3,3'-T2s in the 
latter situation may be explained by extrahepatic T3 to 3,3'-T2 conversion 
(e.g. by PTU-insensitive type III IRD in the brain and skin), clearance of 
3,3'-T2 by the liver (30) and subsequent sulfation (58). The product 3,3'-
T2S is excreted in the bile, as of course ORD of 3,3'-T2s is also inhibited 
by PTU. Evidence for this route was obtained by Rutgers et al (94). 
However, as described above, the presence of a type III-like deiodinase in 
the liver also contributes to the excretion of 3,3'-T2s in bile. 
Metabolism of T4 and T3 in man 
T4G was demonstrated in human bile by Myant in 1956 (95), but less is 
known about the quantitative role of this pathway nor of the possible 
existence of a sulfation pathway for T4 in humans. The presence of T3G has 
been demonstrated in bile, and T3s in plasma and bile of a hypothyroid 
patient after iv injection of [125r]T3 (96). In chapter VII we used the RIA 
for T3s to study the importance of sulfation for the metabolism of T3 in 
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man. Normally, T3s levels are at or below the detection limit of this RIA 
(<0.1 nM). Serum T3s became detectable by treatment of volunteers with 
replacement doses of T3 • Treatment in addition with PTU and especially with 
lOP increased T3S levels 2.5 to 3-fold. However, the serum T3s;T3 ratio is 
at least 10-fold lower in humans than in rats, suggesting that sulfation is 
a less important route for T3 metabolism in humans than in rat. However, as 
described in chapter VII other possible explanations have not been excluded 
to elucidate these differences. 
Enterohepatic cycle 
As described above glucuronidated compounds are excreted in the urine 
as well as in the bile. Whereas renal excretion of a glucuronide invariably 
results in the irreversible elimination of the substance, this is not 
necessarily true for biliary excretion. After passage to the intestinal 
lumen glucuronides may become substrates for the ~-glucuronidases produced 
by bacterial strains of the microflora. The liberated compound may then be 
reabsorbed. 
Enterohepatic cycle for thyroid hormone 
The existence of an enterohepatic cycle for thyroid hormone was 
previously postulated but only recently made plausible for the rat (for a 
review, see ref. 97). Evidence for this enterohepatic cycle is based on the 
following: 1) strains of anaerobic bacteria, belonging to the major 
residents of the intestinal flora, have been isolated and identified, which 
are able to hydrolyse iodothyronine conjugates; 2) In normal 
administered 125r-T G 3 was recovered as plasma radioactive T3 
rats orally 
in similar 
quantities as that observed after oral administration of labeled T3 • In 
feces of these rats no T3G was detectable; and 3) In rats decontaminated 
with antibiotics little hydrolysis of orally administered T3G was observed 
and T3G was excreted unaltered into the feces. In these rats resorption of 
T3 from administered T3G was strongly diminished, although plasma T3 after 
oral T3 administration was actually enhanced in decontaminated rats. 
Quantitative data are needed to fully establish the role of the entero-
hepatic cycle for T3 and T4• 
Sulfatase-producing strains have also been identified in the intes-
tinal micoflora of rats and humans (97). However, since biliary excretion 
of iodothyronine sulfates is normally low, intestinal hydrolysis of these 
conjugates contributes little to the pool of free iodothyronines available 
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for resorption. In pathological situations, however, e.g. as in hypothy-
roidism, this pathway may increase in significance due to the rise in 
biliary T3S excretion (90-93). 
Apart from the above-mentioned identification of iodothyronine glucu-
ronidase-producing microflora, only indirect data on the existence of an 
enterohepatic cycle for thyroid hormone in humans are available. Biliary 
clearance of T4 amounts to about one third of total body clearance, of 
which perhaps 30-50% is reabsorbed (98). Pancreatic disease, the ingestion 
of soy flour or cholestyramine disrupt this cycle and has been shown to 
increase T4 turnover appreciably (98). Development of techniques for the 
biosynthetic preparation of T3G and T4G (99) will undoubtedly stimulate 
further research into this area. 
Quantitative data for the glucuronidation pathway 
The importance of the glucuronidation pathway for thyroid hormone 
metabolism in vivo was studied in the homozygous Gunn rat, a species which 
carries an hereditary defect in hepatic UDPGT activity. This defect is 
expressed as congenital hyperbilirubinaemia. Various changes in thyroid 
hormonal status have been described in this strain. Serum T4 is elevated 
100-102) and serum T3 is decreased (101,103) or equal (100) compared to 
normal Wistar or heterozygous (i.e. phenotypically normal) Gunn rats. 
Biliary clearance of plasma 125I-T4 was decreased 3-fold, while excretion 
of iv injected labeled T4G was not affected in the Gunn rat. This suggests 
that indeed deficiency of thyroid hormone UDPGT(s) is the cause of the 
reduced glucuronide excretion (104). 
Flock and coworkers undertook a detailed analysis of the biliary and 
renal . . 131 131 clearance of iv 1nJected I-T4 or I-T3 in Gunn and normal rats 
(80). After administration of these iodothyronines, biliary excretion of 
T4G or T3G was 4 and 3-fold lower, respectively, in the Gunn rats, while 
renal excretion of T4 and T3 metabolites was increased 20% and 40%, 
respectively. Taken together, these findings suggest that due to diminished 
hepatic glucuronidation, renal excretion of T4 and T3 metabolites is 
increased. In order to compensate for this (irreversible) renal loss and to 
maintain near normal serum T3 levels, thyroid T4 production is stimulated 
by increased TSH levels and serum T4 is elevated. Diminished hepatic T3 
production, which might be due to the high endogenous levels of uncon-
jugated bilirubin, may play an additional pathophysiological role in these 
rats (103). 
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In patients with minor abnormalities of glucuronide conjugation, such 
as Gilbert's disease, there is a reduction of conjugated T4 in the bile 
without evident repercussions on the thyroid function (105). No data are 
available concerning thyroid hormone metabolism in persons suffering from 
the Crigler-Najjar syndrome, the human equivalent of the homozygous Gunn 
rat. 
Summary of the hepatic metabolism of iodothyronines in rats 
The data in the preceding paragraphs on the metabolism of iodothy-
ronines in rat liver are summarized in Fig. 4. Iodide, released in the 
various deiodinative steps, is released into the circulation (not shown). 
An active transport system is involved in the passage of thyroid hormones 
from the plasma compartment across the liver cell membrane. T4 and rT 3 
share the same pathway, which differs from that of T3• Intracellularly, T4 
is converted by type I deiodination to either T3 or rT 3, or glucuronidated 
to T4G, which product is excreted into the bile. Since little is known of 
the precise role of sulfation in the metabolism of T4 , this pathway is 
omitted here. 
The major part of intrahepatically formed T3 is released into the 
circulation. The remainder, in combination with T3 taken up from the 
plasma, is subjected to three pathways. The first pathway is glucu-
ronidation, and the product T3G is excreted into the bile. Secondly, T3 is 
sulfated to T3S, which is mainly further metabolized by type I IRD to 3,3'-
T2S, but also partly excreted into the bile. The third pathway comprises 
direct IRD by a type III-like deiodinase to 3,3'-T2• 
Intrahepatic rT 3, which is formed by IRD of T4 or cleared from the 
plasma, is rapidly degraded by type I ORD to 3,3'-T2• Glucuronidation and 
sulfation of rT 3 are relatively minor pathways and are omitted. 
As described above 3,3'-T2 is formed intracellularly via two pathways, 
i.e. by IRD of T3 and ORO of rT3 • It is sulfated to 3,3'-T2s, which product 
is further metabolized by type I ORO. 
The biliary excretion products T4G, T3G and T3s are hydrolyzed by ~­
glucuronidase and sulfatase producing anaerobic strains in the intestinal 
microflora. The liberated hormones may then be part1y reabsorbed, partly 
preserving these hormones for the body. 
34 
~Re~a~b~s~or=p~tio~n-----+~ T3 Plasma 
Gut Bile Liver 
Figure 4 
Metabolism of iodothyronines. 
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Metabolism of Reverse Triiodothyronine by Isolated Rat Hepatocytes 
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Abstract 
Reverse triiodothyronine (rT3) is metabolized predominantly by 
outer ring deiodination to 3,3' -diiodothyronine (3,3'-T 2) in the 
liver. Metabolism ofrT3 and 3,3'-T2 by isolated rat hepatocytes 
was analyzed by Sephadex LH-20 chromatography, high per-
formance liquid chromatography, and radioimmunoassay, with 
closely agreeing results. Deiodinase activity was inhibited with 
propylthiouracil (PTU) and sulfotransferase activity by sulfate 
depletion or addition of salicylamide or dichloronitrophenol. 
Normally, little 3,3'-T, production from rT3 was observed, and 
125r was the main product of both 3,[3'-125I]T2 and [3',5'-1251]rT3. 
PTU inhibited rT3 metabolism but did not affect 3,3'-T2 clearance 
as explained by accumulation of 3,3'-T2 sulfate. Inhibition of 
sulfation did not affect rT 3 clearance but 3,3'-T 2 metabolism was 
greatly diminished. The decrease in r formation from rT 3 was 
compensated by an increased recovery of 3,3'-T, up to 70% of 
rT3 metabolized. In conclusion, significant production of 3,3'-T, 
from rT3 by rat hepatocytes is only observed iffurther sulfation 
is inhibited. 
Introduction 
In euthyroid subjects the main secretory product of the thyroid 
is thyroxine (T4). 1 Some 3,3',5-triiodothyronine (T3) is secreted 
as well, but thyroidal production of 3,3',5'-triiodothyronine (rT3) 
is negligible. More than 97.5% of plasma rT, and - 80% of 
plasma T3 originate from peripheral deiodination ofT. (1). As 
thyroid hormone bioactivity is exerted largely through T,, it is 
important to understand the regulatory mechanisms of iodo-
thyronine metabolism. 
In rats, three types of iodothyronine-deiodinating enzymes 
have been identified (2). Most likely, the type I deiodinase of 
liver catalyzes both inner ring deiodination (IRD) and outer ring 
deiodination (ORD) of iodothyronines (2). A similar enzyme is 
present in kidney and thyroid (2). Type II deiodinase has been 
localized in brain, pituitary, brown adipose tissue, and placenta. 
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It deiodinates only the outer ring of substrates such as T4 and 
rT3 (2-4). Type III enzyme is found in brain, placenta, and skin, 
and it is a specific inner ring deiodinase (2, 5). Type I deiodinase 
is inhibited by 6-propylthiouracil (PTU), while types II and III 
are PTU insensitive (2). Thus, there may be two sources of 
plasma rT3 , namely type I or type III IRD ofT4 • There are also 
two pathways of rT 3 deiodination, i.e., type I and type II ORD 
to 3,3'-diiodotbyronine (3,3'-T2). 
Considering the high rate of rT 3 ORD by the type I deiodinase 
(2), it is likely that little rT3 produced from T, in the liver is 
released into the circulation. It would seem, therefore, that most 
plasma rT3 is derived from type III deiodination ofT4 , while it 
is cleared mainly by the liver. This hypothesis is substantiated 
by measurements of arterio-venous gradients of rT3 across the 
liver in patients with mild liver failure.' 
In vivo studies in normal rats have demonstrated that the 
type I deiodinase is the predominant site for the peripheral pro-
duction ofT3 (6). Opposite variation in plasma T3 and rT3 con-
centrations has been observed in a number of clinical situations, 
in which changes are due to a decrease in both the production 
of plasma T3 and the clearance of plasma rT3 (7). To investigate 
the potential importance of changes in type I deiodinase activity 
for the regulation of thyroid hormone metabolism, we initiated 
studies of the deiodination of rT 3 by isolated rat hepatocytes. 
Initial results, using outer ring "'I-labeled rT3 , showed that 
radioiodide was the main product, but little production of 3,3'-
T 2 from unlabeled rT 3 could be detected by radioimmunoassay 
(RIA) (8). Further investigations have demonstrated rapid me-
tabolism of added 3,3'-T2 in rat hepatocytes by sulfation and 
subsequent ORD of the 3,3'-T2 sulfate (3,3'-T2S) formed (9). 
3,3'-T2S is a far better substrate for the type I deiodinase than 
3,3'-T, itself(9). This may be the reason for our failure to detect 
significant production of 3,3'-T 2 from rT 3 by liver cells. If so, 
the yield of 3,3'-T, produced by this pathway should increase if 
its further sulfation is inhibited. This hypothesis was tested in 
the present study using rat hepatocytes with diminished phenol 
sulfotransferase activity. 
Methods 
The materials used are essentially the same as described previously ( 10). 
Canier-free 3,[3'.123I]T2 and [3',5'-125I]rT 3 were prepared in our laboratory 
by radioiodination of 3-iodothyronine or of 3,3'-T2 (Henning GmbH, 
Berlin, Federal Republic of Germany) using the chloramine T method 
(II, 12) and purified by Sephadex LH-20 chromatography. Salicylamide 
(SAM) and 2,6-dichloro-4-nitrophenol (DCNP) were purchased from 
Riedel-de Haen AG, Hannover, Federal Republic of Germany. All other 
chemicals were of the highest quality commercially available. 
Hepatocytes. Rat hepatocytes were prepared by collagenase perfusion 
(10). Monolayers ofhepatocytes were obtained by seeding 106 cells in 2 
ml culture medium (10) into uncoated 3.5-cm wells of plastic 6-well 
dishes (Nunc, Roskilde, Denmark). The plates were kept for 4 hat 37°C 
2. Bauer, A. G. C., J. H. P. Wilson, S. W. J. Lamberts, R. Docter, G. 
Hennemann, and T. J. V.isser, manuscript submitted for publication. 
in a culture stove under atmospheric conditions. Before each experiment. 
cell viability was tested by trypan blue exclusion and exceeded 85%. 
Nonviable cells were removed by aspin~:tion of the medium. 
General -incubation procedures. Incubations were done for 60 min 
in 2 rnl of Dulbecco's balanced salt solution which contained I mM 
MgSO,, 0.1% bovine serum albumin (BSA), 2 mM glutamine, and I 
mM vitamin C. Experiments were carried out in triplicate under at-
mospheric conditions at 37oc. The dishes were placed on a slightly angled, 
slowly rotating plate. Substrate levels.were 10oM rT3 or 3,3'-T2 with or 
without 0.1 p.Ci [12!1JrT3 or [12.si]3,3'-T2 , respectively. Sulfation was in-
hibited with 100 pM SAM or 100 pM DCNP and deiodination was 
inhibited with 10 ,.M PTU. 
Su/fa.Je depletion. Hepatocytes were preincubated for 30 min at 37°C 
in Dulbecco's solution which contained l mM MgCh, 2 mM glutamine, 
and I mM vitamin C with or without 100 .u.M SAM. Incubations were 
done as described above in medium without Soi-. Controls were prein-
cubated and incubated in medium containing MgSO ... 
Analysis of incubation medium. Incubation media with unlabeled 
rTJ and ~.3'-T1 were analyzed before and after hydrolysis with specific 
RIAs (II, 12). Hydrolysis of eventual S conjugates was achieved by ad-
dition of 250 ,.! I N HCI to 100-1'1 samples and treatment for I h at 
8o•c ( 13). Thereafter, 300 1<l I N NaOH was added. The nonhydrolyzed 
samples were treated the same way but without heating. RIA was done 
in duplicate on 50-.u.l aliquots of the mixtures. 
Incubation media with labeled rT, and 3,3'-T2 were assayed by column 
chromatography. An equal volume of I N HCI was added to 500-1'1 
samp!es and the mixtures were applied to small (bed volume 0.75 ml) 
Sephadex LH-20 columns equilibrated in 0.1 N HCl. Stepwise elution 
was done py successive application of 2 X I ml 0.1 N HCI, 6 X I ml 
H20, 6 X I ml 0.1 N NaOH-ethanol (9: I, vol/vol), and 3 X I ml 0.1 N 
NaOH-ethanol (1:1, vol/vol). 
High performance liquid chromatography (HPLC). Analysis of rT, 
and 3,3'-T1 conjugates and native iodothyronines was accomplish~d by 
reverse-phase HPLC. For this we used a 10 x 0.3-cm CP Spher C 18 
column (Chrompack, Middelburg, The Netherlands), a model 6000 A 
solvent delivery system and a model440 fixed wavelength detector (Wa-
ters Assoc., Millipore Corp., Milford, MA). Aow was 0.6 ml/min and 
absorbance. was measured at 254 n~. For separation of conjugates a 
20:80 vol/vol mixture of acetonitrile and 0.02 M ammonium acetate 
(pH 4) was used, and for separation ofrT, and 3,3'-T, a 55:4S vol/vol 
mixture Or methanol and 0.02 M ammonium acetate (pH 4) was em-
ployed. · 
To obtain the conjugates for HPLC analysis, the water fractions of 
the LH-20 chromatography were pooled, acidified, and rechromato-
graphed. The columns were washed with 2 ml 0.1 N HCI, 0.5 ml H20, 
and 0.5 ml 0.1 M ammonia in ethanol. Conjugates were then collected 
in a subsequent fraction of 1 ml 0.1 M ammonia in ethanol. The solvent 
was evaporated at 50°C under a stream of N1 • To obtain the iodothy-
ronine fraction, medium was processed as above and LH-20 chroma-
tography was modified as follows. After the H20 fractions, columns were 
washed with 0.5 ml 0.1 M ammonia-ethanol (I: I vol/vol), and iodothy-
ronines were collected in 1 ml 0.1 M ammonia in ethanol. The solvent 
was evaporated as above. · 
Enzymatic analysis ofrT1 and 3,3'-T1 conjugaJes. Another method 
by which the conjugates were identified was by enzymatic hydrolysis 
with glucuronidase and sulfatase in the presence or absence of saccharic 
acid lactone ( 10). Hydrolysis was quantified by LH-20 chromatography 
and the liberated iodothyronines were identified by HPLC. 
Analysis of cell content. CeU-asso.;;iated radioactivity was extracted 
after removing the medium by immediate addition of I ml 0.1 N NaOH. 
After centrifugation, 0.5 ml of superDatant was chromatographed on 
LH-20 as described above for Tnedium. 
¥iscellaneous. The influence of SAM (I 0-1000 ,.M) and DCNP (I-
I 00 phl) on the type I deiodinase was tested by measurement of their 
effects On the release of 12.sl- frOm 10 nM [ml]rT3 in incub~tions with 
rat liver mii:rosomes (14) in 0.1 M phosphate buffer (pH 7.2), 2 mM 
EDT A, and 5 mM dithiothreitol (OTT). The free fractions of rT, and 
3,3'-T1 in incubation medium were determined by equilibrium dialysis. 
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Cellular A TP content was measured according to the method described 
by Jaworek et al. (I 5). 
Data analysis. In each experiment, r production was corrected for 
the amount ofl- recovered from control incubations, while the 3,3'-T2 
production from rT 3 was corrected for the slight contamination of the 
3,3'-T1 fraction with rT3 . Production of unlabeled 3,3'-T2 was corrected 
for rT3 crossreactivi~y (0.03%) in the 3,3'-T2 RlA. Statistical analysis was 
done by Student's t test for unpaired data. 
Results 
Sephadex LH-20 chromatography. The Sephadex LH-20 chro-
matographic pattern of!-, 3,3'-T2S, 3,3'-T2 , and rT3 is depicted 
in Fig. I. More than 97% of '"r activity was found in fractions 
1-4. Recovery of 3,3'-T2S, eluting in the H20 fractions, was 
> 97 .5%. All other 3,3'-T 2 and rT, conjugates eluted also in frac-
tions 5-9. Approximately 97% of3,3'-T, was found in fractions 
10-15, while fractions 16-18 contained at least 95% ofrT3 . Thus, 
there was little overlap of fractions containing the different me-
tabolites, although some 4% ofrT, eluted in the 3,3'-T2 fractions. 
This was not due to contamination ofrT3 tracer with 3,3'-T2 as 
checked by HPLC. 
Time dependence of 3,3'-T2 and rT3 metabolism. Fig. 2 shows 
the LH-20 analysis of the main products in the medium gen-
erated from 3,3'-T2 and rT, as a function of time of incubation 
in the absence or presence of SAM. In 3,3'-T, incubations r 
f?Z//?2 
' 9 15 18 3 ' 15 18 
3,3'-T2 
C:J~~?/.2/.2/.2/.2/~IIIII1~5I;ill¥'\~. ~' "·15 18 
fraction number 
Figure I. Sephadex LH-20 chromatography of iodide, 3,3'-T2S, 3,3'-
T2, a~d rT3 • Each mHabeled compound was applied separately in I 
ml 0.5 N HCI to a small Sephadex LH-20 column with a bed volume 
of0.75 ml which was equilibrated in 0.1 N HCI. Subsequently, col-
umns were eluted using 2 ml 0.1 N HCI (D), 6 ml H20 (B), 6 ml 
ethanol-0.1 N NaOH (I :9 vol/vol) (•), and finally 3 ml etbanol-0.1 N 
NaOH (1:1 vol/vol) (o). Each 1-ml fraction was counted for radioac-
tivity. 
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Figure 2. Time dependence of 3,3'-T 2 
and rT3 metabolism. 10 nM 3,3'-T2 or 
rT3 with 0.1 ~Ci ['"I]3,3'-T2 or ["'l]rT3 
were incubated with 106 hepatocytes in 
2 ml S-supplemented Dulbecco's me-
dium without (dashed line) or with 
(solid line) 100 ~M SAM. After I 5, 30, 
60, 90, and 120 min incubation was 
stopped by removing the medium that 
was analyzed by Sephadex LH-20 chro-
matography. Production of 1-.from 3,3r-
T, (left) and of!" and 3.3'-T2 from rT3 
(right) are expressed as percentage of to-
tal radioactivity in medium. Note that 
no correction was made for the fact ~hat 
the specific radioactivity of the r and 
3,3'-T2 produced is only half of1hat of 
added rT 3 • Data are laken from a repre-
sentative experiment with results that 
were reproduced on at least two other 
occasions. Time (min) 
was the main metabplite, the amount of which was inversely 
correlated with that of remaining 3,3'-T2. The semi-logarithmic 
plot of the latter against time demonstrated that the disappear-
ance of 3,3'-T 2 followed first order kinetics with a rate constant 
of0.031 min-1. Addition of SAM strongly inhibited 1- formation. 
In the presence of thiS inhibitor 3,3'-T2 clearance remained a 
first order process with a rate constant of0.007 min-1• 
In rT3 incubatio~s r- ~as also the main metabolite found, 
while 3,3'-T, formation was undetectable under control condi-
tions. Addition of'SAM resulted in the inhibition of r release 
30 min 60 min 120 min 
1 
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'T3 
~- J ~ •T3 . il: ____A_ ~ 
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Figure 3. HPLC analysis of iodothyronines recovered from incuPa-
tions ofrT3 with hepatocytes. Parallel samples of the same incubations 
described in Fig. 2 were chromatograpbed on Sephadex LH-20 modi-
fied such that 3,3'-T2 and rT3 were eluted collectively with 0.1 M am-
monia in ethanol (see Methods). Solvent was evaporated, the residue 
taken up in a 55:45 vol/vol mixture of methanol and 0.02 M ammo-
nium acetate (pJ-1 4) and subjected to HPLC using the same solvent at 
a flow of 0.6 ml/min. FraCtions of 0.3 ml were collected and counted 
for radioactivity. The elution position of 3,3'-T2 a'nct rT3 was deter-
mined' 9Y monitoring absOrbance at 254 nm after application of pure 
synthetic substances. 
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Time (min) 
with a reciprocal accumulation of3,3'-T2. Clearance ofrT3 was 
also a first order process, characterized by a rate constant of 
0.014 min-1, which was not influenced by SAM. The identity 
of the 3,3'-T2 produced was further tested by HPLC analysis 
(Fig. 3). Little or no 3,3'-T2 formation could be detected in control 
incubations by HPLC, while in the presence of SAM 3,3'-T, 
accumulation was substantial. Relative to the quantity of rT3 
remaining after 30, 60, and 120 min, 3,3'-T2 accumulation 
arj10unted to II, 33, and 80%, respectively. 
Dose-dependent effects of SAM (Fig. 4). As previously shown 
(l 0), addition of 10 ~M PTU greatly inhibited "'r production 
in incubations with 3,3'-T2, but did not affect the clearance of 
this compound. Most raqioactivity recovered from the medium 
now eluted in the water fractions of the LH-20 chromatography, 
which ;,as shown to con;ist mainly of3,3'-T2S (see below). Ad-
dition of PTU also led to an increase in cell-associated radio-
activity, from < 5% in the absence to 22% in the presence of 
the inhibitor. This radioactivity was predominantly in the form 
of conjugates and presum~bly represented the accumulation of 
3,3'-T2S within the cells. Addition of 10-1,000 ~M SAM resulted 
in a progressive decrease in the clearance of 3,3'-T 2 independent 
of PTIJ. This was indicated by the parallel decrease of r for-
mation without PTU and of 3,3'-T 2S accumulation with PTU. 
With the SAM-induced inhibition of 3,3'-T2 clearance there was 
an increase in cell-associated 3,3'-T2, irrespective ofPTU. 
In contrast to 3,3'-T2, rT3 metabolism was almost completely 
blocked by PTU but was not affected by even 1,000 !LM SAM. 
In the absence of SAM, little 3,3'-T2 production was observed 
in the medium once again, and no 3,3'-T2 was detectable in the 
cells. With increasing SAM concentrations, 3,3'-T2 accumulation 
in the medium was accompanied by a rise in cellular radioactivity 
from 5 to 12%, part of which was in the form of 3,3'-T2. Based 
on the dose-effect relationship for SAM on the metabolism of 
both 3,3'-T2 and rT3 , 100 ~M was chosen as the near-maximal 
sulfotransferase in!Jibitory concentration. 
3,3'-T, and rT, metabolism; correlation between LH-20 and 
RIA. Table I shows the effects of 100 I'M SAM or DCNP or 10 
!LM PTU on 3,3'-T2 and rT3 metabolism as measured by LH-
20 chromatography or by RIA. To compare the results obtained 
by these two methods it has to be taken into account that (a) 
LH-20 data are not corrected for cell-associated radioactivity 
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(Fig. 4), and (b) the specific radioactivity of the 3,3'-T2 produced 
is half that of added rT 3 • With this in mind there exists a good 
correlation between the two methods. 
After incubation for 60 min with [125!]3,3'-T 2 , 80% of radio-
activity in the medium was recovered as "'r. SAM, DCNP, 
and PTU reduced r formation by 64, 57, and 95%, and 3,3'-T2 
clearance by 59, 54, and 10%, respectively. If remaining 3,3'-T2 
tO 1001,000 
SAM 
Figure 4. Dose-effect relationship of SAM on the me-
tabolism of 3,3'-T2 and rT3 • Hepatocytes were incu-
bated with !0 nM ['"I]3,3'-T2 or ['"I]rT3 inS-supple-
mented Dulbecco·s medium. SAM was added at con-
centrations of !0, !00, and 1,000 JLM, and PTU at I 0 
,u.M. After 60 min medium was removed and cells 
were extracted immediately by adding I ml 0.1 N 
NaOH. Medium samples of0.5 ml or supernatant ob-
tained after centrifugation of the cellular extracts were 
acidified with 0.5 ml 1 N HC! and chromatographed 
on LH-20. Products in medium are given as percent-
age of radioactivity in medium, while products in cells 
are expressed as percentage of total radioactivity 
added.·Completion of medium radioactivity to 100% 
represents the proportion of unaltered substrate. No 
correction is made for difference in specific radioactiv-
ity between suQstrate and products in rTJ incubations. 
Typical results are shown from one out of three 
closely agreeing experiments. (D) r; (a) conjugates; (•) 
3,3'-T,; and (El) rT,. 
in medium was measured by RIA, inhibition of the clearance 
of 3,3'-T2 by these treatments was 52, 62, and 1%, respectively. 
The 3,3'-T2S accumulating in the presence ofPTU as observed 
in the incubations with [1251]3,3'-T2 was largely recovered as im-
munoreactive 3,3'-T2 after hydrolysis of medium from parallel 
incubations with unlabeled 3,3'-T2 • No 3,3'-T2 was liberated by 
hydrolysis in all other experimental conditions. 
Table !. Comparison of RIA and Sephadex LH-20 Analyses of the Effects of SAM. 
DCNP, and PTU on the Metabolism of 3.3'-T2 and rT, by Rat Hepatocytes 
Products in medium 
LH-20 RIA 
Condition ,. Conjugates 3.3'-Tz <T, 3,3'-Tl(-) 3,3'-T2(+) <T, 
3,3'-T2 30 min 
Control 48.2±4.0 3.9±0.6 44.5±4.4 44.9±2.9 48.8±2.5 
SAM 11.5±1.9* 2.3±0.2' 83.5±1.9* 67.7±2.2' 68.8±2.2* 
DCNP 17.4±2.1"' 2.2±0.31 77.5±2.3* 63.8±0.91 64.6±3.31 
PTU 4 4.7±1.3' 26.3±5.3* 65.6±6.511 45.8±2.4 63.4.t1.3' 
3,3'-T2 60 min 
Control 10 79.0±2.4 5.7±1.2 12.9±1.6 12.7±1.0 16.1±1.3 
SAM 9 28.3±3.3' 4.6±0.8 63.4±3.5' 54.9±3.3' 55.9±4.2' 
DCNP 33.7±4.9* 5.6±0.9 58.5±5.8' 45.9±8.5' 48.5±5.8' 
PTU 4.4±1.3* 68.9±2.4* 21.8±3.211 13.7±2.6 52.8±3.8' 
rT3 60 min 
Control 11 47.7±3.9 1.4±0.2 0.6±0.1 43.9±3.3 1.8±0.4 1.9±0.6 53.8±3.9 
SAM 10 34.5±3.2" 1.8±0.3 14.5±0.5' 42.7±2.9 24.7±2.5' 24.9±2.3* 53.9±4.6 
DCNP 44.5±4.3 2.2±0.4 16.9±1.9' 33.1±6.0 24.6±3.1' 25.9±1.9* 30.9±6.7" 
PTU 1.8±0.6* 5.3±0.7* -0.4±0.3' 87.0±2.0' 2.1±0.8 1.7±0.9 84.8±3.01 
10 nM labeled or unlabeled 3,3'-T2 or rT3 were incubated for 30 or 60 min at 37°C with 106 rat hepatocytes in 2 ml $-supplemented Dulbecco's 
medium with or without 100 JLM SAM or DCNP or 10 JLM PTU. Radioactive products were separated on Sephadex LH-20 and unlabeled 3,3'-T2 , 
and rT3 were measured by RIA before(-) and after(+) hydrolysis as described in Methods. Since acid treatment did not change rT3 1evels, mean 
values of these two measurements are given. RIA values are expressed as percentage ofiodothyronines measured after incubations without cells. 
The results are given as the mean±SE of the number of observations indicated. Statistical analysis of differences between experimental and control 
conditions was done by Student's unpaired t test: • P < 0.00 I. * P < 0.005. 1 P < 0.0 I. 11 P < 0.025. 1 P < 0.05. 
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After incubation for 60 min with [125I]rT 3 , 48% of radio-
activity in the medium was accounted for by "'I-, while the 
sum of the conjugate and 3,3'-T2 fractions was only 2%. Again, 
rT 3 disappearance was not changed by SAM, but I- formation 
was decreased by 13.2% (- 2.6 nM r) while 3,3'-T2 accumu-
lation was increased by 13.9% (- 2.8 nM 3,3'-T2). These results 
correspond with an increase of immunoassayable 3,3'-T2 by 
23.0% (- 2.3 nM 3,3'-T2). On the basis of the results obtained 
by LH-20 chromatography and by RIA, it was calculated that 
with SAM 51 and 54%, respectively, of the amount of rT3 cleared 
was recovered as medium 3,3'-T2. Similar results were obtained 
with DCNP, except that the acceleration of rT 3 metabolism seen 
with this inhibitor was different. PTU inhibited rT 3 disappear-
ance from the medium by 77 and 67% as estimated by LH-20 
and RIA, respectively. 
S dependence of 3,3'-T2 and rT3 metabolism. As discussed 
above, 3,3'-T2 was metabolized predominantly by successive 
sulfation and ORO. The small amount of conjugates found after 
incubation of3,3'-T2 inS-containing medium (Fig. 5) was shown 
by HPLC to consist of similar proportions of 3,3'-T 2 glucuronide 
(3,3'-T,G) and 3,3'-T2S (Fig. 6). In the presence ofPTU, r for-
mation was again strongly suppressed (Fig. 5), while radioactivity 
in the conjugate fraction almost entirely eluted in the position 
of 3,3'-T2S with no change in the absolute amount of 3,3'-T2G 
recovered (Fig. 6). If cells were preincubated with S-free medium 
and incubated with 3,3'-T2 in this medium plus PTU, conju-
gation and clearance were diminished by 55%. A further reduc-
tion in 3,3'-T2 conjugation to 30% was observed if SAM was 
added to the preincubation, while the experiment was otherwise 
conducted under the same S-free conditions (Fig. 5). HPLC 
analysis of the conjugate fraction demonstrated that 3,3'-T2S 
formation was virtually blocked, and that now most radioactivity 
eluted in the position of 3,3'-T2G (Fig. 6). In the absence of 
PTU, 1- release was decreased from 74 to 38% by omission of 
S from the medium, and further to 17% after addition of SAM 
to the preincubation. However, conjugates represented an in-
creasing proportion of the radioactivity in the medium, i.e., 7, 
I 0, and 15%, respectively (Fig. 5). HPLC revealed that this in-
crease was totally accounted for by a rise in 3,3'-T2G (Fig. 6). 
Clearance of rT3 was not S dependent. Iodide production, 
100 
" 
T2 
~ eo 
1 70 
c 
~ 60 
~ 50 
i 40 
:: 30 
u 20 , 
l 10 
12 10 II 10 
however, decreased from 48% in the presence ofS to 38% in the 
absence of S, and further to 33% after preincubation with SAM. 
The loss of 1- was completely compensated for by the accu-
mulation of 3,3'-T2, which amounted to I, 9, and 14% under 
these conditions, respectively (Fig. 5). In S-supplemented in-
cubations the conjugate fraction contained small amounts of 
rT3G, 3,3'-T2G, and 3,3'-T2S. S depletion induced an increase 
in conjugates mostly in the form of 3,3'-T2G, althoug13 even 
after preincubation with SAM the conjugate fraction comprised 
only 5% of medium radioactivity.lnhibition ofdeiodination by 
PTU augmented the appearance of conjugates in S-replete in-
cubations (Table I, Fig. 6). In S-deplete cultures, addition of 
PTU led to a decrease in T2G and an increase in .rT3G with-
out a change in the total amount of conjugate formed 
(Fig. 6). 
Effect of substrate concentration on rT3 metabolism (Fig. 7). 
InS-replete incubations, progressive increases in unlabeled rT, 
concentration from I to 1,000 nM led to minimal increments 
in the recovery of immunoassayable 3,3'-T2 from the medium. 
Medium 3,3'-T2 ranged from undetectable after incubation with 
I nM rT3 until maximally 1.9 pmol per dish (0.1%) at 1,000 
nM rT3 • After addition of SAM, accumulation of 3,3'-T2 rose 
from 0.8 pmol/dish (38%) at I nM rT3 to 29.7 pmol/dish (1.5%) 
at 1,000 nM rT3 • The results indicated that 3,3'-T2 accumulation 
under these conditions was a saturable process; it was half-max-
imal between 10 and 100 nM rT3 • Cell-associated 3,3'-T2 was 
similarly dependent on substrate concentration. 
Effects of SAM and DCNP on free substrate /(!Ve/s, cellular 
integrity, and deiodinase activity (Table II). In the absence of 
inhibitors, the free fraction of3,3'-T2 and rT3 in Dulbecco's me-
dium containing 0.1% BSA was 8.5 and 4.9%, respectively. Up 
to 1,000 I'M, SAM did not influence the free 3,3'-T, and rT3 
fractions. DCNP had no effect on free 3,3'-T 2, while there was 
a dose-dependent increase in free rT 3 up to 7.8% at 100 I'M 
DCNP. 
Up to 100 I'M, SAM did not inhibit rT3 deiodination by rat 
liver microsomes, but a 25% reduction ofr release was observed 
at I ,000 I'M SAM. In contrast, I 00 I'M DCNP resulted in a 
65% lowering of deiodinase activity, while only sligl3t inhibition 
was noted at I 0 !LM. 
Figure 5. S dependence of 3,3'-T2 
and rT 3 metabolism. Monolayers or 
106 hepatocytes were preincubated 
for 30 min in S-supplemented me-
dium or in S-free medium plus or 
minus 100 ,.M SAM. Subsequently, 
incubations were performed for 60 
min with 10 nM [1251]3,3'-T, or 
[ 125l]rT 3 in S-replete or -deplete me-
dium. PTU was added at 10 ,.M. 
Medium was analyzed by Sephadex 
LH-20 chromatography and data are 
expressed as mean±SE of the num-
ber of observations indicated. Com-
pletion of medium radioactivity to 
100% represents the proportion of 
unaltered substrate. No correction is 
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Figure 6. HPLC analysis of conjugates generated in incubations of (A) 
3,3'-T, and (B) rT3 with hepatocytes. Incubations were done with S-
replete or -deplete cells after preincubation in medium Vrith S or in 
medium without S plus 100 ~M SAM as described in the legend to 
Fig. 5. Conjugates were isolated on Sephadex LH-20, concentrated on 
a second LH-20 column, and collected in ammonia-ethanol as de-
scribed in Methods. After evaporation, the residue was analyzed by 
HPLC using a 20:80 vol/vol mixture of acetonitrile and 0.02 M am-
Cell viability as assessed by A TP measurements was not af-
fected by SAM. However, a 35% reduction of cellular A TP was 
found after incubation with 100 I'M DCNP. 
Discussion 
The occurrence ofrT3 and 3,3'-T2 in rat thyroid as well as in rat 
plasma has already been reported by Roche et al. in 1955 (16-
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Figure 7. Conversion of rT3 
to 3,3'-T, by rat hepatocytes 
as a function of substrate 
concentration. Monolayers 
of I 06 hepatocytes were in-
cubated for 60 min with I-
1,000 nM unlabeled rT 3 in 
Dulbecco's medium con-
taining S with or without 
100 ~M SAM. 3,3'-T, con-
tent was measured by RIA 
in duplicate in 50-pJ ali-
quots of medium or 0.1 N 
NaOH extracts of cells. 100 nM rT
3 Data are taken from a rep-
resentative experiment repeated on three different occasions with 
closely agreeing results. 
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monium acetate (pH 4) at a flow of0.6 ml/min. Fractions of0.3 ml 
were collected and counted for radioactivity. Elution position ofS 
conjugates was determined using synthetic standards and conjugates 
were further identified by enzymatic liberation of 3,3'-T2 or rT3 after 
treatment with sulfatase or glucuronidase. Radioactivity eluting in the 
position ofrT ~was not hydrolyzed by sulfatase, in agreement with 
previous observations using synthetic rT3S ( 13). 
18). These workers also provided evidence for the conversion 
of both T3 and rT3 to 3,3'-T2 in vivo by demonstration of the 
presence of radioactive 3,3'-T2 in the kidney after administration 
of labeled T3 or rT3 to thyroidectomized rats (19). In humans, 
most plasma 3,3'-T2 originates from IRD ofT3 (20, 21). Plasma 
3,3'-T,' (22) and rT,' are cleared predominantly by the liver, 
which indicates that they are derived from extrahepatic IRD of 
T3 and T4 , respectively. It is likely that these processes are cat-
alY2ed by the type III deiodinase, which specifically acts on the 
inner ring of iodothyronines and which has been localized in 
tissues such as brain and skin but not in liver (2, 5). In our 
studies we focused on the role of the type I deiodinase in the 
hepatic clearance of rT 3 • 
Numerous studies have appeared on the characteristics of 
the deiodination of different iodothyronines by homogenates 
and subcellular fractions of rat liver (for a review, see reference 
2). These studies have established the existence of a so-called 
type I deiodinase in the endoplasmic reticulum, which is an 
integral membrane protein and requires thiols for deiodinase 
activity. The enzyme is a nonspecific deiodinase that is capable 
of removing iodines from either ringofiodothyronine substrates 
(2). However, the enzyme is most effective in the ORO of rT, 
(2, 23). To test the possible regulatory function of this enzyme 
in peripheral thyroid hormone metabolism, we have therefore 
initiated studies of the breakdown of rT3 by isolated rat hepa-
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Table II. Effects of SAM and DCNP on Medium 
Free rT, and 3,3'-T, Levels. on Microsomal 
Deiodinase Activity, and on Cellular ATP Content 
Free fraction 
{%)• 
Deiodinase* 
Treatment rT, 3,3'-Tl activity ATP' 
Control(%) Control(%) 
Control 4.9 8.5 100 100 
SAM 10~M 4.4 8.7 107 100 
lOO~M 4.6 8.4 103 85 
1,000 ~M 4.8 8.7 77 94 
DCNP 10~M 6.0 8.8 89 97 
100~M 7.8 9.2 35 67 
• Free iodothyronine levels in medium were determined in triplicate 
by equilibrium dialysis. 
* Deiodinase activity was measured in triplicate in mixtures of 10 nM 
[ 125I]rT,, 2 or 5 ~g microsomal proteinjml, and 5 mM DTT in 0.1 M 
phosphate (pH 7.2) and 2 mM EDTA (14). After incubation for 15 
min at 37°C, reactions were halted by addition of serum, and 125r re-
leased was measured by TCA precipitation. Data are expressed as the 
means of the six observations relative to iodide production in the ab-
sence of inhibitors. 
t Cells were incubated for I hat 37°C with Dulbecco's medium plus S 
and the indicated concentrations of SAM and DCNP. ATP was mea-
sured in 0.2-M perchloric acid extracts (0.5 ml/106 cells) after centrifu-
gation and neutralization with 2 M KOH according to the method of 
Jaworek et al. ( 15). Data are taken from a representative experiment 
repeated under different conditions with similar results. 
tocytes. In spite of the high rate ofrT3 to 3,3'-T2 conversion with 
isolated microsomes, and the stability of the product in such 
incubations (23), surprisingly little production of 3,3'-T2 from 
rT 3 was observed in incubations with intact liver cells (8). That 
nevertheless rapid ORD took place in this system was demon-
strated by the large amounts of radioiodide released from outer 
ring labeled rT3 (8). This implies that any 3,3'-T2 formed would 
have undergone further deiodination, as substantiated by analysis 
of the metabolism of added 3,3'-T2. Similar rapid degradation 
of both rT3 and 3,3'-T2 with extensive 1- formation was observed 
by Hock et al. (24) in isolated rat liver perfusions. The unexpected 
rapid deiodination of 3,3'-T 2 in rat liver cells in contrast to mi-
crosomes was subsequently shown to be due to the efficient sul-
fation of 3,3'-T 2 in hepatocytes yielding 3,3'-T 2S, a highly effective 
substrate for the type I deiodinase (I 0). A similar facilatory effect 
ofS conjugation has been described for the IRD ofT3 and T4 
(25, 26). 
In the present study, we tested the hypothesis that it is possible 
to demonstrate production of 3,3'-T2 from rT3 in this system if 
further metabolism, especially sulfation, of3,3'-T2 is prevented. 
In experiments with isolated rat hepatocytes three methods are 
available in principle to manipulate the sulfotransferase activity 
of the cells. Firstly, it has been demonstrated that there is a rapid 
equilibrium between medium and cellular inorganic S levels 
(27-29). Rat liver cells also have the capacity to generate S by 
oxidation of the sulfur-containing amino acids methionine and 
cysteine (28). Therefore, considerable S depletion is obtained by 
keeping cells in medium without Sand possible precursors. Sec-
ondly, sulfation of phenolic substances may be prevented by 
competitive substrates (30). SAM has been shown to undergo 
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extensive sulfation and at higher concentrations also glucuron-
idation in rat liver cells. For instance, Koike et al. (29) have 
reported that in isolated rat hepatocytes, sulfation of SAM is 
characterized by an apparent Km value of 6 I'M with a V m~ 
value of 2 nmol/min per l 06 cells at 1.2 mM inorganic S in the 
medium. This level of S is similar to that used in our system ( 1 
mM), providing near-maximal rates of S conjugation (9, 10). 
Glucuronidation of SAM became more pronounced if the com-
peting pathway of sulfation was saturated at high SAM levels or 
prevented by S depletion (29). G conjugation occured with a 
Km value of0.2 mM and YmM of 1.3 nmol(min per 106 cells as 
determined under S-depleted conditions. Thirdly, specific in-
hibition of phenol sulfotransferase activity may be obtained using 
DCNP, a compound which in itself is not sulfated (31, 32). All 
three abovementioned ways of intervention with the further sul-
fation of3,3'-T2 have been applied to our study of the deiodina-
tion of rT 3 by rat hepatocytes. 
Previous studies from our laboratory have demonstrated the 
feasibility of using small Sephadex LH-20 columns for separation 
of 3,3'-T2 and its main metabolites, 3,3'-T2S and 1- (10). We 
have adapted this method in the present investigation for the 
analysis ofrT3 metabolites. With this modification it was possible 
to separate fractions containing r, conjugates, 3,3'-T2, and rT3, 
respectively. Since the fraction eluted with water may contain 
various conjugates, and also because there is a slight contami-
nation of the 3,3'-T2 fraction with rT3, these analyses were ex-
tended by HPLC and RIA determinations. Despite the limita-
tions of the Sephadex LH-20 method, a good correlation between 
3,3'-T 2 production rates as measured by the three different tech-
niques was observed. 
Time-course studies of the metabolism of 3,3'-T2 and rT, 
demonstrated that under the conditions used, i.e., I 0-nM sub-
strate levels and $-supplemented cells, clearance of both sub-
stances follows first-order rate kinetics (Fig. 2). Such kinetics 
, were also observed in the presence of 100 !LM SAM, which did 
not affect the rate constant for rT3 but lowered that for 3,3'-T2 
by 77%. These results show that conjugation is an important, 
rate-limiting step in the metabolism of 3,3'-T2, but not of rT,. 
SAM does not only inhibit degradation of added 3,3'-T2, but 
apparently also that of 3,3'-T2 produced from rT3 • No evidence 
was obtained by HPLC for the generation of iodothyronines 
other than 3,3'-T2 such as 3',5'-T2 or 3'-iodothyronine (Fig. 3). 
The l 00-!LM SAM concentration used mostly in our exper-
iments was shown to have near-maximal effects on the clearance 
of 3,3'-T 2. The generation of conjugates observed in the presence 
of PTU is inhibited to only a slightly greater extent at 1,000 I'M 
SAM, while 10 I'M of this drug already provided 60% inhibition. 
This value is in excellent agreement with the Michaelis constant 
(Kml value for SAM sulfation of 6 I'M, which was reported by 
Koike eta!. (29). Note that after incubation of·3,3'-T2 in the 
presence of PTU, substantial radioactivity in the form of 3,3'-
T 2S remains associated with the cells, which suggests that exit 
of cellular 3,3'-T2S is a relatively slow process. If the amount of 
cell-bound 3,3'-T2S is taken into account is is obvious that PTU 
does not affect clearance of 3,3'-T2, whereas metabolism of rT, 
is strongly impaired (see below). In the absence of PTU, SAM 
induces a dose-dependent decrease in r formation from 3,3'-T, 
that parallels the decrease of 3,3'-T,S in incubations with PTU. 
However, [- production is not completely suppressed with even 
1,000 !LM SAM, suggesting that direct ORO of 3,3'-T 2 may occur 
to some extent if sulfation is inhibited. Direct ORO of 3,3'-T 2 
has also been observed with isolated rat liver microsomes, albeit 
with only 2% of the efficiency of 3,3'-T2S ORO (9). Therefore, 
with unimpeded sulfation, direct deiodination is a negligible 
pathway. 
Also concerning the accumulation of3,3'-T2 produced from 
rT3 , 1,000 I'M SAM shows only slightly greater effects than 100 
I'M of this drug, while roughly a half-maximal effect is observed 
with 10 ~tM SAM. At the highest SAM concentration, 3,3'-T, 
represents approximately one-third and 1- approximately two-
thirds of the rT3 metabolites, which corresponds to a 70% pro-
tection against further degradation of the 3,3'-T, produced. It 
should be stressed that clearance of rT3 is not affected by even 
1,000 I'M SAM. If added to deiodinase assay mixtures of rT3 
with microsomes, inhibition was observed only with I ,000 I'M 
SAM (Table II). The differential effects of I ,000 ~tM SAM on 
rT 3 deiodination by intact cells, and that by isolated microsomes, 
indicate that intracellular SAM levels are substantially lower 
than those added to the medium. The extremely rapid metab-
olism of SAM by both sulfation and glucuronidation (29) may 
be an important fuctor contributing to this difference. The lack 
of effect of SAM on medium free iodothyronine levels and cel-
lular A TP (Table II) further underscores the usefulness of this 
compound in studies of the conjugation of thyroid hormone. 
Table I illustrates that similar effects on the metabolism of 
3,3'-T, and rT3 are obtained with 100 ~tM DCNP as with 100 
~tM SAM. However, DCNP also exhibits some unwanted side 
effects. DCNP has been shown by Mulder and co-workers to be 
a specific inhibitor of sulfation in vivo as well as in vitro without 
being sulfated itself (31, 32). This compound does not affect 
glucuronidation and was reported to have no major toxic effects, 
which is in contrast with our findings that show a substantial 
decrease in cellular A TP by I 00 ILM DCNP. This effect on ATP 
may be related to the toxic effects on oxidative phosphorylation 
generally observed with phenols (33, 34) which may be promoted 
by the relative deficiency of nutrients and oxygen in our system. 
A further disadvantage of DCNP is that it may inhibit deiodinase 
activity directly, as demonstrated by the influence of DCNP in 
incubations with microsomes (Table II). Similar to SAM, ·how-
ever, intracellular DCNf concentrations may be substantially 
lower than the total concentrations added to the medium. One 
possible reason for this is that DCNP binds extensively to BSA 
(31). The decreased availability ofDCNP to the cells, therefore, 
prevents direct inhibition of the peiodinase, and metabolism of 
rT 3 is even stimulated by 100 ILM DCNP. This latter phenom-
enon is probably due to displacement of rT 3 from .ElSA (Table 
II), which causes a shift of rT 3 into the intracellular compartment. 
Nevertheless, results obtained with DCNP are in confirmation 
of the experiments with SAM which underscore the importance 
ofsulfation for the metabolism of3,3'-T2 but not ofrT3 • 
The Sephadex LH-20 method used in this study does not 
permit the distinction of the different conjugates of 3,3'-T, and 
rT 3 • Previous findings have indicated that sulfate conjugates do 
not crossreact in RIAs of non-conjugated iodothyronines ( 13). 
The RIA data presented in Table I are, therefore, consistent with 
the results obtained by L!:i-20 insofar as they indicate that clear-
ance of 3,3'-T, is not inhibited by PTU. If the product that is 
formed from 3,3'-T, in the presence ofPTU is subjected to acid 
hydrolysis, similar amounts of 3,3'-T, are recovered as those 
measured after incubation with SAM or DCNP. Since iodothy-
ronine sulf~tes are prone to acid hydrolysis ( 13), while glucuro-
nides are much more resistant (Oosterlaken, T., S. J. Eelkman 
Rooda, and T. J. Visser, unpublished observations), this indiCiltes 
accumulation of3,3'-T2S in the presence ofPTU. However, most 
direct evidence for the identity of the conjugates is provided by 
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HPLC in combination with enzymatic analysis using sulfatase 
or glucuronidase. These experiments were made on samples from 
incubations with cells in different degrees of S depletion. 
S-deplete hepatocytes were prepared by preincubation with 
medium lacking inorganic Sand by using the same medium for 
incubation with substrate. The results obtained with 3,3'-T, in 
the presence of PTU showed that under these conditions S de-
pletion was not complete, and led to some reSidual 3,3'-T ,s for-
mation. Further exhaustion of cellular S stores was obtained by 
preincubation with SAM. A similar approach ha>; been followed 
by otjler investigators to reveal the signifiC3Ijce of the conjugation 
reactions in the elimination of drugs (35, 3(i). Thus, substantial 
lowering of hepatic UDP-glucuronic acid and adeQosine · 3'-
pbosphate 5'-phospbosulfate levels has j3een achieved by in vivo 
treatment with SAM due to the consumption of these co-fuctors 
in the glucuronidation and S!llfution of the drug (35, 36). Ap-
plication of a SAM load induces a prolonged lowering of body 
S stores with pronounced decrements in plasma S levels (35), 
but depletion of tissue UDP-glucuronic acid is only transient, 
and co-factor levels are rapidly restored (36). We also obtained 
evidence for the reversible nature of these effects. After prein-
cubation with SAM, 3,3'-T, sulfation rates after readditipn of 
So.'- and T 3 glucuronidation rates (Eelkman Rooda, S. J ., and 
T. J. Visser, unpublished observations) were completely normal. 
In S-replete cells, sulfation is by far the predominant pathway 
of 3,3'-T, metabolism, although little 3,3'-T,S is recovered in 
the absence of PTU due to further deiodination. However, in 
S-deplete cells the contribution of the glucuronidation pathway 
increases, aQd results in augmented accumulation of 3,3'-T,G 
from added 3,3'-T,, as well as from addectrT3 • The latter findings 
indicate that glucuronidation does not facilitate deiodination of 
3,3'-T, which is in contrast to the stimulatory effects of sulfation. · 
Although ORO is the foremost step in the b~patic metabolism 
of rT,, some glucuronidation of this metabolite is observed, es-
pecially in the presence of PTU. The low rate of rT 3 sulfation 
in comparison with the highly efficient sulfation of 3,3'-T2 is in 
agreement with data of the structure-activity relationship for 
the sulfation of iodothyronines by isolated phenol sulfotrans-
ferases (37). 
The effects of substrate concentration on the conversion of 
rT3 to 3,3'-T, by rat liver cells indicate that half-maximal 3,3'-
T 2 production is obtained between 10 and 100 nM rT 3 • This is 
in the same concentration range as the Km value determined for 
rT3 ORO in reactions with microsomes and OTT (23). However, 
the rT 3 levels in the culture medium are largely P.Wtein bound 
and certainly do not reflect intracellularly available substrate 
concentrations. Together with the uncertainty about the satu-
ration kinetics of the type I deiodinase in its natural environment 
it is, therefore, impossible to interpret these findings in terms of 
a possible uphill gradient ofrT3 across the cell membrane (38). 
In conclusion, our results demonstrate that in isolated rat 
hepatocytes, rT3 is metabolized almost exclusively' by ORO. 
However, the immediate product of this reaction, 3,3'-T 2 , is not 
observed unless its further metabolism by successive sulfation 
and deiodination is inhibited. Evidence for formation of 3',5'-
T, in these studies was not obtained. In different clinical situa-
tions, plasma T3 and rT3 levels change in opposite directions 
due to parallel alterations in the rate ofT 3 production and rT 3 
degradation. This is understandable, as both processes concern 
ORO reactions mediated by common enzymes among which 
the type I deiodinase of the liver plays an important function. 
It is expected, therefore, that a detailed knowledge of the ORO 
Metabolism of Reverse Triiodothyronine in ~at Hepatocytes 
of rT 3 by intact liver cells will deepen our insight into the reg-
ulation of the bioavailability of thyroid hormone. 
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ABSTRACT 
This paper is the first description of a radioimmunoassay (RIA) 
for triiodothyronine sulfate (T3S). Rabbits were immunized against 
T3S coupled to bovine serum albumin using carbodiimide. All 
animals produced antibodies to T3S but also even higher titers of 
T3 antibodies. Ka values for bindiny of T3 and T3S to these 
antisera varied between 2x1o10 and 8xl0 0 M-1. One of the antisera 
(#8193) was selected for use in the T3S RIA because of a high 
titer of T3S antibodies (final dilution 1 50,000), a high 
sensitivity to T3S (<2.5 !mol/tube), and a low crossreactivity by 
T3 (0.4%). This RIA provides a tool for the study of the 
importance of sulfation as a metabolic pathway for T3. (KEY WORDS: 
thyroid hormone, triiodothyronine sulfate, radioimmunoassay) 
INTRODUCTION 
Triiodothyronine (T3) is the bioactive form of thyroid 
hormone. Roughly 20% of circulating T3 is derived from thyroidal 
secretion while the majority is produced by phenolic ring 
deiodination of thyroxine (T4) in peripheral tissues, especially 
the liver (1,2). In rats, T3 is metabolized by deiodination of the 
tyrosyl ring and by conjugation of the phenolic hydroxyl group 
Copyright© 1988 by Marcel Dekker, Inc. 
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with sulfate or glucuronic acid (3,4). Although direct 
deiodination of T3 occurs in extrahepatic tissues (2,3), sulfation 
enhances T3 deiodination in the liver (5,6). In contrast, T3 
glucuronide (T3G) is a stable conjugate. Thus, after incubation of 
T3 with isolated rat hepatocytes, iodide and T3G are the major 
products (5). Accumulation of T3 sulfate (T3S) in these cultures 
occurs only after inhibition of deiodinase activity, for instance 
with propylthiouracil (PTU) (5). To further investigate the"role 
of sulfation in T3 metabolism we decided to develop a 
radioimmunoassay (RIA) for T3S. Here we report the characteristics 
of this RIA. 
METHODS 
Production of Antiserum. The T3S-protein conjugate used for 
immunization was prepared as follows. To 100 mg anhydrous T3 
(Sigma) and 1 pCi [125r]TJ (Amersham) was added 0.5 ml of a 
mixture of chlorosulfonic acid and di-methylformamide (1/4, v/v) 
at 0 C (7). After reaction for 40 h at room temperature, T3S was 
precipitated by addition of this mixture to 5 m1 H20 at 0 C. The 
pellet was dissolved in 1 ml 2 M NH40H and reprecipitated with 5 
m1 1 M HCl. The pellet was further washed by repeated suspension 
in 3 m1 0.1 M HCl. Analysis of this material by HPLC (7) indicated 
that it consisted of T3S and only 1% T3. The T3S was dissolved in 
5 m1 dimethylformamide and added to a solution of 100 mg bovine 
serum albumin (BSA) in 20 m1 H20• After adjusting the mixture to 
pH 5 with 0.1 M NaOH, 50 mg 1-ethyl-3-(3-dimethylaminopropyl)-
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carbodiimide (Sigma) was added in 5 ml H20 (8). This was repeated 
after 3 h, and the mixture was further stirred for 16 h at room 
temperature. The product was dialysed at 4 C against successively 
2x2 1 H20, 2 1 0.1 M NaOH and 3x2 1 H20, changed twice daily. 
Analysis of remaining radioactivity indicated a low degree of T3S 
incorporation (<5%), corresponding to <S mol T3S/mol BSA. The 
immunogen was stored at -20 C in a concentration of 2 mg 
protein/ml. 
Four New Zealand white rabbits were immunized by s.c. 
injections with 1 mg conjugate in 1 ml of a 1 : 1 mixture of 
water and complete Freund's adjuvant at multiple sites in the 
back. This was repeated after 2 and 4 months and subsequently at 
irregular intervals of 1-6 months. High-titer antibodies to T3 and 
T3S were detected in serum of all animals from the second 
immunization onwards. Two rabbits (#8190 and #8193) produced high-
affinity T3S antibodies, and the characteristics of antisera 
obtained 2 weeks after the 1oth injection (15 months after start 
of immunization) are described here. 
Radioimmunoassay. Radioactive 
[125I]T3 with chlorosulfonic 
T3S was prepared by reaction of 
acid and purified as previously 
described (7). In general, approximately 25,000 cpm (-8 fmol) 
125I-labeled T3 or T3S were incubated for at least 48 hours at 4 C 
with appropriate dilutions of antiserum #8190 or #8193 in a final 
volume of 1 ml RIA buffer (0.06 M barbital, 0.15 M NaCl, 0.1 % 
BSA, pH 8.6). Preliminary results had shown that this incubation 
period was necessary to obtain equilibrium, and that tracer 
binding was constant over a broad pH range. Antibody-bound 
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radioactivity was precipitated by addition of goat anti-rabbit IgG 
antiserum and polyethylene glycol 6000 (2.5 % final concen-
tration). After incubation for 1 h at 4 C, the tubes were 
centrifuged, the supernatants were aspirated and the pellets were 
counted for radioactivity. Reference iodothyronines were obtained 
from Henning, Berlin, FRG, and sulfate conjugates were synthesized 
in our laboratory (7). Solutions of standards and analogs were 
prepared in 0.01 M NaOH and assayed in duplicate in 50-100 _pl 
aliquots. 
RESULTS 
Figure shows the binding of T3 and T3S tracers to 
progressive dilutions of antisera #8190 and #8193. Both antisera 
contained high titers of antibodies to T3 and T3S. However, higher 
dilutions of antiserum could be used to obtain the same degree of 
T3 binding compared with T3S. Binding of biosynthetic T3G tracer 
to even low dilutions of antiserum was negligible (not shown). As 
a suitable condition for the RIA roughly 35% binding of T3 tracer 
to either antiserum occured at a final dilution of 1 : 800,000 and 
in case of T3S tracer at 1 : 50,000-60,000. 
Using these antiserum dilutions the characteristics of T3 and 
T3S binding were further investigated. Significant displacement of 
T3S tracer was observed with (2.5 (118193) or 5 (118190) fmol 
unlabeled T3S per tube (Fig. 2). In case of the T3 RIA lower 
limits of detection amounted to 3-5 fmol T3 per tube. Logit-log 
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FIGURE 1. Binding of [125I]T3S (e) or [125I]T3 (o) to progressive 
dilutions of antiserum #8190 (left) or #8193 (right). 
plots of the standard curves showed excellent fits (r)0.99). 
Linear transforms were also constructed using the method of 
Scatchard (9) with r values )0.95, which permitted estimation of 
average binding parameters of the antisera. Binding of T3S to 
antisera #8190 and #8193 was characterised by Ka values of 2x1o10 
and 8x1o10 M-1 and by values for the maximal binding capacity 
(MBC) in undiluted antiserum of 1.7 and 0.4 pM. respectively. In 
case of T3, Ka values were 8x1o10 and 3x1o10 M-1 and MBC values 8 
and 15 rM, respectively. 
Not only the affinity but also the specificity of the binding 
of T3S was different between the antisera (Fig. 2 and Table 1). 
Binding of T3S to antiserum #8190 showed a high degree of 
60 
EELKMAN ROODA ET AL. 
[1251]T S 
3 
100 \\""'~. 80 
60 
\ 0 
40 
0 \ \-ID ID 
It: 
w 
u 
< It: 
1-
LL 
0 
0 
z 
c 
z 
ID 
"" 
20 \~ "0 • 
0 8190 
100 
• \\"\ \ ~ T 45 80 
T3s\ T•\ \ 60 40 
\ c~ 
20 \ • ~0 
• ~ c 
0 Tl\ T3\ 0 
\ 
\ i "· 8193 • 0 8193 
10-ll 1o- 10 10- 9 10-8 10- 7 10- 6 10-11 10- 10 10- 9 10- 8 10- 7 10- 6 
COMPETITOR (M) 
FIGURE 2. Inhibition of the binding of [125I]T3S (left) to 
antiserum #8190 (1 : 60,000) or #8193 (1 : 50,000) or that of 
[125I]T3 (right) to antiserum #8190 or #8193 (both 1 : 800,000) by 
increasing concentrations of unlabeled T3S (e), T3 (0), T4 (c) or 
T4S ( •). Results with antiserum 118190 are given in the upper 
panels and those with antiserum #8193 in the lower panels. 
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TABLE 1 
Specificity of Binding of T3S and T3 to Antisera #8190 and #8193 
Competitor Cross reactivity (%) 
[125I]T3s [125I]T3 
/18190 i/8193 i/8190 118193 
(1: 60,000) (1: 50 ,000) (1:800,000) (1 : 800, 000) 
T4 
T4S 
T3 
T3S 
rT3 
rT3S 
3,5-T2 
3,3'-T2 
3,3'-T2s 
3-T1 
_}:-T1 
To 
0.2 
0.9 
31 
100 
<0.01 
<0.1 
2 
0.4 
2 
<0.01 
<O.Ol 
<0.01 
0.6 
9 
0.4 
100 
<0.01 
0.2 
<0.01 
<0.01 
0.5 
<0.01 
<0.01 
<0.01 
0.2 0.2 
<0.1 <0.01 
100 100 
0.9 0.2 
<0.01 <0.01 
<0.01 (0.01 
0.6 0.4 
0.3 0.5 
(0.01 <0.01 
<0.1 <0.01 
<0.01 <0.1 
<0.01 <0.01 
Percentage crossreactivity is defined as the ratio (xlOO) of the 
concentration of ligand divided by the concentration of competing 
substance that each produce 50 % displacement of tracer. Results 
are calculated after logit-log transformation of the dose-response 
curves and represent the means of at least three different 
experiments. rT3, 3,3',5'-triiodothyronine; T2, diiodothyronine; 
T1, iodothyronine; To, thyronine; S, sulfate. 
crossreactivity by T3 but much less interfer~uce by T4 and T4 
sulfate (T4S). On the other hand, T4S was a potent competitor for 
binding of T3S to antiserum #8193 while T3 was much less reactive. 
Low to absent crossreactivity was observed with all other 
iodothyronine analogs whether sulfated or not. Less differences 
were seen between the specificities of T3 binding to the two 
antisera (Fig. 2 and Table 1). T3S was more effective in competing 
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with T3 for antiserum #8190 compared with #8193. However, 
crossreactivity remained below 1% as was the case with all analogs 
tested, including T4. 
DISCUSSION 
This study represents the first report of a RIA for the 
measurement of an iodothyronine conjugate. Previous studies had 
already demonstrated that it is feasible to measure sulfate 
conjugates of steroids by RIA. An established method for the 
determination of plasma dehydroepiandrosterone sulfate makes use 
of the high crossreactivity of the conjugate with antiserum 
produced against the nonconjugated steroid (10). However, recent 
reports have also described th~ production of specific antibodies 
to sulfate conjugates, e.g. estradiol-3-sulfate, that do not 
crossreact with the free steroid (11). 
Although we immunized rabbits against a conjugate prepared by 
coupling pure T3S to albumin, the antisera produced contain 
distinct types of antibody, the most abundant of which 
specifically binds T3. The reason for this is unknown but it is 
possible that part of the sulfate conjugate is hydrolysed during 
immunogen preparation or in vivo. Extensive hydrolysis has been 
observed during coupling of phenolic steroid sulfates to protein 
using the mixed anhydride method but not with carbodiimide (12), 
the coupling reagent also used by us. The crossreactivity of T3S 
with the binding of T3 tracer to the antisera was of similar 
magnitude as that observed with antibodies raised against free T3 
as the antigen (7). It is not excluded that part of this 
63 
A RADIOIMMUNOASSAY FOR TRIIODOTHYRONINE SULFATE 
crossreactivity by T3S is due to slight contamination with free 
Of greater interest to our studies is the other class of 
antibodies that show preference for .T3S as the ligand. Especially 
T3S binding to antiserum #8193 is little affected by T3, although 
this favorable property may in part result from the sequestration 
of T3 by the high-capacity T3-specific antibodies. Notwithstanding 
the low crossreactivity of T4 in the T3S RIA, it may still create 
a significant problem for the measurement of T3S in samples with 
high T4 levels such as plasma. The similar effects of T4 and T3 in 
the T3S RIA with antiserum #8193 suggest that in this case the 
steric hindrance of the extra iodine in T4 is counter-balanced by 
the favorable influence of the dissociated hydroxyl group. The 
latter introduces a negative charge in the same region of the 
molecule as the sulfate group. 
In conclusion, the present study demonstrates the feasibility 
of the development of a RIA for T3S. Preliminary studies have 
shown accumulation of immunoreactive T3S in incubations of T3 with 
isolated rat hepatocytes if subsequent deiodination of the 
conjugate is inhibited (13). T3S immunoreactivity has also been 
detected in plasma of PTU-treated rats (14). Studies are now in 
progress in our laboratory to adapt this RIA for the measurement 
of T3S in human plasma. 
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ABSTRACT 
The metabolism of 3,3',5-triiodothyronine (T3 ) by isolated rat 
hepatocytes was analysed by Sephadex LH-20 chromatography, high 
performance liquid chromatography and by radioimmunoassays for T3 sulfate 
(T3S) and 3,3'-diiodothyronine (3,3'-T2). Type I iodothyronine deiodinase 
activity was inhibited with propylthiouracil (PTU) and phenol sulfo-
2-tranferase activity by so4 depletion or with competitive substrates or 
inhibitors. Under normal conditions, labeled T3 glucuronide (T3G) and I 
were the main products of [3'-125 IJT3 metabolism. Iodide production was 
decreased by a) inhibition (PTU) or saturation (>100 nM T3) of type I 
deiodinase or b) phenolsulfotransferase, accompanied by the accumulation of 
a) T3s and 3,3'-T2S or b) 3,3'-T2 and 3,3'-T2G independent of PTU. 
and its conjugates were only produced at ~10 nM T3 • Thus, 
metabolized in rat liver cells by 3 quantitatively important pathways: 
glucuronidation, sulfation and direct inner ring deiodination (IRD). 
Whereas T3G is not further metabolized in the cultures, T3s is rapidly 
deiodinated by the type I enzyme. As confirmed by incubations with isolated 
rat liver microsomes, direct IRD of T3 is mediated by a low-Km, PTU-
insensitive, type III-like iodothyronine deiodinase, and production of 
3,3'-T2 is only observed if its rapid sulfation is prevented. 
INTRODUCTION 
In euthyroid subjects thyroxine (T4 ) is the predominant secretory 
product of the thyroid. T4 itself has virtually no thyromimetic activity 
but it serves as a precursor of the bioactive thyroid hormone 3,3',5-
triiodothyronine (T 3). Approximately 20 % of plasma T3 is secreted by the 
thyroid and 80% is derived from peripheral deiodination of T4 (1). This 
process involves the outer ring deiodination (ORD) of T4 by the so-called 
type I iodothyronine deiodinase in many extra thyroidal tissues, 
predominantly liver and kidney (2,3). In rats two other iodothyronine 
deiodinases ,type II and III, have been described which differ in several 
aspects from the type I enzyme. While the type I enzyme is capable of both 
ORD and inner ring deiodination (IRD), the type II enzyme catalyses only 
the ORD and the type III enzyme only the IRD of iodothyronines (for a 
review, see refs. 2,3). Thus, there are two routes for peripheral T3 pro-
duction, namely type I and II ORD of T4• Likewise, there are two T3-deiodi-
nating pathways, i.e. type I and III IRD to 3,3'-diiodotyronine (3,3'-T2). 
The metabolic kinetics of many iodothyronines have been studied 
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extensively in vivo both in man and rat (1,4). However, the use of these 
plasma sampling techniques do not allow to estimate the actual contribution 
of the different tissues to the total body metabolism of thyroid hormone. 
Moreover, the rapid succession of intracellular processes may remain 
undetected. Therefore, detailed studies of thyroid hormone metabolism in 
isolated tissues may contribute to a better understanding of the integral 
process. 
Previously, we reported on the metabolism of both 3,3'-T2 and T3 in 
monolayers of isolated rat hepatocytes (5,6). Whereas deiodination and 
conjugation with either glucuronic acid or sulfate have been generally 
considered as independent metabolic pathways, our studies revealed that 
sulfation is a rate-limiting step preceding the hepatic deiodination of 
these compounds (5,6). In contrast to 3,3'-T2, which is mainly metabolized 
by sulfation and subsequent deiodination, r 3 metabolism also involves 
conjugation with glucuronic acid. T3 sulfate (T 3S) is metabolized in rapid 
succession by IRD and ORD with 3,3'-T2 sulfate (3,3'-T 2S) as a transient 
intermediate (5,7). 
In this paper we describe the quantative contributions of the 
different pathways contributing to the metabolism of T3 in rat hepatocytes 
as well as the effects of several compounds that interfere with sulfation 
and glucuronidation. 
MATERIALS AND METHODS 
The materials used are essentially the same as described previously 
(8). 3,3'-T2 and T3 were obtained from Henning GmbH, Berlin, Federal 
Republic of Germany. Carrier-free [3'-125I]T 3 with a specific activity of 
3300 Ci/g was prepared in our laboratory by radioiodination of 3,3'-T2 
using the chloramine-T method. [3'-125 I]T3S and unlabeled T3S were prepared 
by reaction of labeled or unlabeled r 3 with chlorosulfonic acid and 
purified by Sephadex LH-20 (Pharmacia Fine Chemicals, Uppsala, Sweden) 
chromatography (9). Standard T3S was also a gift from Henning. Salicylamide 
(SAM), 2,6-dichloro-4-nitrophenol (DCNP) and pentachlorophenol (PCP) were 
purchased from Riedel-de Haen AG, Hannover, Federal Republic of Germany. 6-
Propyl-2-thiouracil (PTU) and galactosamine (GAM) were from Sigma Chemical 
Co., St. Louis, MO. All other reagents were of the highest quality 
commercially available. 
Hepatocytes 
Male Wistar rats were used (180-250 g BW). After isolation of the 
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hepatocytes by collagenase perfusion (10), the cells were suspended in 
culture medium (106 cells/2 ml). This culture medium was composed of Ham's 
FlO' 10.6 mM PIPES, 11.2 mM BES, 8.9 mM Hepes (pH7.4), 2 mM CaC12, 12 -mU/1 
insulin, 10 U/ml penicillin, 10 ug/ml streptomycin sulfate and 10% fetal 
calf serum. Monolayers of hepatocytes were obtained by plating 2 ml of the 
cellsuspension into uncoated 3.5-cm wells of plastic 6-well dishes (Nunc, 
Roskilde, Denmark). The plates were kept for 4 hat 37 C in a culture stove 
under atmospheric conditions. Cell viability, tested before each experiment 
by trypan blue exclusion, exceeded 85%. 
Incubation procedures 
All experiments were performed in triplicate under atmospheric 
conditions at 37 C. The dishes were placed on a slightly-angled, slowly-
rotating plate. Hepatocytes were preincubated for 30 min with Dulbecco's 
balanced salt solution containing 2 mM glutamine, 1 mM vitamin C and either 
1 mM MgS04 without SAM or 1 mM MgC12 with 100 uM SAM (8). Incubations were 
mM MgS0 4 (so42--performed for 180 min 
containing incubations) 
in Dulbecco's medium with 
2-
or 1 mM MgC1 2 (so4 -free incubations) in the 
presence or absence of 0.1% bovine serum albumin (BSA). Sulfation was 
inhibited with 10-1,000 uM SAM, 1-10 uM DCNP or 1 uM PCP, deiodination 
with 100 uM PTU and glucuronidation with 0.5-5 mM GAM (8,11-13). Substrate 
levels were 1-1,000 nM T3 with or without 0.1 uCi [
125I]T3• 
Analysis of incubation medium 
Incubation media with labeled T3 were analysed by Sephadex LH-20 
column chromatography. For this purpose 0.5 ml medium was acidified with 
an equal volume of 1 M HCl. This mixture was applied to small Sephadex LH-
20 columns (bed volume 0.75 ml) equilibrated in 0.1 M HCl. The columns were 
eluted with 1 ml fractions of 0.1 M HCl (2x), 0.1 M sodium acetate (pH 4) 
(8x) , H2o (5x) and 0.1 M NaOH-ethanol (1:1, vol/vol) (3x). 
After incubation with unlabeled T3 , media were analysed by specific 
radioimmunoassays (RIA) for T3, 3,3'~T2 (14) and T3s content (15). The T3s 
RIA was recently described by us. In short, antibodies against T3S were 
obtained by immunizing rabbits with T3S coupled to BSA using carbodiimide. 
Antiserum #8193 was selected for use in the T3S RIA because of a high titer 
of T3s antibodies (final dilution 1: 50,000), a high sensitivity to T3s 
(<2.5 fmol/tube), and a low crossreactivity by T3 (0.4 %). Aliquots of 
100 ul incubation medium were assayed in duplicate in mixtures 
approximately 25,000 cpm [125I]T3S (-8 fmol) and T3S antiserum in a 
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with 
final 
volume of 1 ml RIA buffer (0.06 M barbital, 0.15 M HCl, 0.1 % BSA, pH 8.6). 
After 48-72 h at 4 C, antibody-bound radioactivity was precipitated by 
addition of goat anti-rabbit IgG antiserum and polyethylene glycol 6000. 
After 1 h at 4 C the tubes were centrifuged, the supernatants were 
aspirated and the pellets were counted for radioactivity. 
High performance liquid chromatography (HPLC) 
The various 3,3'-T2 and T3 conjugates and nonconjugated iodothyronines 
were analysed by reversed-phase HPLC. This system consists of a 10x0.3-cm 
CPtmSpher C18 column (Chrompack, Middelburg, The Netherlands), model 6000 
A and 510 solvent pumps (Waters, Milford, MA, USA) and a model 680 
automated gradient controller. Flow was 0.8 ml/min and absorbance was 
measured at 254 nm by a Model 440 fixed wavelength detector (Waters). 
Separation of 3,3'-T2 and T3 was accomplished by isocratic elution 
with a 50:50 (vol/vol) mixture of methanol and 0.02 M ammonium acetate (pH 
4). By employing a non-linear gradient of acetonitrile in 0.02 M ammonium 
acetate (pH 4) (15-40% in 30 min using program 7) 3,3'-T2 , T3 and their 
sulfate and glucuronide conjugates were separated in a single run. 
Sample preparation for the HPLC analysis of nonconjugated iodothy-
ronines was done by Sephadex LH-20 chromatography of medium as described 
above. After the H2o fractions, columns were rinsed with a mixture of 0.1 
M ammonia and ethanol (1:1, vol/vol) and the iodothyronines were eluted 
with 1.25 ml 0.1 M ammonia in ethanol. The solvent was evaporated at 50 C 
under a stream of N2 • For the simultaneous analysis of free and conjugated 
3,3'-T2 and T3 on HPLC, precleaning of samples on Sephadex LH-20 was 
modified as follows. After application of acidified medium, columns were 
washed with 2x1 ml 0.1 M HCl and with 0.75 ml H20. All retained 
radioactivity was eluted subsequently with 1.25 ml 0.1 M ammonia in 
ethanol. The solvent was evaporated as described above. 
The elution position of reference compounds was determined using 
s.ynthetic T3 , 3,Y-T2 , T3s, 3,3'-T2s (9) and biosynthetic T3 glucuronide 
(T3G) and 3,3'-T2G (16). 
Analysis of cell content 
The incubation medium was removed after 180 min and cells were 
extracted immediately with 1 ml 0.1 M NaOH. After centrifugation, 0.5 ml 
supernatant was chromatographed on Sephadex LH-20 as described for medium, 
or cellular T3 , 3,3'-T2 and T3s content were determined by RIA. 
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Miscellaneous 
Deiodination of [ 125I]T 3 and [
125I]T3G (isolated from hepatocyte 
cultures; ref. 16) was also studied using rat liver microsomes (14). In 
125 
short, [ I]T3 (100,000 cpm) and 0-1,000 nM T3 were incubated for 1 h at 
37 C with 0.5 mg/ml microsomal protein in 0.2 ml 0.1 M phosphate (pH 7.2), 
2 mM EDTA and 10 mM dithiotreitol (DTT) in the absence or presence of 1 mM 
1 T I b · h [ 125I]T 3G (20,000 cpm) PTU and, if applicable, uM r 3• ncu at1ons wit 
were performed for 15-30 min with 0.1 mg/ml microsomal protein in 
phosphate-EDTA buffer and 5 mM DTT, Reactions were stopped with 800 ul 0.1 
or M HCl and the mixtures were chromatographed on Sephadex LH-20 as 
described above to isolate the iodide, conjugate and iodothyronine 
fractions. The latter fractions were further analysed by HPLC for the 
quantitation of the production of 3,3'-T2G and 3,3'-T2 , respectively (see 
above). 
The effect of phenol sulfotransferase inhibitors on the 
d d 1 [ 125I]rT3 eiodinase was teste in simi ar experiments using 
type I 
as the 
substrate (8). The effect of these inhibitors on cellular ATP content was 
measured as described previously (8). 
Data analysis 
In each experiment I production was corrected for the amount of I 
recovered from control incubations (<2%). Production of 3,3'-T2 and T3s 
were corrected for crossreactivity of T3 in the 3,3'-T2 (<0.1%) and T3s 
(0.4%) RIA. Results are given as means ~ SEM. Statistical analysis of the 
data was performed with a one way classification, first performing an 
analysis of variance followed by comparisons among class means (17). 
RESULTS 
Sephadex LH-20 chromatography 
In Fig. 1 are shown the chromatographic patterns of I 
and T3 on Sephadex LH-20. The stepwise elution procedure resulted in the 
clear separation of these compounds with minimal overlap between the 
different fractions. More than 97.5% of I eluted in fractions 1-4, )98% 
of T3G in fractions 5-12 (sodium acetate), >98% of T3S in the H20 
fractions 13-16 and )98% of T3 in fractions 17-19 (NaOH-ethanol). Not shown 
are the chromatographic profiles of 3,3'-T2G, 3,3'-T2s and 3,3'-T2• More 
than 98% of 3,3'-T2G activity eluted in fractions 4-8. Approximately 80% of 
· 3,3'-T2s activity was found in fractions 6-12 and 15% in fractions 13-16 
3,3'-T2 had the same elution profile as T3• 
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Figure 1 
Sephadex LH-20 chromatography of 1-, T3G, T3S and T3 . Each 
1251-Iabeled compound was applied separately in 1 ml 0.5 N HCI 
to a small Sephadex LH-20 column with a bed volume of 0.75 ml 
which was equilibrated in 0.1 N HCI. Subsequently, columns 
were eluted with 1 ml fractions of 0.1 N HCI (2x), 0.1 M sodium 
acetate pH 4 (8x), H20 (5x), and finally" ethanol-0.1 N NaOH 
(1 :1 vol/vol) (3x). Each 1-ml fraction was counted for radioactivity. 
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Figure 2 
Effects of SAM, DCN P and PCP on T 3 metabolism. 10 nM T 3 with 
0.1 uCi [1251]T 3 were incubated for 180 min with 1 o6 hepatocytes 
in 2 ml S04 2--containing Dulbecco medium (n = 5) with or 
without 10-1,000 uM SAM, 1-10 uM DCNP and 1 uM PCP (upper 
panels). Parallel incubations were performed in the presence of 
100 uM PTU (bottom panels). Incubations were performed in the 
absence of BSA. Medium was analyzed by Sephadex LH-20 
chromatography. 1- production in incubations without PTU and 
T3S production in incubations with PTU wassignificantlyreduced 
by any concentration of inhibitors tested (p < 0.001). 
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Effects of SAM, DCNP and PCP on T3 metabolism 
Initially, incubations were performed in 
without BSA at a substrate concentration of 10 
so4
2
--containing medium 
nM [125I]T3• Under these 
conditions I- and T3G were the main metabolites in incubations without PTU. 
Inhibition of type I deiodination with PTU did not affect T3G, but induced 
a large increase in T3s. To elucidate the importance of sulfation for I 
production, the effects of the competitive sulfotransferase inhibitors SAM, 
DCNP and PCP were investigated (Fig. 2). These inhibitors produced a dose-
dependent diminution of I production in the absence of PTU and that of T3s 
production in the presence of PTU. At the various inhibitor levels, 
percentage I production in incubations without PTU (Y) was significantly 
correlated with the percentage T3s formation in incubations with PTU (X) 
according to the equation Y = 0.83X + 14.8 (r= 0.79; p(0.001). This 
indicates that the effects of these inhibitors on medium I- are somewhat 
less than their effects on medium T3s. For example, at 100 uM SAM I 
production without PTU was inhibited by 50%, whereas T3s production with 
PTU was inhibited by 73%. Only at the highest concentration (1,000 uM) SAM 
also affected the T3 glucuronidation rate, while DCNP and PCP had no such 
effect at the concentrations tested. 
After the 3 h incubation period, cellular ATP levels were little 
affected by the sulfotransferase inhibitors. Expressed as percentage of 
controls, ATP levels amounted to 88+ 12% at 1,000 uM SAM, 81+ 6% at 10 uM 
DCNP and 109+ 9% at 1 uM PCP. 
-~ 
Effect of SO~ concentration on the metabolism of T3 (Fig. 3) 2! 
In so4 -deplete cultures , T3 clearance was low and T3G was the main 
metabolite found in the medium, independent of the presence of PTU. 
Addition of 0.1- 1 mM so4
2
- induced an increase in T3 sulfation (see 
incubations with PTU), in I production (without PTU) and in T3 
disappearance rate. Once again, I production in incubations without PTU 
(Y) and T~ generation in incubations with PTU (X) showed a close 
correlation: y 0.97X + 2.8 (r= 0.995, p(0.001). T3G 2-
constant over this range of so4 concentrations. 
production was 
Effect of substrate concentration on the metabolism of T3 (Fig. 4) 
Initially, incubations were performed in the absence of BSA. In so4
2
--
containing incubations without PTU, I was the main metabolite at low 
substrate concentrations, i.e. 47.1% of medium radioactivity at 1 nM and 
40.7% at 10 nM. At higher T3 concentrations, I production gradually 
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Figure 3 
Effects of S042- concentration on fhe metabolism ofT 3. Mono-
layers of 1 as hepatocytes were preincubated for 30 min in 
S042--free Dulbecco's medium plus 100 uM SAM. Subsequently, 
incubations were performed for 180 min with 10 nM [1251]T 3 in 
2 ml Dulbecco's medium containing 0-1 mM MgS04 and 0.1 o/o 
BSA. Parallel incubations were performed in the presence of 100 
uM PTU. Medium was analyzed by Sephadex LH-20 chromato-
graphy. Data are taken from one out of three closely agreeing 
experiments. (e 1-, D T3G, o T3S and .A. T3). 
75 
-S04 - PTU -S04 +PTU +S04 -PTU +S04 +PTU 
50 
40 
30 
l 20 
::;; 6 10 
w 
::;; Dooo DODD 
! ~:t 1111 lljfiiil ii~l 
~ 
ii5 50 
0: 
&.; 40 
•• 1111 
i5 
30 
20 
10 
Iii iii Iiiii ..... 
10 100 1000 10 100 1000 10 100 1000 10 100 1000 
Figure 4 
Effects of substrate concentration, SQ42- and PTU on the meta-
bolism of T3 . Mono layers of 1 as hepatocytes were preincubated 
for 30 min in S042--deplete Dulbecco's medium plus 100 uM 
SAM or S04 2--replete medium. After removal of the medium, 
parallel incubations were performed for 180 min in 2 ml S042-_ 
deplete or S04 2--replete Dulbecco's medium with or without 
100 uM PTU in the absence of BSA (n = 4). Substrate concen-
tration was 1-1 ,000 nM [1251]T 3. Medium was analyzed by 
Sephadex LH-20 chromatography. Completion of medium radio-
activity to 100% represents the proportion of unaltered T 3 . 
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2-decreased to ultimately 7.4% at 1,000 nM T3• In incubations without 804 , 
I- production was lowered but not completely nullified compared with 
2-incubations with 804 , varying from 12.9% at 1 nM to 5.9% at 1,000 nM T3• 
In incubations with PTU, generation of I was always less than 4.6%, 
2-independent of the presence of 804 • 
In 804
2
--containing incubations without PTU, little (<8%) T38 
accumulated in the medium at 1-10 nM T3 • At higher T3 concentrations (100-
1,000 nM) or in incubations with PTU, T38 accumulated to 20.9-39.9%. In 
incubations without so4
2
- <3% of radioactivity in the medium eluted in the 
H2o fractions. 
Despite the 103-fold rise in T3 concentrations radioactivity in the 
T3G peak was a fairly constant fraction of total radioactivity in the 
medium. 
HPLC analysis of products (Figs. 5 & 6) 
HPLC analysis of incubations especially with the 
experiments described in Fig. 4 demonstrated the presence of 3,3'-T2 and 
its conjugates. Furthermore, in incubations without B8A, a considerable 
amount of T3 and the various metabolites accumulated intracellularly. We 
therefore made a detailed investigation of all possible metabolites 
produced in incubations of 1 and 10 nM T3 with hepatocytes in the presence 
of 0.1% B8A. The results of these studies are presented in Fig. 5 which 
depicts the quantitation of iodide, conjugates and iodothyronines on 
8ephadex LH-20. The conjugate and iodothyronine fractions were subdivided 
into the different components as determined by HPLC (Fig. 6). 
When hepatocytes were incubated with 804
2
-, I production amounted to 
2-48.5% at 1 nM and 29.3% at 10 nM T3• In 804 -deplete incubations I 
production was still considerable, i.e. 20.7% at 1 nM and 8.9% at 10 nM T3• 2-This was not due to slight 804 contamination in these incubations as no 
sulfate conjugates were detected by HPLC even in the presence of PTU (Fig. 
6). Addition of PTU to the incubations always decreased I production to 
2-less than 5.5%, independent of 804 • 2-Total conjugates in 804 -replete cultures with PTU varied from 52.4-
46.0% and without PTU from 19.2-26.1% at 1 and 10 nM T3 , respectively. 
Whereas T3G production was fairly constant in these incubations, T38 
production increased from 4-5% in the absence to 17.5% in the presence of 
PTU. Beside these T3-conjugates, HPLC also demonstrated the accumulation of 2-3,3'-Tz8 in incubations with 80 4 and PTU. At 1 nM T3, contribution of 
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Effects of S042- and PTU on the metabolism ofT 3 at low substrate 
levels. Monolayers of 106 hepatocytes were preincubated and 
incubated in the presence of 0.1% BSA (n = 14), essentially as 
described in the legend of Fig. 4. Substrate level was 1-10 nM 
[125]T3 . Medium was analyzed by Sephadex LH-20 chromato-
graphy. The conjugate and iodothyronine fractions were subdi-
vided into the different components on the basis of HPLC ana-
lysis of 6-7 experiments. 
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Identification and quantitation of metabolites of T3 incubations 
byHPLCanalysis. Medium of incubations with 1 nM (upper panel) 
or 10 nM T 3 (lower panel) as described in the legend of Fig. 5 was 
chromatographed on Sephades LH-20 with slight modification 
(see Methods). All radioactivity, except 1-, was collected in 1.25 
ml 0.1 M ammonia in ethanol and evaporated at 50°C under a 
stream of N2. Free and conjugated 3,3'-T2 and T3 were separated 
in a single run on HPLC using a non-linear gradient of 15-40% 
acetonitrile in 0.02 M ammonium acetate (pH 4). Fractions of 
0.4 ml were collected and counted for radioactivity. The elution 
position of reference compounds was determined using synthetic 
T3, 3,3'-T2, T3S and 3,3'-T2S and biosynthetic T3G and 3,3'-T2G. 
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3,3'-T2s to total conjugates was 33%, at 10 nM only 11%, and at 
substrate levels 3,3'-T2S was undetectable (not shown). 2-
higher 
than Total conjugates in incubations without so 4 or PTU were higher 
in the corresponding incubations with so 4
2
-. Addition of PTU to incubations 
2-
without so4 had little effect on total conjugate formation, in particular 
on T3G production. However, HPLC analysis also demonstrated the presence of 
3,3'-T2G. At 1 and 10 nM T3 , contribution of 3,3'-T2G to total conjugates 
was 40% and 18%, respectively, independent of PTU. 
In these experiments, the percentage remaining T3 was slightly higher 
in incubations without so4
2
- than with so4
2
- (p<0.001) and always higher at 
the 10 nM than at the 1 nM substrate level (p(0.001). In incubations 
2-
without so4 , HPLC analysis showed that the iodothyronine fraction of the 
Sephadex LH-20 chromatography also contained significant amounts of 3,3'-
T2, the production of which was hardly influenced by addition of PTU. At 1 
and 10 nM T3 , contribution of 3,3'-T2 to the iodothyronine fraction was 22% 
and 12%, respectively. At higher T3 concentrations or in so4
2
--replete 
incubations no 3,3'-T2 or 3,3'-T2G could be demonstrated by HPLC analysis. 
Cell-associated 
2-in so4 -containing 
Addition of PTU led 
radioactivity amounted from 20% of total radioactivity 
incubations to 25-30% in so4
2
-- deplete cultures. 
to a slight (25%) increase in cellular radioactivity. 
However, independent of the different circumstances, )80% of total T3G and 
T3s and >65% of total T3 radioactivity was found in the incubation medium. 
In 
without 
view 
so 2-
4 
of the presence of 3,3'-T2 (and 3,3'-T2G) in incubations 
independent of PTU and the presence of 3,3'-T2s in 2-incubations with so4 plus PTU, we hypothesized the involvement of a PTU-
insensitive, type Ill-like deiodinase. We therefore performed incubations 
in which the type I enzyme was completely inhibited by preincubation of 
hepatocytes with PTU and 1 uM rT3 • Otherwise, the incubations were done as 
described above in the presence of PTU at a substrate concentration of 1 
nM T3• As demonstrated by HPLC (not shown), 3,3'-T2G and 3,3'-T2 production 
in so42-~deplete cultures and 3,3'-T2s production in so42--containing 
cultures were not inhibited by complete inactivation of type I deiodinase. 
The latter was confirmed in parallel incubation with radioactive rT3 (not 
shown). 
RIA of medium 3,3'-T2~3 and T~ 2-Fig. 7 shows the effects of so4 2- and PTU on T3 metabolism as measured 
readily saturable 3,3'-T2 production by RIA. In so4 -deplete cultures a 
80 
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Figure 7 
RIA of medium 3,3'-T 2, T 3 and T 3S content. Monolayers of 106 
hepatocytes were preincubated and incubated in the presence 
of BSA as described in the legend of Fig. 4 (n = 8-16). Substrate 
concentration was 1-1000 nM unlabeled T 3 . In S042--deplete 
incubations no T3S and in 8042--replete incubations no 3,3'-T2 
could be measured. 
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Figure 8 
Effect of GAM on the metabolism ofT 3 . Monolayers of 1 06 hepato-
cytes were preincubated and incubated in 804 2--replete 
Dulbecco medium in the presence of 0.1 o/o BSA. Parallel incu-
bations were performed with 0-5 mM GAM at a substrate level of 
1 nM [1251]T3. Medium was analyzed by Sephadex LH-20 
chromatography. Results are taken from a representative 
experiment reproduced twice. 
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Figure 9 
Metabolic pathways ofT 3 in rat hepatocytes. 
82 
was observed, ranging from 8.7- 0.04% at 1- 1,000 nM T3 • Production of 
3,3'-T2 was not inhibited by PTU at 1 nM T3 and only partially at 10 nM. In 
804
2
--containing incubations without PTU only 5-6% of the substrate was 
recovered as immunoreactive T38 at 1-10 nM T3 • Addition of PTU or 
incubation at higher substrate concentrations (100-1,000 nM) induced the 
accumulation of T38 up to 17%. 3,3'-T2 was not detectable by RIA in 804
2
--
2-
replete cultures and T38 was not detectable in 80 4 -deplete cultures. 
As shown by T3 RIA, in all 804
2
--containing incubations less T3 2-
remained after 180 min than in the corresponding 804 -deplete cultures 
(p<0.001). Addition of PTU did not greatly influence the percentage 
remaining T3• 
RIA measurements were also performed in cell extracts. Again, a fairly 
constant medium:cell ratio was observed for the different compounds 
irrespective of the different circumstances: 71-83% of total 3,3'-T2 , >92% 
of total T38 and 74-85% of total T3 was found in the medium. 
Effect of GAM on the metabolism of T3 (Fig. 8) 
The effects of GAM, an inhibitor of UDP-glucuronyl transferase 
(11,12), on the metabolism of T3 were investigated. Addition of 0.5-5 mM 
GAM in the incubation medium led to a stepwise reduction in medium T3G 
content by 65%. T3 clearance was inhibited with 25%, but I production was 
not influenced. Cellular ATP levels were only slightly reduced by GAM, i.e. 
8% at 2.5 mM and 19% at 5 mM. 
The metabolism of T3G was further investigated in incubations of 
[ 125I]T3G with microsomes as described in Materials and Methods, or with 
hepatocytes. Under these conditions, which resulted in extensive 
deiodination of T38 (ref. 7 and Eelkman Rooda, 8.J., and T.J. Visser, 
unpublished observations), I 
undetectable. 
and 3,3'-T2G production from T3G were 
Conversion of T3 to 3,3'-T2 by rat liver microsomes (Table 1) 
At the lowest substrate concentration (<0.1 nM), 5.8% of [ 125I]T 3 was 
converted to 3,3'-T2• The percent production of 3,3'-T2 progressively 
decreased with increasing substrate concentration to a plateau of 2.3% at 
100-1,000 nM T3 • Inhibition of 3,3'-T2 production by PTU was minimal at 
<0.1-1 nM T3 , partial at 10-100 nM T3 and complete at 1,000 nM T3• 
Coincubation of microsomes with PTU and rT3 resulted in the complete 
inactivation of the type I deiodinase as demonstrated in experiments with 
125I-rT3 as substrate (not shown). This led, once again, to the complete 
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inhibition of 3,3'-T2 production at the highest T3 concentration, while the 
fraction of T3 converted to 3,3'-T2 at each lower substrate concentration 
was also diminished by -2%. 
Table 1 
--~~~~~~~:~~-~~-:3_:~-~~~:::2_~:-~:-~:~~~-~:~~~~~~~--
% 3,3'-T 
-----------------------2------------------Control PTU PTU+rT 
nM T (n=6) (n=5) (n=3)3 _____ 3 ________________________________________________ _ 
0 6.1+0.1 5.3+0.1 4.0+0.1 
1 
10 
100 
1000 
5.0+0.1 
3.2+0.1 
2.4+0.1 
2.2+0.2 
4.4+0.1 
2.1+0.1 
0.9+0.3 
0.1+0.1 
3.0+0.1 
1.8+ 0 
0.7+0.3 
0 
------------------~---------------~----------------------Rat liver micosomes were incubated for 1 h at 37C with 
125 . [ I]T3 plus 0-1,000 nM T3 ~n 0.1 M phosphate buffer (pH 
7.2), 2 mM EDTA and 5 mM DTT in the presence or absence 
of PTU or rT3• The reactions were stopped by addition of 
0.1 M HCl and analysed by Sephadex LH-20 as described in 
Materials and Methods. 
DISCUSSION 
It has been known for some time that T3 is metabolized in rats 
primarily by conjugation and deiodination. Morreale de Escobar and Escobar 
del Rey reported on the metabolism of T3 in thyroidectomized rats, 
substituted with r 3 (18). After isotopic equilibration with 
125I-labeled 
r 3 , approximately equal proportions of radioactivity appeared in the urine 
and feces. Administration of PTU led to a decrease in urinary I excretion 
with a concomitant increase in fecal radioactivity. The identity of the 
excretory products was not investigated in this study. 
Already in 1960 Flock et al. observed that glucuronidation and 
sulfation are important pathways in the metabolism of r 3 and r 4 (19,20). 
After administration of labeled r 3 , T3G was the predominant excretory 
product in the bile of normal rats. Excretion of especially r 3s was 
increased by treatment of the rats with butyl-4-hydroxy-3,5-diiodobenzoate 
(BHDB) (19,20), a known inhibitor of the type I deiodinase (2,3). 
In contrast to rats, normal dogs injected with 125I-r3 also excrete, 
in addition to T3G, significant amounts of r 3s and 3,3'-T2s into the bile 
and the urine (19), In hepatectomized dogs urinary I and r 3G excretion 
84 
diminished while that of T3s and 3,3'-T2S increased. Nephrectomy, however, 
led to a decrease in the production of the latter conjugates (19). This 
suggested that in dogs the liver is an important site for deiodination and 
for the glucuronidation of T3 , while the kidneys and perhaps other organs 
may be more important for the sulfation of iodothyronines. 
Roche and coworkers identified T3S as the main T3 metabolite in the 
bile and plasma of thyroidectomized rats (21,22), a finding which can now 
be ascribed to the impaired type I deiodinase activity in hypothyroidism 
(2,3). Recently, we have used HPLC to identify T3 metabolites in the bile 
and plasma of rats (23,24). Within 4 h after injection of 125I-T3 to normal 
rats, 22.4% of the dose was excreted in the bile, mainly in the form of 
T3G. In PTU-treated rats the biliary excretion amounted to 36% of the dose 
after 4 h, due to an increased output of T3s and 3,3'-T2s (23). PTU-
treatment also induced a 4-5 fold increase in plasma T3S after 
125I-T3 
injection (24). Although DCNP by itself had little effect on the biliary 
clearance of T3 , it greatly diminished the PTU-induced excretion of T3S and 
3,3'-T2S (23). This indicates that, in vivo, sulfation of T3 in rats is 
mediated predominantly by a DCNP-sensitive phenol sulfotransferase. 
There is now overwhelming evidence that the type I deiodinase 
catalyses both the IRD and ORD of iodothyronines (2,3). Thus, the same 
enzyme generates T3 from T4 as well as catalyses the degradation of this 
hormone. Another important aspect of type I deiodination is the fact that 
sulfate conjugation of the 4'-hydroxyl group of T3 greatly facilitates this 
reaction (7). This is reflected in the 30-fold increase in the V of the 
max 
IRD of T3s compared with IRD of nonconjugated T3• Sulfation has also been 
shown to accelerate the IRD of T4 (25) and the ORD of 3,3'-T2 (5). Previous 
studies have demonstrated that deiodination of T3 and 3,3'-T2 in rat 
hepatocytes greatly depends on the prior sulfation of these compounds (5). 
It was the purpose of the present study to determine into more detail the 
contribution of the various pathways to the metabolism of T3 in rat liver 
cell cultures. Based on findings from the literature and data presented in 
this paper the hepatic metabolism of T3 in rats can be summarized as shown 
in Fig. 9 (p 82). 
In rat liver, T3 is metabolized via three, quantitatively important 
pathways which will be described consecutively. The first metabolic 
pathway is glucuronidation. In vivo, the product T3G is probably excreted 
by hepatocytes directly into the bile (see above). The undetectable levels 
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of T3G in plasma suggest that it is exported specifically through the 
canalicular cell membrane of the hepatocyte, perhaps involving the same 
transport system as described for the excretion of other conjugates and 
organic anions (26). Glucuronidation has a high capacity in view of our in 
vitro experiments, which show that the fraction of T3 which is 
glucuronidated is constant over a wide range of substrate concentrations 
(Fig. 4). Furthermore, T3G is not liable to further metabolism, e.g. 
d · d" · 125 I- 3 3' T G d d f i b . f e~o ~nat~on, as no or , - 2 were emonstrate a ter ncu at~on o 
T3G with liver microsomes or hepatocytes. 
The second metabolic pathway for the metabolism of T3 in hepatocytes 
is sulfation. This process also has a high capacity, as it is not saturated 
even at 1,000 nM T3 (Figs. 4 & 7). As mentioned above, the product T3S is a 
good substrate for IRD by the type I deiodinase. This deiodinative process 
is readily saturated at added T3 concentrations >10 nM (through 
intracellular T3S production) and is inhibited by PTU, resulting in the 
accumulation of T3S (Fig. 4). At the low endogenous concentrations of type 
I deiodinase substrates, the enzyme is probably not saturated to a 
significant extent in vivo and deiodination of T3s will not be limited, 
explaining the low levels of T3S in bile and plasma in normal rats 
(19,23,24). However, biliary excretion and plasma levels of T3s increase 
when the type I enzyme activity is impaired in the hypothyroid state and by 
PTU or BHDB treatment (2,20-24). 
The third pathway for T3 metabolism in rat liver cells is direct IRD 
to 3,3'-T2 • The latter was only observed at low (<10 nM) T3 concentrations 2-in so4 -deplete cultures, independent of the presence of PTU (Figs. 5 & 
7). The 3,3'-T2 produced by IRD of T3 accumulates in these cultures because 
the main pathway for the metabolism of 3,3'-T2 (i.e. sulfation) is 
excluded. Similar findings have been obtained in studies of the production 
of 3,3'-T2 from rT3 in this system (8). Direct IRD of T3 
apparently due to the presence of a PTU-insensitive, 
to 3,3'-T2 is 
type III-like 
iodothyronine deiodinase. This was concluded from experiments in which type 
I deiodinase activity was completely inactivated by incubation of 
hepatocytes (see Results) or the microsomal fraction (Table 1) with rT3 and 
PTU. It is known that rT 3 is the preferred substrate for the type I enzyme 
and that PTU is an uncompetitive inhibitor which reacts with an enzyme 
intermediate generated during catalysis (2,3). The degree of PTU 
inhibition, therefore, depends on both quality and quantity of the 
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substrate. T3 itself is a poor substrate for the type I deiodinase with a 
high K of -10 uM (14), and at T3 concentrations <1 uM PTU inhibition m is 
only partial. However, complete inactivation of the type I enzyme is 
achieved with PTU in the presence of 1 uM rT3 , independent of the T3 
concentration (2,3). Under these conditions production of 3,3'-T2 from low 
T3 concentrations persists (e.g. Table 1), compatible with the involvement 
of a type III-like deiodinase (see below). 
Although production was only observed in 2-804 -deplete 
2-804 replete) hepatocytes, direct IRD of T3 also occurs under normal (i.e. 2-
conditions. In 804 -containing incubations in which the type I enzyme was 
completely inhibited (i.e. by PTU and rT3), 3,3'-T28 production was still 
observed. As under these conditions type I IRD of T38 is prevented and 
evidence exists that type III IRD of T38 does not occur (27,28), the only 
remaining route for this 3,3'-T28 production is direct IRD of T3 and 
successive sulfation of 3,3'-T2• 2-In 804 -deplete cultures production of 3,3'-T2G in addition to 3,3'-
T2 was observed at low T3 concentrations. As T3G is no substrate for IRD by 
the type I enzyme, 3,3'-T2G is only formed by glucuronidation of 3,3'-T2• 
Virtually no 3,3'-T2G is observed in rat bile (23), consistent with our in 
vitro observations that glucuronidation of 3,3'-T2 is much slower than its 
sulfation (8). 
The production of radioiodide in incubations of outer ring-labeled T3 
with hepatocytes may be derived from different routes (Fig. 9). Roughly 
-
equal amounts of I are produced via the pathways T3_..T38~3,3'-T2 8 and 
T3~3,3'-T 2~3,3'-T28. This is concluded from the similar quantities of 2-T38 and 3,3'-T28 that accumulate in 804 -replete cultures at 1 nM T3 in 
the presence of PTU (Fig. 5). At higher substrate concentrations levels the 
contribution via the pathway T3~3,3'-T2--+3,3'-T2 8 decreases due to 
saturation of the first reaction (Fig. 5). In 804
2
--deplete cultures I is 
mainly produced by PTU-sensitive (type I) ORD of 3,3'-T2 (Figs. 4 & 5). 
Principally, two other I- producing pathways are possible, namely type I 
ORD of T3 or T38. However, no 3,5-T2 could be measured by specific RIA in 2-804 -deplete cultures (Visser, T.J., and 8.J.Eelkman Rooda, unpublished 
observations). Furthermore, experiments with microsomes strongly suggest 
that T38 primarily undergoes IRD and succesive ORD of the product 3,3'-T28 
(7). 
As described above, we obtained evidence for the presence of a type 
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III-like enzyme in our hepatocyte cultures. So far, the type III enzyme, 
which is PTU insensitive and catalyses only the IRD of iodothyronines, has 
been localized in rat brain (29), skin (30) and placenta (31). A similar 
enzyme has been described in less-differentiated liver tissues and cells, 
i.e. monkey hepatocarcinoma cells (27,28) and in fetal rat (32) and chicken 
liver (33), but to our knowledge not in adult liver. One explanation for 
our finding is the possible induction of the enzyme under our culture 
conditions. Direct IRD of T3 in the hepatocytes appeared more variable than 
the other metabolic pathways. However, the results in Table I clearly show 
for the first time that the type III enzyme is present in the microsomal 
fraction of adult rat liver. The reason that no type III-like activity has 
been described previously in liver microsomes is probably due to the low 
Vmax and Km values of this enzyme for T3 • Therefore, the contribution of 
this enzyme to the 3,3'-T2 production at the high T3 concentrations 
generally used in studies of the type I IRD of T3 is also low. Further 
studies are needed to characterize this type III-like deiodinase of rat 
liver. 
The principles of the various methods used in this paper have been 
described previously (8). Firstly, a 30 min preincubation of hepatocytes in 
Dulbecco medium without so4
2
- or possible so4
2
- precursors such as 
methionine and cysteine in the presence of 100 uM SAM, provides an easy and 
2-
reliable method to deplete cells of so4 (8). Since SAM is extensively 
sulfated in liver cells, it is added to the preincubations to further 
2-deplete cellular so4 stores. This action of SAM in the preincubation does 
not interfere with T3 metabolism in the incubation 
restoration of 
cultures (8). 
T3 metabolism after readdition of 
Secondly, at T3 concentrations 
period, as 
SO 2- to 4 
shown by the 
2-so4 -deplete 
)10 nM Sephadex LH-20 
chromatography provides a rapid means for the study of the T3 metabolism, 
with results in close agreement with HPLC analysis and RIA measurements. 
For analysis of incubations with <10 nM T3 Sephadex LH-20 chromatography is 
less suitable, due to accumulation of 3,3'-T2 and its conjugates. 
Therefore, these incubations were analyzed by HPLC and specific RIA's. 
Thirdly, analysis of the medium reflects intracellular events and can thus 
be used for quantitation of the T3 metabolism. This is concluded from the 
findings that, especially in the presence of BSA, the various products are 
observed predominantly in the medium while, furthermore, their distribution 
over medium and cells is independent of the different circumstances. 
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CHAPTER VI 
INCREASED PLASMA T3 SULFATE IN RATS WITH INHIBITED TYPE I IODOTHYRONINE 
DEIODINASE ACTIVITY AS MEASURED BY RADIOIMMUNOASSAY 
92 
ABSTRACT 
In contrast to the glucuronide conjugate, T3 sulfate (T3S) undergoes 
rapid deiodinative degradation in the liver and accumulates in rats and in 
rat hepatocyte cultures if type I iodothyronine deiodinase activity is 
inhibited. We here report the radioimmunoassay (RIA) of plasma T3s in rats 
treated with the antithyroid drugs propylthiouracil (PTU) or methimazole 
(MMI), of which only PTU inhibits type I deiodinase. Male Wistar rats were 
treated acutely by ip injection with 1 mg PTU or MMI per 100 g body wt and 
subsequently for 4 days by twice-daily injections with these drugs together 
with 0.5 ug T4 or 0.25 ug T3 per 100 g body wt. Blood was obtained 4 h 
after the last injection and plasma T4 , rT3 , T3 and T3s were determined by 
RIA and compared with pretreatment values. Serum concentrations (mean ~ SEM 
nmol/1) in untreated rats were: T4 51 ~ 1; T3 1.37 ~ 0.03; T3S 0.09 ~ 0.01; 
rT3 0.03 ~ 0.002. Serum T3 was decreased and T3s and rT3 were increased by 
acute PTU treatment (T3 1.16 ~ 0.05, p<O.Ol; T3S 0.33 ~ 0.04, p<O.OOl; rT3 
0.27 + 0.02, p<O.OOl) but unaffected by acute MMI treatment (T3 1.37 + 
0.05; T3S 0.09 ~ 0.01; rT3 0.02 ~ 0.003). In T4-treated rats, serum T3 was 
decreased and T4, T3S and rT3 were increased by PTU vs MMI (T4 86 ~ 5 vs 58 
~ 4, p<O.OOl; T3 0.51 ~ 0.07 vs 0.88 ~ 0.06, p<O.OOl; r 3s 0.38 ~ 0.03 vs 
0.12 ~ 0.01, p< 0.001; rT3 0.86 ~ 0.19 vs 0.08 ~ 0.01, p<0.005). In T3-
substituted rats T3s was increased by PTU vs MMI (1.09 ~ 0.13 vs 0.25 + 
0.03, p<O.OOl). The T3s;r3 ratio in the PTU-treated, T3-replaced rats (0.60 
+ 0.09) was in agreement with that determined by HPLC of serum 
radioactivity in animals that in addition to this treatment also received 
-lo uCi [125I]T3 with the last 2 injections (0.92 ~ 0.13). In conclusion, 
this investigation demonstrates the feasibility of the measurement of serum 
T3S by RIA. Our findings confirm previous observations with radioactive 
isotopes, suggesting that sulfation is an important pathway for the 
metabolism of T3 in rats. Analogous to rT3, the accumulation of T3S in PTU-
treated rats indicates that this conjugate is metabolized predominantly by 
type I deiodination. 
INTRODUCTION 
Although thyroxine (T4 ) is the predominant secretory product of the 
thyroid, it is thought to have little intrinsic biological activity (1). 
Outer ring deiodination (ORO) of T4 yields the bioactive hormone 3,3',5-
triiodothyronine (T 3). Complete loss of bioactivity results from the inner 
ring deiodination (IRD) of T4 with the formation of 3,3',5'-
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triiodothyronine (rT3). Peripheral conversion of T4 is the major source for 
circulating T3 ( 80%) and rT3 ( 95%) in normal humans and rats (1). For 
this purpose many tissues contain iodothyronine deiodinases (called type I, 
II and III), enzymes 
(2,3). The type I 
that act not only on T4 but also on its metabolites 
deiodinas'e, located in liver and kidney, is a 
nonselective enzyme capable of both ORD and IRD, while the type II and III 
enzymes specifically act on either the outer or the inner ring (2,3). A 
further distinction is the potent inhibition of type I deiodinase by 
propylthiouracil (PTU), which drug does not influence type II or III 
activity. In euthyroid rats, peripheral production of plasma T3 is effected 
primarily by type I ORD of T4 and to a minor extent through the type II 
deiodinase (4). Besides conjugation, T3 is metaboliz~d by type I and III 
IRD to 3,3'-diiodothyronine (3,3'-T2). 
We have recently investigated the metabolism of T3 in primary cultures 
of rat liver cells (Chapter V, ref. 5) and in intact rats (6,7). In 
hepatocytes, T3 is metabolized via three quantitatively important pathways, 
i.e. glucuronidation, sulfation and direct IRD. Both in vitro (at <10 nM T3 
concentrations) and in vivo, radioiodide and labeled T3G were the main 
metabolites of outer ring 125I-labeled T3 (5-7). While T3 glucuronide (T3G) 
is a stable conjugate that is rapidly excreted into the bile, normally 
little T3 sulfate (T3S) was observed in vitro and in vivo due to rapid 
deiodination of T3s by the type I enzyme. Inhibition of the deiodinase with 
PTU induced the accumulation of T3S and 3,3'-T2 sulfate (3,3'-T2S) in the 
hepatocyte cultures (5) as well as in bile and plasma of the intact animal 
(6,7). These results strongly suggested that successive sulfation and 
deiodination is an important pathway in the hepatic metabolism of T3• 
We have developed a specific radioimmunoassay (RIA) for T3S (8) and we 
now report its use in the measurement of plasma T3S levels in rats treated 
with PTU or methimazole (MMI). 
METHODS 
Materials 
3,5-Diiodothyronine (3,S-T2), T3 , rT3 and T4 were obtained from 
Henning Berlin GmbH (Berlin, FRG). [3'-125IJT 3 was obtained from Amersham 
(Amersham, UK; )1200 uCi/ug) or synthesized by radioiodination of 3,S-T2 in 
our laboratory (3300 uCi/ug) using standard methods. [3'-125I]T3S and non-
radioactive T3S were prepared by reaction of labeled or unlabeled T3 with 
chlorosulfonic acid and purified by Sephadex LH-20 (Pharmacia Fine 
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Chemicals, Uppsala, Sweden) chromatography as previously described (9). 
Standard T3S was also a gift from Dr. H. Rokos (Henning). PTU was purchased 
from Sigma Chemical Co. (St Louis, MO) and MMI (2-mercapto-1-methyl-
imidazole) from Janssen Chimica (Beerse, Belgium). All other reagents were 
of analytical grade. 
Experimental procedures 
Male Wistar rats, 200-250 g body wt, were treated acutely (day 0) by 
ip injection with 1 mg PTU or MMI in 250 ul 0.1 N NaOH in saline per 100 g 
body wt. Subsequently the rats were injected ip twice daily with 1 mg PTU 
or MMI together with 0.5 ug T4 or 0.25 ug T3 in 250 ul 0.1 N NaOH in saline 
per 100 g body wt for 4 days. Blood samples (2 ml) were taken under ether 
anesthesia from the tail vein or by orbital puncture before treatment and 4 
h after the initial PTU or MMI injection on day 0. The animals were bled by 
heart puncture 4 h after the last injection on day 4 (Scheme 1). In 
addition, 5 rats were treated with PTU and T3 as described above, but with 
the last 2 injections they also received -10 uCi [ 125I]T3 • 
Treatment PTU or MMI 
Protrtatmont OJ 1 2 3 
days 
------------Blood samples--------------------
Analysis of samples 
RIA 
Scheme 1 
Serum was kept at -20 C until assayed for T4 , T3 , T3S and rT3 content 
by specific RIA. RIA of plasma T4, T3 and rT3 was performed using standards 
prepared in thyroid hormone-free human or rat serum with identical results. 
The T3S RIA was recently described by us (8) and adapted for serum T3S 
measurements. Although the antiserum (#8193) used in this assay is fairly 
specific, the low crossreactivities with T3 (0.4%) and, more importantly 
because of its higher plasma levels, T4 (0.6%) are not negligible and 
necessitate the isolation of the serum T3s fraction as follows. To 0.25-0.5 
ml serum was added 3 volumes of a HCl-ethanol solution to obtain final 
concentrations of 0.5 M HCl and 10% ethanol. The mixtures were applied to 
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small Sephadex LH-20 columns (0.7S-3 ml bed volume), which were eluted 
successively with 1-2 ml 0.1 M HCl (2x), H2o (2x), 20% ethanol in water 
(7x) and ethanol-0.1 M NaOH (1:1, vol/vol) (3x). Appropriate 20% ethanol in 
water fractions (usually 3) were pooled and freeze-dried. Alternatively, 
the pooled r 3s fractions were concentrated on a second Sephadex LH-20 
column and transferred to a small volume of 0.1 M ammonia in ethanol as 
described (Chapter V), followed by evaporation of the solvent at SO C 
under a stream of N2 • Residues were dissolved in O.S-1 ml 0.01 M NaOH or 
RIA buffer and assayed for r3s content. r3s fractions were identified by 
chromatography of parallel serum samples spiked with [ 12SI]T 3s. Recovery of 
the tracer over the entire procedure amounted to 76 + 2% (mean + SEM, 
n=19). 
Recovery of SOO pM r3s added to pool serum was 106 ~ 6% (n=8). Addition of 
T3 (10 nM) and T4 (1 uM) increased serum T3S immunoreactivity with <SO pM 
(n=8). The within-assay GV was found to be 7.4% (n=8). The between-assay GV 
calculated on the basis of repeated determinations on the same samples in 
separate assays was 12.0%. 
Radioactive products 
were analyzed as Serum samples from rats treated with [ 12SI]T 3 
follows. Plasma 12SI- was measured as trichloroacetic acid (TCA)-soluble 
S0-100 ul serum was mixed with 10% radioactivity. For this purpose, 
(wt/vol) ice-cold TCA to a final volume of SOO ul. After 10 min at 0 C, 
mixtures were centrifuged and radioactivity was determined in the 
supernatant. For identification of T3 metabolites by HPLC, iodothyronines 
and conjugates were separated on Sephadex LH-20 or they were obtained 
collectively by solid-phase extraction (SPE). Fractionation of serum was 
done by stepwise Sephadex LH-20 chromatography similar to the method 
described above, modified such that conjugates were eluted with H2o and 
iodothyronines with 0.1 M ammonia in ethanol. SPE of serum was performed as 
follows. Serum (O.S ml) was mixed with an equal volume 0.2S M NaOH and 
applied to a c18-SPE column (SOO mg, J.T. Baker Chemical Co., Philipsburg, 
NJ). Columns were washed successively with 2x1 ml of each 0.1 M NaOH, H2o, 
0.1 M HCl and H2o, before both conjugates and iodothyronines were collected 
in 1 ml methanol. Reversed-phase HPLG was done using a 10x0.3-cm Ghromspher 
c18 analytical column (Chrompack BV, Middelburg, The Netherlands) as 
described previously (6). Elution was performed with a 2S min gradient of 
16-40% acetonitrile in 0.02 M ammonium acetate (pH 4). Flow was 0.8 ml/min 
96 
and fractions of 0.5 min were collected. 
Data analysis 
125 RIA was corrected for recovery of [ I]T 3s added to pool 
serum run in triplicate parallel with experimental samples in each 
chromatography session. Data are presented as mean + SEM. St~dent's t-test 
was used to determine the significance of the difference between serum 
levels in untreated rats versus (vs) acute PTU or MMI treatment, or between 
those in the chronically PTU- vs MMI-treated rats. 
RESULTS 
Fig. 1 shows the results of the serum T4 , T3 , rT3 and T3S measurements 
as well as the T3;r4, rT3/T 4 and T3s;r3 ratios in rats before and 4 h after 
a single MMI or PTU injection. Control values were: T4 51! 1, T3 1.37 + 
0.03, T3S 0.09 + 0.01 and rT 3 0.03! 0.002 nmol/1. Serum T4 was not 
affected while serum T3 was decreased by 15% and serum rT 3 and T3s were 
increased 9- and 3.7-fold, respectively, by acute PTU treatment. No changes 
were observed after a single MMI-injection. Control values for the 
different ratios were: T3/T4 (xl0
2 ) 2.8! 0.1, rT3/T4 (xl0
2) 0.6! 0.05, and 
T3S/T3 0.07 ! 0.005. Acute PTU treatment decreased the T3 /T4 ratio by 25% 
and increased the rT3/T4 and T3s;T3 ratios 8- and 4.7-fold, respectively. 
Acute MMI treatment did not produce significant changes in any of these 
parameters. 
Figure 2 shows the results of the longer-term treatment of rats with 
PTU or MMI in combination with replacement doses of T4• Treatment of T4-
substituted rats with PTU res~lted in 48% higher T4, 42% lower T3, 11-fold 
higher rT 3 and 3.2-fold higher T3s (0.38 ! 0.03 vs 0.12 + 0.01 nmol/1) 
levels compared with corresponding values in MMI-treated rats. As a result, 
PTU induced a 63% decrease in the T3/T4 ratio, a 6-fold increase in the 
rT3/T4 ratio and a 6.5-fold increase in the r 3s;r3 ratio (0.91 + 0.16 vs 
0.14! 0.01). 
Figure 3 shows the effects of prolonged PTU or MMI administration in 
T3-treated rats. Treatment with T3 for 4 days lowered serum T4 levels to 5-
8 nmol/1 in both groups of rats (not shown), and serum T3 levels were not 
significantly different after PTU (1.87 ! 0.15 nmol/1) or MMI (2.22 ! 0.16 
nmol/1). Compared with MMI, PTU-treatment caused a 4-fold increase in the 
serum T3s levels (from 0.25 ! 0.03 to 1.09 ! 0.13 nmol/1) and a 5-fold 
increase in the T3S/T3 ratio (from 0.12! 0.02 to 0.60! 0.09). 
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0.6 rT3!T4 (X 100) 3 T3!T4 (X 100) 0.6 T3S/T3 
D Contr .. 
D . MMI 0.4 2 0.4 
~ •• PTU I * P < O.D1 0.2 0.2 ** p <0.001 (vs Control) 0 0 o 0 ... 0 0 0 . . 
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Figure 1 
Serum T 4, rT 3, T 3 and T 3S (nmol/1} and the rT 3 fT 4, T 3fT 4 and 
T 3S!f 3 ratios in rats before and 4 h after acute treatment with 
1 mg MMI or PTU per 100 g bodywt. Results are given as mean± 
SEM and the significance of the effects of PTU and MMI was 
estimated using Student's t-test: * p < 0.01, ** p < 0.001 
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Figure 2 
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Serum T4 , rT3, T3 and T3S (nmol/1) and the rT3/T4 , T3/T4 and 
T3S/T3 ratios in rats treated with twice daily injections with 1 mg 
PTU orMMI and 0.5 ugT4 per 100 g bodywt. Results are given as 
mean ± SEM and the significance of the differences between 
PTU and MMI treatment was estimated using Student's t-test: 
* p < 0.01' ** p < 0.005, *** p < 0.001 
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Figure 3 
Serum T 3 and T 3S (nmol/1) and the T 3S/T 3 ratio in rats treated with 
twice-daily injections with 1 mg MMI or PTU and 0.25 ug T3 per 
100 g body wt. Results are given as mean± SEM and the signifi-
cance of the differences between PTU and MMI treatment was 
estimated using Student's t-test: * p < 0.001 
Figure 4 
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HPLC analysis of a solid-phase extract of serum from a rattreated 
with twice-daily injection of 1 mg PTU and 0.25 ug T 3 per 1 00 g 
body wt. On the last 2 occasions the rat also received 1 0 uCi 
[1251]T 3 (for details, see methods). The elution position of 
reference compounds was determined using synthetic 3,3'-T2S, 
T3S and T3 . 
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Determination of the serum [ 125I]T3S/T3 ratio 
Serum 
received 
(determined 
+ 4% T3' 
radioactive 
radioactivity of the 5 rats treated with PTU and r 3 that also 
[125 I]T with the last 2 injections contained 25 + 3% I 3 
by TeA-precipitation), 36 + 4% water-soluble conjugates and 40 
as determined by Sephadex LH-20 chromatography. The ratio of 
T3S/T3 estimated by HPLC was 0.92 ~ 0.13 (n=5). In Fig. 4 a 
representative HPLC profile is shown of one of the rats with a T3S/T3 ratio 
of 0.76. The metabolites identified are 3,3'-T2S, T3S, r 3 and an additional 
conjugate which is probably the sulfate conjugate of 3,3'-diiodothyroacetic 
acid (M. Rutgers and T.J. Visser, unpublished observations). 
DISCUSSION 
Monodeiodination is the major pathway of T4 metabolism, accounting for 
-so% of its disposal in humans (1). Roughly equal proportions of r 4 are 
converted to T3 and rT3, although estimates of especially the total body 
rT3 production vary considerably in the literature (1). In euthyroid rats, 
most plasma T3 appears to be derived from the PTU-sensitive, type I ORD of 
T4 in liver and kidney (4). PTU is also a strong inhibitor of the 
peripheral production of T3 in humans (10-14). In contrast, PTU does not 
seem to affect the peripheral production of rT3 but greatly inhibits the 
metabolic clearance of this compound (14). Although rT3 is also produced in 
the liver by type I IRD of T4, probably little of this metabolite is 
released into the circulation but instead is rapidly further degraded by 
type I ORD to 3,3'-T2 (2). This explains that plasma rT3 is mainly cleared 
by the liver and perhaps to some extent by the kidneys as substantiated by 
measurements of arterio-venous gradients of rT3 across these organs in 
patients with mild liver failure (15). The source of plasma rT3 has not 
been established but is probably derived from the type III IRD of T4 
perhaps in brain and skin (2). 
Whereas type I deiodination is the major metabolic pathway of rT3 , the 
metabolism of T3 is more complex. In extrahepatic tissue's T3 is deiodinated 
to 3,3'-T2 especially by the type III IRDase while in rat liver two 
additional pathways have been detected, i~e. glucuronidation and sulfation 
(5). Whereas T3G is a stable conjugate, T3s is metabolized in rapid 
succession by IRD and ORD with 3,3'-T2s as a transient intermediate. Due to 
its high susceptibility to type I deiodination (16), little T3s is observed 
under normal conditions in rat serum or bile and in T3 incubations with 
isolated rat hepatocytes (5-7). Only if type I deiodinase activity is 
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inhibited for instance with PTU, T3S has been shown to accumulate in vivo 
and vitro (5-7). 
The present experiments in rats were designed to investigate the 
usefulness of the RIA of plasma T3s in the study of the peripheral 
metabolism of thyroid hormone. The properties of this RIA have been 
described in detail elsewhere (8). Although the cross-reactivity of T4 and 
with the T3S antibody are low, their relatively high serum 
concentrations necessitate that these iodothyronines are removed prior to 
the assay. This has been accomplished by isolation of the serum 
iodothyronine conjugate fraction in a simple, batch-wise precleaning step 
using Sephadex LH-20 as an adsorbent. This method is characterized by 
reproducible and high recoveries for T3s. Using this procedure, 
interference with the estimation of plasma T3S levels by even supra-
physiological T4 and T3 concentrations was circumvented. 
In this study we used PTU as a selective inhibitor of the type I 
deiodinase in liver and kidney. This drug has little or no effect on the 
type II and III deiodinases in other tissues (2). As a control, parallel 
groups were treated with MMI, another thyrostatic drug. Overwhelming 
evidence has been presented in the literature that MMI does not inhibit the 
peripheral deiodination of thyroid hormone (17), although a recent study 
has suggested that MMI may enhance tissue T4 to T3 conversion (18). No such 
action of MMI was evident in the present study. For instance, treatment of 
rats for 4 days with a replacement dose of T4 in combination with MMI 
resulted in plasma T4 levels 4 h after the last injection that were equal 
to those in untreated animals. The T3/T4 ratio in these animals was 40% 
lower than in the controls, which is largely accounted for by the cessation 
of thyroidal r 3 secretion. 
Plasma r 3s levels were low in untreated rats and the r 3s;T3 ratio in 
these animals (0.07) was not changed after a single injection with MMI 
(0.06) or after prolonged treatment with this drug in combination with T4 
(0.14) or T3 (0.12). The effectiveness of PTU as an inhibitor of the type I 
deiodinase was demonstrated by the greater reduction in the plasma T3/T4 
ratio compared with the parallel, MMI-treated rats. This was already 
evident 4 h after a single PTU injection but most impressive were the 
differences in the T4-replaced animals, where the T3/T 4 ratio was decreased 
by 63% in the PTU-treated rats compared with the corresponding MMI group. 
This figure is in excellent agreement with the findings reported by Silva 
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et al. (4), indicating that roughly 70% of peripheral T3 production in 
euthyroid rats is accomplished by the PTU-sensitive (i.e. type I) 
deiodination of T4 • In the T4-substituted rats, plasma T4 levels were 
considerably higher in animals treated with PTU than in those receiving 
MMI, indicating that type I deiodination is an important, rate limiting 
step in the disposal of T4 • Plasma T3s was increased 3.5-fold 4 h after 
acute PTU administration and was also greatly elevated by chronic treatment 
with this drug in the T4-substituted rats despite the decrease of plasma T3 
in these animals. This seems to indicate that PTU exerts a greater 
inhibition on the metabolic clearance of T3s than on the production of T3 
from T4• This is explained by assuming that type I deiodination is 
virtually the only pathway for the metabolism of T3s, while there exists an 
alternative, PTU-insensitive (type II) pathway for the peripheral 
production of T3 • The mean T3S/T3 ratio in the PTU-treated rats varied from 
0.31 in the acutely treated rats to 0.60-0.91 after prolonged treatment 
of the animals substituted with T3 or T4• The magnitude of these T3S/T3 
ratios was similar to that found previously 4 h after iv administration of 
[ 125I]T to rats treated with a single PTU dose. This was further 3 
substantiated in the present study by the results obtained with PTU-
treated, T3-substituted rats that also received [
125I]T 3• The [
125I]T3s;T3 
ratio in these animals (0.92 ~ 0.13) was not significantly different from 
the T3s;T3 ratio determined by RIA. 
In the absence of accurate data on the MCR of T3s and steady-state 
plasma levels of this conjugate under different conditions, it is not 
possible from the results in this paper to provide estimates of the 
quantitative contribution of sulfate conjugation to the metabolism of T3 in 
rats. However, the in vitro studies with isolated rat hepatocytes (chapter 
V, ref. 5) as well as the analyses of T3 metabolites in bile (7) suggest 
that sulfation is equally important as glucuronidation, accounting together 
for roughly half of the T3 disposal. 
Except, of course, for the T3-replaced rats there appears to be a 
close correlation between the PTU-induced increase in plasma rT3 and T3s. 
The plasma rT3 levels in the untreated rats (0.03 nmol/1) were close to the 
detection limit of our RIA and in agreement with the values reported by 
Kaplan et al. (19) but substantially lower than those published by most 
other investigators (20-23). The 8-fold increase in plasma rT3 in response 
to acute as well as chronic PTU-treatment is also in excellent agreement 
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with data published by Kaplan et al. (19) and Heinen et al. (23). The 
parallel increase in plasma rT3 and T3S after PTU further underscores the 
importance of the type I deiodinase for the disposal of these compounds. 
In conclusion, this paper demonstrates the feasibility of the RIA for 
plasma T3S as a valuable tool in the study of the peripheral metabolism of 
thyroid hormone in rats. Analogous to rT3 , the accumulation of plasma T3S 
in PTU-treated rats confirms previous findings with radioactive isotopes 
(6,7). showing that type I deiodination is the main pathway for the 
metabolism of T3s. The high plasma T3s levels encountered in PTU-treated 
rats suggests that indeed sulfation is an important step in the elimination 
of T3• Preliminary results of the RIA of plasma T3S in humans indicate that 
although levels are much lower than in rats, they are also increased by 
drugs that inhibit type I deiodinase activity (S.J. Eelkman Rooda and T.J. 
Visser, unpublished observations). 
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CHAPTER VII 
SERUM TRIIODOTHYRONINE SULFATE IN MAN MEASURED BY RADIOIMMUNOASSAY 
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ABSTRACT 
In humans deiodination and, perhaps, glucuronidation are important 
pathways in thyroid hormone metabolism. In addition, sulfation plays an 
important role in T4 and especially in T3 metabolism in rats, but little is 
known about sulfate conjugation of thyroid hormone in humans. In the 
present study we used a specific T3 sulfate (T3S) RIA to address this 
question. Eight euthyroid volunteers were treated for 7 weeks with oral T3 
(1 ug/day/kg body wt). In the 5th week they also received during 2 days 
propylthiouracil (PTU, 4x250 mg/day) and in the 7th week during 3 days 
iopanoic acid (IOP, 1 g/day). Pretreatment values were (mean~ SEM nmol/1): 
T4 92 ~ 6; rT 3 0.24 ~ 0.02; T3 2.30 ~ 0.10 and T3s <0.1 (at or below the 
detection limit of the RIA). After 4 weeks of T3-suppression these values 
were: T4 39 ~ 6; rT3 0.11 ~ 0.01; T3 5.31 ~ 0.39; T3s 0.10 ~ 0.01. After 2 
days of PTU treatment, T4 increased to 48 ~ 7 (p<O.Ol), rT3 to 0.20 ~ 0.03 
(p<0.01), T3S to 0.13 ~ 0.01 (p(0.025), but T3 did not change (4.91 + 
0.35). The effect of lOP was more pronounced; after administration for 3 
days it increased T4 to 49 ~ 8 (p(0.001), rT3 to 0.48 ~ 0.09 (p<0.005), T3S 
to 0.29 ~ 0.04 (p(0.005), and it decreased T3 to 3.95 ~ 0.25 (p(0.005). The 
T3s;T3 ratio was increased by PTU from 0.018 + 0.003 to maximally 0.024 + 
0.004 (p(0.025) and by lOP to maximally 0.055 + 0.007 (p<0.005). In 
conclusion: 1) serum T3s is virtually undectable in euthyroid humans; 2) 
low but significant serum T3S concentrations are detected in humans treated 
with T3 ; 3) serum T3S in T3-treated subjects is increased by inhibition of 
type I deiodinase activity with PTU and especially lOP; and 4) in 
comparison with previous estimates of the serum T3S/T3 ratio in rats, the 
low ratios determined in humans may be explained by: a lesser importance of 
sulfation for the metabolism of T3 in humans, and/or differences in 
kinetics of plasma T3 and T3S between humans and rats. 
INTRODUCTION 
In the rat, conjugation with glucuronic acid and sulfate are important 
pathways in the metabolism of thyroxine (T4) and 3,3',5-triiodothyronine 
(T3). The glucuronides of T4 (T4G) and T3 (T3G) are the main products in 
the bile of rats injected with radioactive T4 or T3 (1-3). Glucuronidation, 
in contrast to sulfation, does not seem to be an irreversible pathway for 
the elimination of these iodothyronines, since strains of obligately 
anaerobic bacteria in the intestine are capable of deconjugating these 
glucuronides (4-5). The liberated iodothyronines are, at least partly, 
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reabsorbed but the extent of such an enterohepatic cycle for thyroid 
hormone has not been established (6-8). However, the sulfate conjugates of 
T4 (T4S) and T3 (T3S) are much better substrates than the nonsulfated 
hormones for the type I iodothyronine deiodinase, which is located mainly 
in the liver and kidneys (9). This explains why little labeled T1s was found in serum and bile of normal rats after iv injection of [3'- 25 JT 3• 
Treatment of rats with propylthiouracil (PTU) or iopanoic acid (lOP), which 
inhibit the type I deiodinase, strongly increased T3s in serum and bile 
(10). 
Little is known about the possible role of glucuronidation and 
sulfation in the. metabolism of T4 and T3 in man. T4G and T3G have been 
detected in human bile (11) but the quantitative importance of this pathway 
has not been assessed. Recent findings suggest that successive sulfation 
and deiodination of T3 may occur ~n humans. Young and coworkers have 
that in human liver T3 is a substrate for both the thermostable 
thermolabile forms of phenol sulfotransferase (12). Visser et al. 
shown 
and 
have 
shown that in vitro the type I deiodinase of human liver is capable of 
inner ring deiodination (IRD) of T3s, which reaction is much more efficient 
than the IRD of T3 itself. PTU and lOP are also effective inhibitors of the 
human type I deiodinase (13). Finally, T3S, although in a very small 
amount, has been identified after an iv injection of labeled T3 in serum of 
euthyroid volunteers (14) _and in serum and bile of a hypothyroid patient 
(15). 
With the use of a recently developed T3S RIA (16), we demonstrated 
that it is possible to measure serum T3s levels in rats (17). In the 
present study we used this RIA to investigate the role of sulfation in the 
metabolism of T3 in humans by measurement of plasma T3S before and during 
treatment with PTU and lOP. As mentioned above, both drugs inhibit the type 
I deiodinase, but lOP also inhibits other (i.e. type II and III) 
iodothyronine deiodinases (18). As inhibition of the type I enzyme by these 
drugs does not only lead to a decreased breakdown of T3S but also, through 
a diminished T4 to T3 conversion, to a reduced T3 substrate supply for 
sulfation, the ultimate effect on plasma T3s levels is unpredictable. 
Therefore, the present study was carried out in healthy human volunteers in 
whom the endogenous T4 production was suppressed by oral T3 administration. 
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SUBJECTS AND METHODS 
Subjects 
Eight euthyroid volunteers, 6 males and 2 females, who took no 
medication participated in the study. The mean age was 33 yrs (range 27-
39), and informed consent was obtained from all subjects. During the entire 
study period subjects were treated with oral T3 (CytomelR), ug/day/kg th body wt, divided in 3 doses taken at 7 am, 3 pm and 11 pm. In the 5 week 
of the study, the subjects also received oral treatment with PTU (250 mg/6 
th h) for 2 days, and in the 7 week they were given oral doses of lOP 
R (Telepaque ; 1 g daily) for 3 days. (Telepaque was obtained from Sterling 
Winthrop, courtesy of Dr. D. GlinoMr). Blood samples were always taken at 
th PM, once a week during the first 4 weeks and in the 6 week, and once a 
day during the 5th and 7th week in which PTU and lOP were given (for 
details, see also the legend to Fig.1). 
RIA measurements 
Serum was kept at -20 C until assay. TSH was measured with a sensitive 
immunoradiometric assay (RIA-gnostR, Behring, Marburg, FRG). The free T4 
(FT4) concentration was calculated by multiplying the FT4-fraction (SPAC, 
BYK Mallinckrodt, Dietzenbach, FRG) and the total T4 concentration. Total 
T4 and T3 were measured by established RIA procedures and total rT3 as 
previously described (19). Iodothyronine standards were obtained from 
Henning Berlin GmbH (West Berlin, FRG). Stanqard T3S was prepared in this 
laboratory (20) or was a gift from Dr. H. Rokos (Henning). [3'-125I]T3S was 
prepared in this laboratory (20). The T3s RIA has been described recently 
(16) and subsequently modified for serum T3S measurements (17). The small 
but significant cross-reactivities of T4 and T3 necessitate the isolation 
of the T3s fraction from 
20 as an adsorbant. T3s 
recovery of 76 + 2% of 
serum in a batch-wise procedure using Sephadex LH-
was isolated from 0.5-1.0 ml serum samples with a 
added 125r-T S (17). Results were corrected for 3 
recovery as determined in pool serum run in triplicate parallel with 
experimental samples in each chromatography session. Residues were 
dissolved in 0.5-1 ml RIA buffer and 50-100 ul aliquots were assayed in 
duplicate for T3S content. Recovery of 500 pmol/1 T3S added to pool serum 
was 106 ~ 6% (n=8). Addition of T3 (10 nmol/1) and,T4 (1 umol/1) increased 
serum T3S immunoreactivity with <SO pmol/1. The within and between assay 
CV's were 7.4 and 12.0%, respectively (17). 
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Data analysis 
All serum samples from the same subject were processed for T3s RIA in 
a single series. Except for t 4 and TSH, all rT3, T3, T3s and 3,3'-T2 
samples were run in the same assay. Serum thyroid concentrations (nmol/1) 
and ratios thereof are given as mean + SEM. Statistical analysis was done 
by Students t-test for paired data. 
RESULTS 
In Table I are given the serum thyroid hormone measurements before and 
after 3 or 4 weeks of T3 suppression. Thyroid parameters of all subjects 
were in the normal range before treatment. TSH levels were suppressed 
(<0.10 mU/L) by T3 from the first week onward during the entire study 
period. After 3 weeks on T3 , serum T4 was already maximally decreased by 
54%. A close correlation was observed between the decrease in T4 and the 
decrease in FT4 and rT3 during the first 4 weeks. At the start of the study 
serum t 3s was (0.1 nmol/1, at or below the detection limit of the RIA, and 
increased to 0.10 ~ 0.01 nmol/1 after 4 weeks of T3 treatment. Serum 
thyroid parameters in week 6 were identical to those in week 4. 
Table I 
Serum TSH (mU/1) and iodothyronine measurements (nmol/1) before 
and after 3 or 4 weeks of T3 suppression 
TSH 
T4 
FT4 
T3 
rT3 
T3S 
Pretreatment 
values 
1.53 + 0.17 
92 + 6 
11.2 + 0.6 
2.30 + 0.10 
0.24 + 0.02 
<0.1 
After 3 weeks of 
T 3 suppression 
0.02 + 0.003 
42 + 5 
5.7 + 0.7 
4.55 + 0.27 
0.11 + 0.01 
ND 
Data are mean + SEM. ND= not determined 
After 4 weeks of 
t 3 suppression 
0.02 + 0.004 
39 + 6 
5.0 + 0.8 
5.31 + 0.39 
0.11 + 0.01 
0.10 + 0.01 
Normal 
values 
0.20-4.90 
60-150 
8.1-15.4 
1.30-3.10 
0.15-0.52 
In Fig. 1 are shown the effects of PTU and lOP-treatment on serum t 4 , 
rt3 and t 3 concentrations. PTU and lOP both slightly increased t 4 , which 
effect was evident from the second day of drug treatment onward. Two days 
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Figure 1 
Effect of PTU (left) and lOP (right) on serum T 4 , rT 3 and T 3 (nmol/1) 
during continuous T 3-suppression. Subjects were treated with 
1 ug T 3 /kg body wt per day divided over 3 oral doses at 7 am, 3 pm 
and 11 pm. In the 5th week, they also received oral doses of 
250 mg PTU starting at 1 pm of day 0 and continuing at 6-h inter-
vals until 7 am of day 2. In the 7th week lOP was given in oral 
doses of 1 gat 1 pm of day 0 and 7 am of days 1 and 2. Blood was 
obtained just before the first gift of the drugs on day 0 and at the 
same time (1 pm) of all subsequent days of week 5 and 7. Data are 
given as mean± SEM. Serum measurements were compared to 
those on day 0 using Students paired t-test: *P < 0.025 +p < 0.01. 
112 
I X 
0.3 ,x 
0.2 T3S I 
* I 
0.1 ~I 
I 
0 
X 
6 
5 
I T3S/T3 
4 I (X 100) 
* 
I 
3 ~ 2 
0 
0 2 3 4 0 2 3 4 days 
Figure 2 
Effect of PTU (left) and lOP (right) on serum T 3S (nmol/1) and the 
T3S/T3 ratio during continuous T3-suppression. Data are given 
as mean± SEM. For further details, see the legend to Fig. 1. 
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after the last lOP dose T4 was still 23% higher than before lOP. Reverse T3 
was increased to 180% by PTU, which effect was maintained until 1 day after 
the last PTU dose. lOP gradually increased rT3 , i.e. 2.5-fold after 1 day 
of treatment to 4.4-fold 2 days after the last lOP dose. Serum T3 was 
decreased by PTU, although not significantly, and by lOP. Maximal 
decrements in serum T3 , i.e. 11 and 22%, occured 1 day after the last dose 
of PTU and lOP, respectively. 
In Fig. 2 are depicted the effects of PTU and lOP treatment on serum 
T3s levels and the serum T3S/T3 ratio. Again, the pretreatment values at 
the start of these 2 regimens were fairly similar. PTU and lOP increased 
T3s maximally 1.4 and 3.2-fold, respectively. These maximal effects were 
reached after 1 day of PTU treatment and 2 days after the last lOP dose. 
The increase in the T3s;T3 ratio was more marked with lOP (maximal increase 
3.2-fold) than with PTU (maximal increase 1.5-fold). 
DISCUSSION 
The thyroid predominantly secretes T4 and a small amount of T3 , while 
thyroidal secretion of rT3 is negligible. Normally, the major fraction of 
circulating T3 (-80%) and rT3 (>95%) is derived from peripheral conversion 
of T4 (21). Most studies on the enzymatic mechanisms of thyroid hormone 
deiodination have been conducted in the rat. These studies have led to the 
recognition of three different iodothyronine deiodinases, termed type I, II 
and III (for a review, see ref. 9). The type I deiodinase is located in 
liver, kidney and thyroid, is capable of both outer- (ORD) and inner ring 
deiodination (IRD), and is inhibited by PTU. The type II enzyme, a 
selective outer ring deiodinase, is found, among others, in the central 
nervous system (CNS), pituitary gland and brown adipose tissue. The type 
III enzyme is found in the CNS and skin (22) and is only capable of IRD. 
The latter two enzymes are PTU-insensitive (9). 
In euthyroid rats plasma T3 production is predominantly derived from 
type I and to a minor extent type II ORO of T4 (23). Although PTU-treatment 
lowers plasma T3 levels in T4-substituted subjects (24), it is presently 
unknown to what extent type I deiodination contributes to plasma T3 
production in humans. Plasma rT3 is probably derived from type III IRD of 
T4 (9), but the contribution of the different tissues with type III 
deiodinase activity has not been determined. Plasma rT3 is mainly cleared 
by type I ORD to 3,3'-T2 especially in the liver but also in the kidneys 
(19). In humans, the liver does not seem important for the clearance of 
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plasma T3 (25), but this probably occurs predominantly by type III IRD in 
extrahepatic tissues. 
In euthyroid rats small amounts of labeled T3S were found in serum and 
bile after iv injection of [125 r]T3 • When the type I enzyme was inhibited 
by PTU, levels of T3S and 3,3'-T2S in serum and bile were increased 
dramatically (10,26). These tracer findings were recently confirmed and 
extended in a study using a specific T3S RIA (17). Serum T3S levels were 
low (0.09 nmol/1) in euthyroid rats and increased 4 h after an ip injection 
with 1 mg PTU/100 g body wt (to 0.33 nmol/1) or after 4 days of treatment 
with PTU in combination with replacement doses of T4 (to 0.34 nmol/1) or T3 
(to 1.09 nmol/1). Serum T3S/T 3 ratios varied between 0.6-0.9 in these 
latter treatment regimens, indicating that in rats sulfation is an 
important pathway in the metabolism of T3(17). Similar results were 
obtained when rats were treated with lOP (27). 
The present report shows that in euthyroid humans serum T3S values are 
at or below the detection limit of our RIA. During the first 4 weeks of T3-
suppression T3s became detectable but remained low. Inhibition of the type 
I deiodinase by PTU and more particularly by lOP increased T3s. Under the 
latter treatment, however, serum T3S is still considerably lower than in 
rats with inhibited type I deiodinase activity. Also the serum T3s;T3 ratio 
in humans (maximally 0.055) is much lower than previously observed in rats. 
Several explanations are possible for this difference. Firstly, the potency 
of the drugs to inhibit type I deiodinase activity may differ between human 
and rats. Although in vitro the type I deiodinase of human liver shows the 
same or even higher sensitivity to PTU and lOP (13) than the enzyme from 
rat liver (9), possible differences in the bioavailability of these drugs 
may contribute to the relatively low response of serum T3s to especially 
PTU in humans. The latter consideration is supported by the smaller effects 
of PTU on serum rT3 in humans compared with rats (17). Secondly, sulfation 
may be a less important pathway of T3 metabolism in humans than in rats. At 
present, there is little in vitro evidence to support. this possibility but 
extension of the recent observation of T3 sulfation by human liver 
sulfotransferases (12) may provide more information on this point. 
Thirdly, the lower serum T3S concentrations in humans may be related to 
species-specific differences in plasma T3 and T3s kinetics. Although the 
half-life of plasma T3 is much higher in humans (28) than in rats (23), 
preliminary evidence suggests that the half-lifes of plasma T3S are less 
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different (10,29). This seems to indicate that differences between the 
rates of T3 sufation between humans and rats are greater than those in 
plasma T3S clearance. Finally, it is possible that after sulfation of T3 in 
the human liver a greater proportion of T3S is excreted into the bile 
rather than released into the circulation compared with the situation in 
the rat. Again, no evidence is available to support this possibility. 
Only one previous attempt to measure serum T3s levels in humans has 
been reported in abstract form (30). This method was based on the 
difference in T3 RIA values before and after treatment of serum with 
arylsulfatase. In accordance with our results, serum T3s levels in normal 
subjects were consistently (0.1 nmol/1. Increases were found after 
administration of propranolol (0.30 nmol/1), and after an acute oral T4 
load. In these conditions, T3s was reported to represent 22 and 11% of 
circulating T3 , respectively. In patients with severe systemic illness 23-
65% of serum T3 was in the form of T3S but absolute values were not 
mentioned. 
The drug-induced increases in serum T3S and rT3 levels appeared to 
correlate very well. As mentioned above, the magnitude as well as the 
duration of the effects of lOP were greater than those of PTU with respect 
to both serum T3S and rT3• These findings are compatible with the view that 
type I deiodination is the main route for the metabolism of T3S and rT3 in 
vivo. 
Finally, the decrease in serum T3 by lOP is remarkable since the 
metabolism of T3 by the type III deiodinase is also inhibited. This was 
substantiated by serum 3,3'-T2 measurements (19), which showed a 
significant decrease during lOP (from 0.082 ~ 0.006 to 0.048 + 0.003) but 
not during PTU. Displacement of T3 from plasma transport proteins by lOP is 
unlikely since the free fraction of T4 was not changed (not shown). 
Furthermore, thyroidal secretion of T3 in the T3-suppressed subjects is 
already negligible before lOP treatment. Therefore, inhibition of T3 
production from residual circulating T4 is the most likely explanation for 
the lOP-induced decrease in serum T3• 
In conclusion, this paper demonstrates that T3S is virtually 
undetectable in serum of euthyroid humans. Low but significant serum T3S 
concentrations are detected in humans treated with suppression doses of T3• 
Inhibition of the type I enzyme by PTU but more particularly by lOP induces 
a significant increase in serum T3S levels. Compared with the earlier 
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reported serum T3s;T3 ratio in rats the much lower ratio in humans 
suggests that sulfation of T3 is a less important pathway in humans than in 
rats, although other possible explanations have not been excluded. 
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SUMMARY 
The thyroid produces all circulating thyroxine (T4), but plasma 
3,3',5-triiodothyronine (T 3) and 3,3',5'-triiodothyronine (rT3) are mainly 
derived from extrathyroidal conversion of this prohormone. T3 is the only 
iodothyronine with significant thyromimetic bioactivity. The liver and 
kidneys are most important in the peripheral production of T3 • The exact 
sites of rT3 production are presently not known, but the CNS and skin are 
thought to be important in this respect. Both T3 and rT3 are deiodinated to 
3,3'-diiodothyronine (3,3'-T2). These conversion reactions are catalyzed by 
iodothyronine deiodinases, of which at least 3 different types have been 
identified in the rat. These deiodinases, type I, II and III, differ in 
several aspects like substrate specificity, reaction kinetics and 
distribution among various tissues. 
Chapter I provides a general introduction concerning thyroid hormone 
synthesis and factors which regulate thyroid hormone bioavailability. 
In Chapter II the two conjugation pathways, glucuronidation and sul-
fation, are reviewed. Enzymes catalyzing these phase II detoxication 
reactions are ubiquitously present in mammals and serve the purpose to 
increase the water solubility of compounds to facilitate their excretion 
into bile and urine. They frequently compete for the same substrate. 
Glucuronidation appears to be a high-Km, high-capacity process, whereas 
sulfation is a low-Km, low-capacity reaction. In general, therefore, at low 
substrate concentrations sulfation prevails and at higher concentrations 
glucuronidation is predominant. The recent progress in the isolation and 
characterisation of the specific iodothyronine sulfotransferases in rat and 
man will stimulate further research in this area, whereas identification of 
the specific iodothyronine UDP-glucuronyltransferase(s) has not 
reported. 
been 
In Chapter IIC available evidence concerning the importance of 
conjugation and deiodination for thyroid hormone metabolism is discussed. 
In the rat conjugation with glucuronic acid and sulfate are, next to 
deiodination, important metabolic pathways. Glucuronidation of T4 and T3 
yields metabolites that are more water-soluble than the nonconjugated 
hormones, and the products T4 glucuronide (T4G) and T3G are excreted into 
the bile. After biliary excretion, T4G and T3G are not lost in the feces 
but are hydrolyzed by ~-glucuronidase-producing bacteria in the intestine. 
The liberated hormones are then, at least in part, reabsorbed (entero-
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hepatic cy~le). Whereas glucuronidation does not lead to the irreversible 
loss of thyroid hormone, sulfation does. This conjugation reaction is not 
an independent pathway of thyroid hormone metabolism but leads to the 
formation of derivatives that are better substrates for deiodination than 
the nonsulfated iodothyronines. The Vmax/Km ratios of the type I deiodinase 
for iodothyronine sulfates are 40-200 fold higher than those for the native 
hormones. Finally, the quantitative role of glucuronidation in T4 and T3 
metabolism is deduced from studies in the Gunn rat, a species with an 
inherited deficiency of UDP-glucuronyltransferase. Little is known about 
the quantitative role of glucuronidation and sulfation in the metabolism of 
thyroid hormone in humans. T4G and T3G have been identified in human bile, 
and T3s, although in a very small amount, has been detected in bile and 
serum of a hypothyroid patient after iv injection of labeled-T3• 
In Chapter III the role of the type I deiodinase in rT 3 metabolism in 
isolated rat hepatocytes was investigated. The results indicate that rT3 is 
mainly metabolized by outer ring deiodination (ORD) to I and 3,3'-T2 • 
Normally, the product 3,3'-T2 is not observed due to rapid sulfation and 
subsequent ORD of 3,3'-T2s. Inhibition of sulfation does not affect rT3 
clearance, but the decrease in I- formation from rT3 is compensated by an 
increased recovery of 3,3'-T2 up to 70% of rT3 metabolized. 
In Chapter IV a description of the development of a RIA for T3S is 
given. Specific antibodies were raised by immunization of rabbits with a 
T3S-bovine serum albumin conjugate. With one of the antisera (#8193) the 
studies described in Chapters V-VII were performed. 
Chapter V contains a detailed investigation into the metabolism of T3 
in isolated rat hepatocytes. Three major pathways were identified: glucu-
ronidation, sulfation and direct inner ring deiodination (IRD). Whereas T3G 
is not further metabolized in these cultures, T3S is rapidly deiodinated by 
the type I enzyme. Evidence is provided for the presence of a type Ill-like 
enzyme in rat liver which has not been recognized before. Direct IRD of T3 
by this enzyme is characterized by a low Km and is not inhibited by PTU. 
In Chapter VI the RIA for T3s was used for determination of plasma T3S 
in rats treated with PTU or methimazole (MMI). In contrast to the MMI 
treated rats, treatment with PTU alone or in combination with T3 or T4 
increased plasma T3S. The T3S/T3 ratio of 0.6-0.9 in the PTU-treated rats 
confirms previous observations with radioisotopes that sulfation is an 
important pathway in T3 metabolism in rats. 
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In Chapter VII the role of sulfation in T3 metabolism in man was 
investigated. Normally, serum T3S was <0.1 nM, at or below the detection 
limit of the T3S RIA. Inhibition of the type I enzyme by PTU and especially 
by lOP in combination with oral T3 therapy led to a significant increase in 
plasma T3s, although levels were much lower than in rats. Accordingly, the 
T3s;T3 ratio was lower in man than in rats. This suggests that sulfation is 
a less important route in T3 metabolism in man than it is in rats, although 
the results may also be due to different rates of T3 and T3s turnover in 
rats and humans. 
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SAHENVATTING 
Schildklierhormoon speelt een belangrijke rol in de stofwisseling en 
stimuleert de groei en ontwikkeling van het organisme. Het heeft o.a. 
invloed op het transport van aminozuren en electrolyten vanuit de 
extracellulaire ruimte naar de eel, en speelt een rol bij de synthese van 
eiwitten binnen de eel. Dit alles leidt tot veranderingen in celgrootte, 
celaantal en celfunktie. 
Hoewel thyroxine (T4 ) het belangrijkste door de schildklier gepro-
duceerde hormoon is, worden bovenstaande effekten vrijwel uitsluitend 
gemedieerd door het biologisch aktieve 3,3',5-trijodothyronine (T3). Van 
het in het plasma circulerende T3 wordt slechts 20% door de schildklier 
geproduceerd, terwijl 80% afkomstig is van enzymatische dejodering van T4 
in de lever en nieren. Een derde jodothyronine dat in plasma aanwezig is, 
is het 3,3',5'-trijodothyronine (reverse T3 , rT3). Deze stof he eft 
voorzover nu bekend geen invloed op bovengenoemde biologische processen. 
Ook plasma rT3 is voor het overgrote deel afkomstig van enzymatische 
dejodering van T4 , waarschijnlijk in het centrale zenuwstelsel en de huid. 
Bij de rat zijn drie enzymen gevonden, die deze dejoderings-reakties 
katalyseren. Deze worden wel aangeduid met type I, II en III. 
In hoofstuk I wordt een algemeen overzicht gegeven van de synthese van 
schildklierhormoon en van faktoren die een rol spelen bij de regulatie van 
schildklierhormoon op cellulair niveau. 
In hoofdstuk II worden de twee conjugatie reakties, glucuronidering en 
sulfatering, besproken. Glucuronidering wordt gekatalyseerd door het enzym 
UDP-glucuronyltransferase. Phenolsulfotransferase is het enzym dat betrok-
ken is bij de sulfatering. Beide conjugatie-reakties komen wijdverspreid 
voor, niet alleen bij de mens en andere dieren, maar ook in planten en 
bacterign. Ze spelen een rol bij de detoxificatie van een groot aantal 
stoffen, zowel endogeen (bv. hormonen) als exogeen (bv. geneesmiddelen). 
Koppeling van deze stoffen met glucuronzuur of sulfaat maakt deze stoffen 
beter water oplosbaar, waarna ze uitgescheiden worden met de gal of urine. 
In hoofstuk IIC wordt het belang van conjugatie en dejodering van 
schildklierhormoon besproken. In de rat en mens worden T4 en T3 geglu-
curonideerd tot de beter in water oplosbare stoffen T4 glucuronide (T4G) en 
T3G. Deze worden in de gal uitgescheiden. In de darm worden deze stoffen 
echter weer gehydrolyseerd door glucuronidase-producerende bacterign, 
waarna T4 en T3 worden gereabsorbeerd. Dank zij deze enterohepatische 
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kringloop wordt op een meer economische manier met deze hormonen 
omgesprongen dan wanner zij onveranderd het lichaam zouden verlaten met de 
faeces. 
Sulfatering van schildklierhormoon is lange tijd een onopgemerkt 
proces geweest, omdat onder normale omstandigheden vrijwel geen sulfaten 
van schildklierhormoon aantoonbaar zijn. Nader onderzoek heeft uitgewezen 
dat deze conjugatie reaktie, althans bij ratten, wel degelijk voorkomt, 
maar dat bv. T3 sulfaat (T3S) na vorming snel gedejodeerd wordt. 
Sulfatering blijkt dus geen onafhankelijke route te zijn, maar nauw 
verbonden met dejodering. Bij de mens is weinig bekend over de rol van 
glucuronidering en met name sulfatering in het metabolisme van 
schildklierhormoon. 
De vraagstelling, die ten grondslag ligt aan dit proefschrift, is in 
hoeverre sulfatering van belang is voor het metabolisme van het schild-
klierhormoon T3 en de isomeer rT3• 
In hoofdstuk III is het metabolisme van rT3 in geisoleerde ratte-
hepatocyten onderzocht. Dejodering van rT3 in de buitenring levert jodide 
(I-) en 3,3'-dijodothyronine (3,3'-T2) op. Dit laatste produkt wordt echter 
onder normale omstandigheden niet waargenomen, omdat 3,3'-T2 snel gesul-
fateerd wordt en vervolgens door dejodering verder afgebroken. Wordt nu 
deze sulfatering van 3,3'-T2 geremd, hetzij door sulfaat te onttrekken aan 
hepatocyt-cu1turen danwel remmers van deze reaktie toe te voegen, dan kan 
3,3'-T2 wel terug gevonden worden. Ret metabolisme van rT 3 is echter niet 
afhankelijk van sulfaat. 
Om het belang van sulfatering in het metabolisme van T3 beter te 
kunnen bestuderen werd een radioimmunoassay (RIA) voor T3S ontwikkeld. De 
methode die hiervoor gebruikt is wordt beschreven in hoofdstuk IV. 
In hoofdstuk V is het metabolisme van T3 in rattehepatocyten onder-
zocht. T3 wordt op drie manieren gemetaboliseerd. Ten eerste wordt het ge-
glucuronideerd, waarna T3G in de gal wordt uitgescheiden. Ten tweede kan T3 
worden gesulfateerd tot T3S, welk produkt snel verder afgebroken wordt door 
het type I enzym. Ten derde kan T3 via direkte binnenring-dejodering worden 
gemetaboliseerd. Deze route was tot nu toe onbekend. Deze reaktie blijkt 
gekatalyseerd te worden door een enzym dat een tweetal eigenschappen gemeen 
heeft met het type III enzym (dat voorkomt in het centrale zenuwstelsel, 
huid en foetale lever), nl. 1) de reaktie wordt gekarakteriseerd door een 
lage Km voor T3 en 2) het enzym is ongevoelig voor het thyreostaticum 
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propylthiouracil (PTU). Nader onderzoek zal moeten uitwijzen of dit enzym 
gelijk is aan het type III enzym dan wel of het hier een nieuw enzym 
betreft. 
In hoofdstuk VI wordt de r3s RIA gebruikt om in ratteplasma r3s te 
bepalen. Hiertoe werden ratten behandeld met de thyreostatica PTU of 
methimazol (MMI), waarvan alleen PTU ook het type I enzym remt. Behandeling 
met PTU alleen of in combinatie met r 4 of r 3 , leidt tot een aanzienlijke 
stijging van het plasma r 3s, in tegenstelling tot de met MMI behandelde 
ratten. De plasma r3s;r3 ratio van 0.6-0.9 bevestigt eerdere studies met 
radioactief r 3 dat in ratten sulfatering een belangrijke route is in het 
metabolisme van r 3• 
Tot slot wordt in hoofdstuk VII een eerste aanzet gegeven tot het 
onderzoek naar het belang van sulfatering in het metabolisme van r 3 bij de 
mens. Onder normale omstandigheden is r 3s in een lage concentratie 
aanwezig. Wanneer het type I enzym wordt geremd door PTU, maar meer in het 
bijzonder door IOP, wordt een aanzienlijke stijging van plasma r 3s 
gevonden. Desalniettemin zijn ook dan de waarden veel lager dan bij ratten. 
Ook de r3s;r3 ratio is veel lager bij de mens dan de rat, hetgeen sugge-
reert dat sulfatering een minder belangrijke rol speelt in het metabolisme 
van T3 bij de mens. 
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NAWOORD 
Velen ben ik dank verschuldigd bij de tot stand koming van dit proef-
schrift. 
Allereerst mijn promotor Theo Visser, die mij vanaf het begin op dit voor 
mij onbekende biochemische terrein begeleidde. Theo, jouw enthousiasme, ook 
in tijden met mindere resultaten, werkte zeer aanstekelijk. Daarnaast heb 
ik veel geleerd van de manier waarop jij ogenschijnlijk moeilijke proble-
men op eenvoudige manier wist op te lossen. 
Marla van Loon voerde alle leverperfusies en een groot deel van de 
experimenten uit. Marla, je was altijd bereid om "nog even een assay in te 
zetten of een chromatografie te doen". Dit proefschrift is voor een belang-
rijk deel mede door jou tot stand gekomen. 
Ellen Kaptein heeft de T3S radioimmunoassay mede ontwikkeld en de vele T3S 
bepalingen verricht. 
Aan de discussies en experimentele samenwerking met Marja Rutgers denk ik 
met plezier terug. 
Roel Docter was steeds behulpzaam met het geven van statistische adviezen. 
Zijn computerprogramma's waren van grote waarde bij het uitwerken en 
tekenen van de vele chromatografiegen. 
Joop van Buuren wijdde mij in in de geheimen van de "pc" en was 
bereid eventuele problemen op te lossen. Alle medewerkers van het 
klierlab wil ik graag bedanken voor de gezelligheid en goede sfeer 
rende de afgelopen jaren. 
De Audiovisuele Dienst verzorgde op uitstekende wijze de figuren. 
Tot slot, Anky, jouw steun was in een woord geweldig. 
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